Author Index For Volume 31

Abarzua M (abst) 185, 397
Abboud HE (abst) 158, 175, 182, 184
Abdelhamid S (abst) 244
Abraham PA (abst) 189, 212
Abramson RG (abst) 389, 429, 439
Abrass CK (abst) 323
Abreo K (abst) 225
Abuelo JG (abst) 229
Abuful A (abst) 450
Abu-Hamdan D (abst) 294, 361, 463
Abuyousef M *See* Bertolatus JA 1257
Acara M (abst) 422
Acchiardo S (abst) 226
Aceto R (abst) 269
Ach JP (abst) 412
Ackerman DM (abst) 268
Adam E (abst) 282
Adamopoulos J (abst) 864
Adamson JW (abst) 198
Adamson JW *See* Segal GM 72
Adan L (abst) 341
Adelberg EA (abst) 168
Adler AJ (abst) 226
Adler S (abst) 265, 288, 312, 404
Adler SG (abst) 158
Adler S *See* Stahl RAK 1126
Adreopoulou M (abst) 864
Adrogue HJ (abst) 443
Aelvoet I (abst) 451
Affre J (abst) 210
Agarwal N (abst) 168
Agishi T (abst) 220
Agrafiotis A (abst) 861, 862, 869, 871
Agrawal M (abst) 232
Agrawal MK (abst) 221
Agrogiannis V (abst) 870
Aguilera G *See* Mendelsohn FAO S-40
Agulian S (abst) 441
Agus ZS (abst) 444
Ahmad S (abst) 226, 233
Ahn SY (abst) 248
Aitboum I (abst) 257
Aizawa S (abst) 330
Akano N (abst) 334
Akiba T (abst) 431
Akmal M (abst) 384
Al-Abdulla S (abst) 465
Alavi N (abst) 159
Al-Bander H (abst) 301
Albarano L (abst) 365
Alberetto M *See* Wiseman MJ 1012
Albini B (abst) 315, 321
Alcock N (abst) 341
Alden BM (abst) 425
Alder S (abst) 315
Alevizaki K (abst) 864
AlevizouTerzaki V (abst) 865
Alexander D (abst) 452
Alexander EA (abst) 180, 181, 405
Alexander M (abst) 166
Alexander R (abst) 222
Alexander S (abst) 249
Alexiou P (abst) 863
Alexopoulos E (abst) 865, 870
Alexopoulos I (abst) 862
Alexopoulos J (abst) 869
Alexopoulu V (abst) 218
Alfieri KM (abst) 461
Alfino P (abst) 305, 379
Alfrey A (abst) 247
Alfrey AC (abst) 189, 198
Alfrey AC *See* Andress DL 1244
Alfrey AC *See* Molitoris BA 986
Alfrey PS *See* Molitoris BA 986
Alhenc-Gelas F *See* Marchetti J 744
Alijani MR (abst) 453, 457, 459
Alkjaersig N, Fletcher AP, Narayanan M, Robson AM: Course and resolution of the coagulopathy in nephrotic children (Clinical Investigation) 772
Allen RD (abst) 170
Alliapoulos JC (abst) 251
Allison N (abst) 267
Allon M (abst) 341, 348
Almeida FA (abst) 257, 288
Alper SL (abst) 159
Alpern R (abst) 411
Alpern RJ (abst) 428
Alpern RJ Jr (abst) 414
Alpers CE (abst) 312, 392
Alpers CE, Rennke HG, Hopper J Jr, Biava CG: Fibrillary glomerulonephritis: An entity with unusual immunofluorescence features (Clinical Investigation) . 781
Alpert MA (abst) 248
Altman R (abst) 193
Alupovic P (abst) 379
Alvarado JA (abst) 295
Alvestrand A (abst) 189
Aly A (abst) 255
Amend W (abst) 453, 456
Amend WJC (abst) 453, 456
Amiel C (abst) 166, 418
Amiens CHU (abst) 1417
Amoah E (abst) 189
Anagnostopoulos T (abst) 413, 442
Anastasio P (abst) 365
Andersen K-J, Haga H-J, Dobrota M: Lysosomes of the renal cortex: Heterogeneity and role in protein handling (Laboratory Investigation) 886
Anderson CF *See* Torres VE 1383
Anderson J (abst) 211
Anderson PS (abst) 158
Anderson RJ (abst) 164, 257, 445
Anderson S (abst) 222, 279, 281, 379, 385
Anderson S *See* Meyer TW 752
Anderson S *See* Zatz R S-123
Anderson WP, Woods RL: Intrarenal effects of angiotensin II in renal artery stenosis S-157
Ando K (abst) 278

Andreoli SP (abst) 159
Andreoli TE (abst) 431, 439, 440
Andreoli TE *See* Hebert SC 580
Andreoni K (abst) 274
Andres G (abst) 314, 320, 338
Andres GA *See* Fliger FD 800
Andress DL (abst) 341, 349
Andress DL, Nebeker HG, Ott SM, Endres DB, Alfrey AC, Slatopolsky EA, Coburn JW, Sherrard DJ: Bone histologic response to deferoxamine in aluminum-related bone disease (Clinical Investigation) 1244
Andrews PM (abst) 363, 370, 435
Andriani F (abst) 226
Andriani M (abst) 226
Andriole VT *See* Schachner MS 77
Ang KS (abst) 218, 229
Angel J (abst) 162
Anger M (abst) 258
Anlauf M (abst) 304
Antoniadou R (abst) 861
Antoniou S (abst) 861, 866
Antonovych T (abst) 334
Antonovych TT (abst) 453
Aperia A (abst) 173, 178, 258
Apostolidis N (abst) 861, 866
Appel G (abst) 336
Appel GB (abst) 193, 454, 456
Appel RG (abst) 258, 273
Arakawa M (abst) 227
Araneo B (abst) 452
Arbeit LA (abst) 245, 366
Ardaillou N *See* Ardaillou R S-74
Ardaillou R (abst) 258, 284, 287
Ardaillou R, Sraer J, Chansel D, Ardaillou N, Sraer JD: The effects of angiotensin II on isolated glomeruli and cultured glomerular cells S-74
Arend LJ (abst) 259
Arendshorst WJ (abst) 284
Argyropoulos A (abst) 868
Argyropuolos A (abst) 867
Arias R (abst) 245
Arieff AI (abst) 190, 191
Arisz L (abst) 1048
Arnaout MA (abst) 312
Arnold WC (abst) 294
Arnow PM (abst) 227
Aronoff GR (abst) 395
Aronson PS (abst) 412, 416, 438
Arrizurieta E *See* Panese S 1377
Arruda JAL (abst) 407, 418
Arseni P (abst) 863
Artopoulos J (abst) 869
Arvanitidoy-Vayonas M (abst) 865
Asano Y (abst) 359
Ash SR (abst) 227
Ashbrook D (abst) 226, 233
Assan R (abst) 418
Assmann KJM (abst) 1043
Ast MB (abst) 446
Atienza C (abst) 1418
Atkins RC *See* Hooke DH 964
Atlas S (abst) 269
Atlas SA (abst) 282
Attman P (abst) 379
Aubry JP (abst) 335
Auer IK (abst) 423
Aukland K *See* Heyeraas KJ 1291
Ausiello DA (abst) 162, 280
Ausiello DA, Skorecki KL, Verkman AS, Bonventre JV: Vasopressin signalling in kidney cells 521
Austin H (abst) 224, 334
Avasthi PS (abst) 419
Avasthi PS *See* Koshy V 52
Avioli L (abst) 349
Avioli LV (abst) 356
Avioli LV *See* Reid IR 1113
Aviv A (abst) 271, 301, 305
Avner ED (abst) 159, 165, 394
Avram MM (abst) 204
Awni WM (abst) 462
Aynedjian HS (abst) 259
Aynedjian HS *See* Bank N 897
Ayus JC (abst) 190, 207
Azadegan A (abst) 317
Azar S (abst) 294
Azevedo LS (abst) 459
Bacallao R (abst) 160
Backer A (abst) 391
Bacon R (abst) 350
Badie-Dezfooly B (abst) 428
Badr KF (abst) 286, 363
Baer PG *See* Kauker ML 1092
Bagby S (abst) 294
Bagdon WJ *See* MacDonald JS S-148
Bailey D (abst) 468
Baines AD (abst) 395
Baird L (abst) 338
Bakaletz A (abst) 316
Baker K (abst) 227
Baker P (abst) 315
Baker PJ (abst) 265, 288, 312, 313, 329
Baker PJ *See* Stahl RAK 1126
Bakker WW (abst) 1045
Bakker WW, Kalicharan D, Donga J, Hulstaert CE, Hardonk MJ: Decreased ATPase activity in adriamycin nephrosis is independent of proteinuria (Laboratory Investigation) 704
Bakris GL (abst) 363
Balaban R (abst) 176
Balaban RS, Burg MB: Osmotically active organic solutes in the renal inner medulla 562
Baldamus CA (abst) 242
Baldridge SL (abst) 264
Baldwin DS (abst) 198, 305, 379
Baldwin DS, Neugarten J, Feiner HD, Gluck M, Spinowitz B: The existence of a protracted course in crescentic glomerulonephritis (Clinical Investigation) 790
Baldwin WM (abst) 1047
Ballal SH (abst) 454
Baller JFW (abst) 1045
Ballerman BJ (abst) 259, 271, 281, 282
Balow J (abst) 334
Balsan S *See* Bourdeau AM 15
Balsan S *See* Lieberherr M 736
Baluarte HJ (abst) 460
Banchereau J (abst) 335
Bander S (abst) 216
Banga JD (abst) 192, 1048
Bank N (abst) 259

Bank N, Klose R, Aynedjian HS, Nguyen D, Sablay LB: Evidence against increased glomerular pressure initiating diabetic nephropathy (Laboratory Investigation) ... 897
Bankir L (abst) ... 379, 403, 430
Bankir L, Bouby N, Trinh-Trang-Tan M-M: Heterogeneity of nephron anatomy ... S-25
Bankir L *See* Trinh-Trang-Tan M-M ... 549
Banks RO (abst) ... 312
Bannister D (abst) ... 226
Bansal M (abst) ... 341
Bansal V (abst) ... 388
Bansal VK (abst) ... 190
Barajas L (abst) ... 259, 285
Barak H (abst) ... 347
Baranowski RL (abst) ... 202, 261, 274, 292, 368, 389, 419
Baranowski RL *See* Cheung AK ... 1072
Barcelli U (abst) ... 386
Bardin T (abst) ... 1417, 1418
Bargman JM (abst) ... 246, 253, 342
Baricos WH (abst) ... 177, 313, 330
Bariety J (abst) ... 328
Barjon JN (abst) ... 190, 191
Barnett R (abst) ... 260
Barratt TM *See* Vermylen CG ... 1396
Barre PE (abst) ... 240
Barrett PQ (abst) ... 260
Barrido D (abst) ... 212
Barron H (abst) ... 274
Barros VS (abst) ... 231
Barry CS (abst) ... 188
Barsanti J (abst) ... 380
Bashirelahi N (abst) ... 460
Basta MT *See* Sobh MA ... 1006
Bastin J, Cambon N, Thompson M, Lowry OH, Burch HB: Change in energy reserves in different segments of the nephron during brief ischemia (Laboratory Investigation) ... 1239
Bataille P (abst) ... 1417
Bates SB (abst) ... 363, 370, 453
Batlle DC (abst) ... 202, 230, 302, 454
Batsford S (abst) ... 289
Batsford SR, Rohrbach R, Vogt A: Size restriction in the glomerular capillary wall: Importance of lamina densa (Laboratory Investigation) ... 710
Batuman V (abst) ... 224
Baudin G (abst) ... 1418
Baudouin B (abst) ... 1418
Bauer JH (abst) ... 295, 307
Baum HP (abst) ... 340
Baum M (abst) ... 428, 435, 436
Baumal R (abst) ... 385
Bauman CA (abst) ... 173, 429
Bauman JW Jr (abst) ... 380
Bay WH (abst) ... 210, 227
Baylis C (abst) ... 265, 281, 367, 419, 448
Bayliss J (abst) ... 294, 405
Bazzato G (abst) ... 250
Beach RE (abst) ... 160, 178
Beam TR (abst) ... 249
Beason-Griffin CL (abst) ... 392, 426
Beauregard H (abst) ... 194
Becaus I (abst) ... 1417
Beck J (abst) ... 375
Beck JC (abst) ... 429, 439
Beck T (abst) ... 309
Beckman B (abst) ... 290
Beekman K (abst) ... 454
Behar M (abst) ... 313
Beirwaltes WH (abst) ... 419
Bekersky I (abst) ... 213
Belechri A (abst) ... 868
Belendiuk GW (abst) ... 211
Belghiti D (abst) ... 1419
Beliveau R (abst) ... 160, 182
Belknap S *See* Weinberg M ... 836
Bell P (abst) ... 197, 204, 295, 297
Bell PD (abst) ... 423
Bell P *See* Sedman A ... 1000
Bell S (abst) ... 233
Belldegrun A (abst) ... 224
Bello-Reuss E (abst) ... 160
Bellrorin-Font E (abst) ... 173, 355
Belzer FO (abst) ... 464
Benabe JE (abst) ... 260
Ben-Air J (abst) ... 315
Ben-Ari J (abst) ... 175
Ben-Bassat M (abst) ... 388
Benedetti RG, Linas SL: Mechanism of decreased vascular response to angiotensin II in renal vascular hypertension (Laboratory Investigation) ... 906
Bengele HH (abst) ... 180, 181, 405
Benigni A *See* Zoja C ... 1335
Bennett C (abst) ... 429
Bennett W (abst) ... 211, 364, 367
Bennett WM (abst) ... 193, 200, 209, 367, 368, 370
Bens M (abst) ... 287
Benson B (abst) ... 462
Benter I (abst) ... 310
Bentley MD (abst) ... 420
Bentzel CJ (abst) ... 161
Benvenisty AI (abst) ... 456
Berden JHM (abst) ... 1044
Beretta-Piccoli C *See* Bianchetti MG ... 956
Berg J (abst) ... 271
Berger E (abst) ... 369
Bergmann JE (abst) ... 415
Bergstrom J (abst) ... 189
Berkseth RO (abst) ... 218
Berl T (abst) ... 258
Berl T: The cAMP system in vasopressin-sensitive nephron segments of the vitamin D-treated rat (Laboratory Investigation) ... 1065
Berlyne GM (abst) ... 226, 244
Berman TL (abst) ... 385
Berndt WO (abst) ... 447
Bernheim J (abst) ... 251
Berns JS (abst) ... 429
Bernstein K (abst) ... 172
Berquist B (abst) ... 213
Berry C (abst) ... 411, 438
Berry P (abst) ... 336
Bersin RM (abst) ... 191
Bertani T (abst) ... 321
Bertani T, Livio M, Macconi D, Morigi M, Bisogno G, Patrono C, Remuzzi G: Platelet activating factor (PAF) as a mediator of injury in nephrotoxic nephritis (Laboratory Investigation) ... 1248
Bertani T *See* Zoja C ... 1335
Berthoux FC (abst) ... 335

Berthoux P (abst) 335
Bertolatus JA (abst) 313
Bertolatus JA, Abuyousef M, Hunsicker LG: Glomerular sieving of high molecular weight proteins in proteinuric rats (Laboratory Investigation) 1257
Bertorello A (abst) 258
Bertrand S (abst) 194
Besarab A (abst) 233
Bettcher K (abst) 250
Better OS (abst) 257, 420
Betz M (abst) 228
Beukers EKM (abst) 1050
Beukers JJB (abst) 1043, 314
Beukhof JR (abst) 1046
Beyer WEP (abst) 1046
Beyne P (abst) 248
Bezbak H (abst) 461
Bhan A (abst) 338
Bhaskaran DD (abst) 342
Bhat S (abst) 463
Bia M (abst) 454
Bianchetti MG, Weidmann P, Beretta-Piccoli C, Ferrier C: Potassium and norepinephrine- or angiotensin-mediated pressor control in pre-hypertension (Clinical Investigation) 956
Bianchi G (abst) 296
Biava CG *See* Alpers CE 781
Biber UL (abst) 164
Bichara M (abst) 405, 407
Bichet D (abst) 190
Bichet DG (abst) 191
Bidani A (abst) 314
Bie P (abst) 260, 270
Bielakoff J (abst) 238, 345
Bierne G (abst) 254
Biewenga J (abst) 1046
Billis A (abst) 863, 864, 867, 868
Billis AG (abst) 862
Billstein SA (abst) 196
Bilo HJG (abst) 197, 255, 1050
Bingel M (abst) 237, 245
Birch F (abst) 274
Birch FM (abst) 261
Bird JE (abst) 364
Birenboim N, Donoso VS, Huseman RA, Grantham JJ: Renal excretion and cyst accumulation of microglobulin in polycystic kidney disease (Clinical Investigation) 85
Bisogno G *See* Bertani T 1248
Bixler GB *See* Wingo CS 1225
Blair HC (abst) 342
Blair IA (abst) 323
Blake DE (abst) 227
Blake S (abst) 267
Blanchet F (abst) 418
Blantz R (abst) 213, 367
Blantz RC (abst) 364, 386
Blantz RC, Gabbai FB: Effect of angiotensin II on glomerular hemodynamics and ultrafiltration coefficient S-108
Blantz RC *See* Gabbai FB 1267
Blas SD (abst) 266
Blayney D (abst) 220
Blazy I (abst) 266
Blecher M (abst) 166
Blecher SR *See* Crocker JFS 1088
Blendis LM (abst) 262
Blondin J (abst) 230
Blonsky SL (abst) 229
Blumberg A (abst) 267
Blumenfrucht MJ (abst) 364
Bobadilla N (abst) 295
Bock HA (abst) 261, 411
Bock KD (abst) 304
Boechat I (abst) 213
Boer P (abst) 433, 437, 1049
Boer WH (abst) 349, 430
Bogden J (abst) 224
Bogerg U (abst) 420
Bogman MJJT (abst) 1043
Bokelman DL *See* MacDonald JS S-148
Boletis J (abst) 861, 869, 870
Bolton K (abst) 204, 463
Bolton WK (abst) 179, 189, 332
Bommer J (abst) 228
Bonventre JV (abst) 161, 162, 370
Bonventre JV *See* Ausiello DA 521
Booker BB (abst) 433
Border WA (abst) 389
Borgia JF (abst) 360
Boron WF (abst) 161, 408, 412, 415
Borow K (abst) 346
Borum P (abst) 393
Bosch J (abst) 191
Bosch JP (abst) 208, 241, 247
Bosch R (abst) 211
Bosman F (abst) 1047
Boswell J (abst) 257
Bouby N (abst) 379, 403, 430
Bouby N *See* Trinh-Trang-Tan M-M 549
Bouby N *See* Bankir L S-25
Bougenot B (abst) 1418
Bouillon P (abst) 1417
Bouillon R *See* Bourdeau JE 913
Boukouvala J (abst) 866
Boulanger Y (abst) 430
Boulanger Y *See* Vinay P 946
Boulpaep E (abst) 451
Boulpaep EL (abst) 429
Bourdeau AM, Plachot J-J, Cournot-Witmer G, Pointillart A, Balsan S, Sachs C: Parathyroid response to aluminum in vitro: Ultrastructural changes and PTH release (Laboratory Investigation) .. 15
Bourdeau JE, Langman CB, Bouillon R, Theisen L: Parathyroid hormone-stimulated calcium absorption in cTAL from vitamin D-deficient rabbits (Laboratory Investigation) 913
Bourgoignie JJ (abst) 213, 380
Bourgoignie JJ *See* Pardo V 1167
Bourke E (abst) 191, 219, 341, 348, 397
Bouthier M (abst) 442
Boutopoulos J (abst) 865, 867, 868
Bovi R (abst) 317
Bower JD (abst) 254
Bower JD *See* Kirchner KA 1097
Boxer DC (abst) 161
Boyarsky G (abst) 161
Boyce NW, Holdsworth SR: Intrarenal hemodynamic alterations induced by anti-GBM antibody (Laboratory Investigation) 8

Braam B (abst) ... 104, 192
Bradford D (abst) ... 338
Brady HR (abst) ... 455
Brancaccio D (abst) ... 226
Brandis A (abst) ... 296
Brandon S *See* Kirchner KA ... 1097
Brands MW (abst) ... 291
Branger B (abst) ... 1418
Braquet P (abst) ... 271, 283
Brater D (abst) ... 218
Brater DC (abst) ... 222
Braun L *See* Wilcox CS ... 135
Bravo EL (abst) ... 274
Bray SH (abst) ... 228
Brazy P (abst) ... 395
Brazy PC (abst) ... 350
Breckon R (abst) ... 164
Brehier A *See* Mounier F ... 121
Brelje TE (abst) ... 319
Brem AS (abst) ... 252, 261
Brem FS (abst) ... 252
Brennan S (abst) ... 444
Brenner BM (abst) ... 171, 271, 279, 281, 282, 293, 328, 379, 385
Brenner BM *See* Meyer TW ... 752
Brenner BM *See* Zatz R ... S-123
Brenner BM *See* Ichikawa I ... S-213
Brentijens JR *See* Fliger FD ... 800
Brentjens J (abst) ... 314, 320, 338, 393
Breyer J (abst) ... 261
Breyer MD (abst) ... 266, 405
Brezin JH (abst) ... 194
Brezis M (abst) ... 367, 374, 376
Brier ME (abst) ... 395
Briggs JP (abst) ... 430
Brill J (abst) ... 357
Brinkema E (abst) ... 398
Brinker K (abst) ... 458, 468
Brodsky I (abst) ... 194
Brodsky WA (abst) ... 406
Brommage B (abst) ... 346
Brookins J (abst) ... 290
Brooks CS (abst) ... 461, 462
Broquist HP (abst) ... 188
Brouhard B (abst) ... 420
Brouhard BH (abst) ... 262
Broukhim M (abst) ... 428
Brown D (abst) ... 162, 167
Brown DM (abst) ... 171, 178
Brown GP (abst) ... 262, 290
Brown KS (abst) ... 165
Brown S (abst) ... 380
Brown ST (abst) ... 225
Browne JK (abst) ... 198
Bruijn JA (abst) ... 1047
Bruneau C (abst) ... 1416, 1419
Brunette MG (abst) ... 342
Brunkhorst R (abst) ... 300
Brunner FP (abst) ... 380
Brunner H (abst) ... 1044
Brunner HR, Waeber B, Nussberger J: Angiotensin converting enzyme inhibition and the normal kidney ... S-104
Bruno C (abst) ... 445
Bucht H (abst) ... 189
Buckalew VM Jr (abst) ... 192, 303, 307
Budet C (abst) ... 210
Buerkert J (abst) ... 364, 405
Bührle CP *See* Hackenthal E ... S-4
Buijs WC *See* Geven WB ... 1140
Buisseret P (abst) ... 461
Buisson V (abst) ... 335
Bukoski R (abst) ... 343
Bukoski RD (abst) ... 307
Bulger RE: Composition of renal medullary tissue ... 556
Buller G (abst) ... 228
Bullis WJ (abst) ... 396
Bullough P (abst) ... 341
Bunchman T (abst) ... 192
Bunke M (abst) ... 365
Burbea ZH (abst) ... 406
Burch HB *See* Bastin J ... 1239
Burckhardt G (abst) ... 406
Burg M (abst) ... 176, 185, 408, 416
Burg MB *See* Balaban RS ... 562
Burgess WP (abst) ... 229, 337
Burk L (abst) ... 226
Burkart JM (abst) ... 192
Burke C (abst) ... 164
Burke JF (abst) ... 233
Burke TJ (abst) ... 375
Burke TJ, Schrier RW: Angiotensin converting enzyme inhibition and acute tubular necrosis ... S-143
Burke TJ *See* Harris DCH ... 41
Burnatowska-Hledin M (abst) ... 259, 406
Burnett JC Jr (abst) ... 268, 280, 286, 293, 363
Burnier M (abst) ... 470
Burns GL (abst) ... 261, 274
Burns V (abst) ... 250
Burschenfelde KH (abst) ... 340
Bursten S (abst) ... 314, 320
Bush JV *See* Caruana RJ ... 1351
Bushinsky D (abst) ... 343, 351, 360, 361
Bushinsky DA (abst) ... 346
Bushman M (abst) ... 206
Buss W (abst) ... 364
Bussel A (abst) ... 258
Busutil R (abst) ... 213
Busuttil RW (abst) ... 195
Buszta C (abst) ... 468
Butkowski RJ (abst) ... 206
Butkowski RJ *See* Fliger FD ... 800
Butler D (abst) ... 262
Butler-Simon N *See* Sedman A ... 1000
Butt KMH (abst) ... 205, 466, 469
Bygren P, Wieslander J, Heineguard D: Glomerulonephritis induced in sheep by immunization with human glomerular basement membrane (Laboratory Investigation) ... 25
Cadnapaphornchai P (abst) ... 1621, 70
Caflisch CR (abst) ... 407
Calcagno PL (abst) ... 286, 310
Calvet JP (abst) ... 163
Cam G (abst) ... 218, 229
Camargo MJF (abst) ... 269
Cambon N *See* Bastin J ... 1239
Cameron JS (abst) ... 335
Cameron JS *See* Nolasco FEB ... 1160
Campbell C (abst) ... 313
Campbell J (abst) ... 229
Campbell PJ (abst) ... 262

Campbell RA (abst) 381
Campbell W (abst) 263, 272
Campbell WG Jr (abst) 219
Campese VM (abst) 295, 342
Camussi G (abst) 314
Candiano G (abst) 199, 200
Canessa M (abst) 388
Canin J (abst) 451
Cannon M (abst) 263
Cantiello HF (abst) 162, 280, 431
Cantin M *See* Vinay P 946
Canzanello V (abst) 192
Capasso G (abst) 365
Capdevila J (abst) 269, 289
Capodicasa G (abst) 193, 344
Capperrelli A (abst) 343
Caramelo C (abst) 211, 291
Carbone G (abst) 464
Carbone L (abst) 193, 336
Carbonell LF (abst) 263
Cardella CJ (abst) 455
Carlson JE (abst) 297
Carmines PK *See* Navar G S-81
Carmines PK, Perry MD, Hazelrig JB, Navar LG: Effects of preglomerular and postglomerular vascular resistance alteration on filtration fraction S-229
Carney K (abst) 454
Carone FA (abst) 212, 383, 392
Carpenter CB (abst) 466, 467
Carpi-Medina P (abst) 444
Carr DJ (abst) 227
Carr DR (abst) 456
Carr M (abst) 193
Carretero OA (abst) 263, 281, 419
Carroll HJ (abst) 212
Cartwright-Brown D (abst) 222
Caruana RJ (abst) 193
Caruana RJ, Raja RM, Bush JV, Kramer MS, Goldstein SJ: Heparin free dialysis: Comparative data and results in high risk patients (Clinical Investigation) .. 1351
Carvalho JS (abst) 263
Carvounis CP (abst) 343
Casado S (abst) 211
Casanova P *See* Robert A 830
Casellas D (abst) 421
Casellas D *See* Mimran A S-57
Castellazzo T (abst) 315
Castiglione A (abst) 337
Cataland S (abst) 210
Cataldo J (abst) 326
Catheline M (abst) 229
Catt KJ *See* Mendelsohn FAO S-40
Cavaleiro AMS (abst) 395
Cavallo T (abst) 321, 331
Caverle Y (abst) 229
Centor R (abst) 218
Cerda J (abst) 315
Ceremeno JL (abst) 295
Chabala J (abst) 343
Chabardes D (abst) 262
Chabardges D *See* Morel F 512
Chafe L (abst) 347
Chagnac A (abst) 194
Chaimovitz C (abst) 249
Chakrabarti E (abst) 252
Challoner-Hue L (abst) 288
Challoner-Hue L *See* Steele TH 941
Chalmers KE (abst) 316
Chalopin JM (abst) 1416
Chambers C (abst) 266
Chambers PJ (abst) 360
Chami J (abst) 341
Chan AYM (abst) 381
Chan L (abst) 371, 375, 381, 398, 401, 464
Chan M (abst) 342
Chan YL (abst) 291
Chandan R (abst) 365
Chander P (abst) 315, 335
Chandler JT (abst) 229
Chandra M (abst) 332
Chang CS (abst) 407
Chang H (abst) 431
Chang L (abst) 181
Chang YM (abst) 305
Chansel D *See* Ardaillou R S-74
Chapuy P (abst) 345, 353
Charney AN (abst) 433
Chase H (abst) 162
Chatelet F (abst) 327, 329, 401
Chatziconstantinou V (abst) 865
Chaudhari A (abst) 163, 264, 275
Chaudhary B (abst) 193
Chazan JA (abst) 229, 245
Chebotareva VD (abst) 335
Checkley L (abst) 350
Cheeks C (abst) 364, 365
Cheema-Dhadli S (abst) 396
Cheigh J (abst) 467, 469
Cheigh JS (abst) 296, 455
Chen A (abst) 323
Chen C (abst) 205, 461
Chen CB (abst) 443
Chen P-Y (abst) 437, 444
Chen T (abst) 355
Chen TC (abst) 264
Chen Y-P (abst) 265, 288, 313, 312
Chen YP *See* Stahl RAK 1126
Cheng HF (abst) 335
Cheng ML (abst) 381
Chenoweth DE *See* Lewis SL 112
Chesney RW (abst) 452
Cheung AK (abst) 230, 241
Cheung AK, Baranowski RL, Wayman AL: The role of thromboxane in cuprophan-induced pulmonary hypertension (Laboratory Investigation) 1072
Cheung JY (abst) 264
Chevalier RL (abst) 421
Chezzi PM (abst) 870
Chiang M (abst) 336
Chimochowski G (abst) 230
Chinitz JL (abst) 194
Chiu AS (abst) 249
Chobanian MC (abst) 396
Chocair PR (abst) 455, 459
Choi K-C (abst) 212
Cholevas G (abst) 870
Choremi H (abst) 862
Chou S-T *See* Mendelsohn FAO S-40
Chou SY (abst) 264
Choudat L *See* Michel J-B S-168

Chretien P (abst) 217
Christiansen JS *See* Jensen PK 47
Christlieb AR (abst) 207, 388
Christodoulidou C (abst) 870
Christodoulou S (abst) 868, 871
Christodulidou K (abst) 865
Christodulou S (abst) 869
Christopher TG (abst) 194
Chung DC (abst) 175
Churchill DN (abst) 230
Churg J (abst) 269
Chusid P (abst) 206
Ciabatonni G (abst) 283
Cielinski DA (abst) 371
Cieslinski D (abst) 372
Cieslinski DA (abst) 323, 366
Cinotti GA (abst) 283
Civardi R (abst) 339
Civitelli R (abst) 356
Civitelli R *See* Reid IR 1113
Clapp W (abst) 417
Clapp WL, Madsen KM, Verlander JW, Tisher CC: Intercalated cells of the rat inner medullary collecting duct (Laboratory Investigation) 1080
Clardy C (abst) 455
Clark M (abst) 397
Clark WF (abst) 316
Claus H (abst) 296
Clausen C (abst) 164
Clavdianos E (abst) 868
Clayberger C (abst) 461
Clayman M (abst) 183
Clayman MD (abst) 316, 322
Cleland JGF, Dargie HJ: Heart failure, renal function, and angiotensin converting enzyme inhibitors S-220
Clemens M (abst) 168
Clementi RA *See* Fruncillo RJ S-117
Clemons GK *See* Walle AJ 1205
Click R (abst) 294
Clowers B (abst) 251
Coachman D (abst) 164
Coburn JW (abst) 214, 245, 349, 357
Coburn JW *See* Andress DL 1244
Cody RJ (abst) 282
Cody RP (abst) 247
Coe F (abst) 209, 359, 361
Coe FL (abst) 176, 325, 352
Coelho A *See* Nolasco FEB 1160
Coffmann TM (abst) 456
Cogan MG (abst) 412
Cogan MG *See* Jaschke W 1038
Cogan MG *See* Hernandez RE 1356
Cohen A (abst) 198, 288
Cohen AH (abst) 158, 213, 336, 389
Cohen BH (abst) 249
Cohen DJ (abst) 454, 456
Cohen E (abst) 230
Cohen RA (abst) 366
Cohen S (abst) 261
Coil J (abst) 211
Cole LA (abst) 400
Collart F (abst) 231
Collins A (abst) 235
Collins B (abst) 338
Collins R (abst) 265, 419
Colman J *See* Hernandez RE 1356
Colombe BW (abst) 457
Colonna JO II (abst) 195
Colsanti G (abst) 339
Colucci R *See* Wilcox CS 135
Columbe B (abst) 453
Colvin RB (abst) 463
Comesanas M (abst) 464
Comtois R (abst) 194
Condamin MC (abst) 210
Conger J (abst) 374
Conger JD (abst) 381
Conger JD *See* Kelleher SP 725
Conrad KP (abst) 421
Conroy JD (abst) 194
Conroy JF (abst) 194
Constantellou E (abst) 868
Constantine JM (abst) 264
Conti FG (abst) 163
Contiguglia R (abst) 247
Convery ME (abst) 460
Cook T (abst) 489
Coombs J (abst) 376
Cooperberg C (abst) 245
Copeland J (abst) 202
Copley JB (abst) 344
Corbett ML (abst) 292
Cordova HR (abst) 265
Cornejo M (abst) 431
Corry DB (abst) 382
Cortes P (abst) 396, 397
Coruzzi P (abst) 304
Corvol P *See* Michel J-B S-168
Corwin HL (abst) 195, 219
Cosby RL (abst) 195
Cosio F (abst) 316
Cosio FG (abst) 210, 227, 465
Cosio FG *See* Hebert LA 877
Costello J (abst) 311
Costello JF (abst) 382
Costoyianni G (abst) 868
Cotran RS (abst) 322
Coulson R (abst) 186, 265, 343
Cournot-Witmer G *See* Bourdeau AM 15
Cournot-Witmer G *See* Lieberherr M 736
Cournoyer G *See* Vinay P 1194
Couser WG (abst) 265, 288, 312, 313, 315, 329
Couser WG *See* Stahl RAK 1126
Cowley BD Jr (abst) 163
Cox M (abst) 177, 183, 186
Crabos M (abst) 431, 435
Cragoe EJ (abst) 414
Cragoe EJ Jr (abst) 168, 184
Crews B (abst) 266
Cristopoulos S (abst) 869
Crocker JFS (abst) 316
Crocker JFS, Blecher SR, Givner ML, McCarthy SC: Polycystic kidney and liver disease and corticosterone changes in the *cpk* mouse (Laboratory Investigation) 1088
Cronin RE (abst) 376
Cronin W (abst) 317
Crooke E (abst) 160
Crouch EC (abst) 342
Crowell W (abst) 380

Cullen P (abst) 296
Culpepper RM (abst) 401
Cunningham EE (abst) 249
Cuny C (abst) 274
Cupples WA (abst) 421
Curd JG *See* Wyatt RJ 1019
Curtis JJ (abst) 266
Curtis WS (abst) 274
Cusano AJ (abst) 195
Cushner HM (abst) 344
Cutler JA (abst) 453
Cybulsky AV (abst) 317, 328
D'Amico G (abst) 337, 339
D'Agati V (abst) 193, 336
D'Elia JA (abst) 207
D'Haenens P (abst) 1417
D'Haese PC (abst) 196, 344
Dabbagh S (abst) 344
Dafnis E (abst) 862, 869, 871
Dagan D (abst) 174
Daha MR (abst) 1043, 1047
Daniel TO (abst) 169
Daniilidis M (abst) 870
Danovitch GM (abst) 195, 211, 471
Dargie HJ *See* Cleland JGF S-220
Darmon D (abst) 347
Darzynkiewicz Z (abst) 470
Dass P (abst) 341, 348
Dass PD (abst) 397
Daugirdas JT (abst) 234, 237, 243, 250
Davidman M (abst) 196
Davidson KK (abst) 412
Davidson WD (abst) 158
Davies M *See* Davin J-C 32
Davies RK (abst) 232
Davillas N (abst) 867
Davin J-C, Malaise M, Foidart J, Mahieu P: Anti-α-galactosyl antibodies and immune complexes in children with Henoch-Schönlein purpura or IgA nephropathy (Clinical Investigation) 1132
Davin J-C, Davies M, Foidart J-M, Foidart JB, Dechenne CA, Mahieu PR: Urinary excretion of neutral proteinases in nephrotic rats with a glomerular disease (Laboratory Investigation) 32
Davis CL (abst) 445
Davis FB (abst) 266
Davis J (abst) 218
Davis JA (abst) 185, 397
Davis L (abst) 416
Davis LJ (abst) 176
Davis PJ (abst) 266
Davis TA (abst) 386
Dawidson I (abst) 459, 468
de Abreu R (abst) 1047
De Bos Kuil RJ (abst) 349, 1048
De Broe ME (abst) 196, 344, 377
De Candido S (abst) 285
De Heer E (abst) 1043
de Jon PE (abst) 1044
de Jon PE *See* Navis G 815
De Jong PE (abst) 273, 296, 1049
De Keijzer MH (abst) 1045
De Koster E (abst) 231
De Meyer M (abst) 1418
de Moor EAM (abst) 1048
de Rouffignac C, Jamison RL: Symposium introduction (Introduction) 501
de Rouffignac C, Elalouf J-M, Roinel N: Physiological control of the urinary concentrating mechanism by peptide hormones 611
De Santo NG (abst) 193, 365
De Smet R (abst) 221
De Vernejoul MC (abst) 238, 345, 353, 354
de Vernejoul M-C *See* London GM 873
de Vos D (abst) 1047
de Vries PMJM (abst) 1046
De Zeeuw D (abst) 273, 296, 299, 1044, 1049
de Zeeuw D *See* Navis G 815
Deane N (abst) 196
Dechaux M (abst) 266, 424
Dechenne CA *See* Davin J-C 32
Deelder AM *See* Sobh MA 1006
Deen WM *See* McNeely EZ 662
Degoulet P *See* Vinay P 1194
Del Greco F (abst) 244
Delahousse M (abst) 407
Delaini F (abst) 267, 283
Delaney V (abst) 397
Delaney VB (abst) 191, 397
Delarue F (abst) 172
Deleon C (abst) 450
Delfino G (abst) 199, 200
Delgado F (abst) 196
Delidi A (abst) 871
Delidis G (abst) 871
Delmez JA (abst) 382
Delmez JA, Dougan CS, Gearing BK, Rothstein M, Windus DW, Rapp N, Slatopolsky E: The effects of intraperitoneal calcitriol on calcium and parathyroid hormone (Clinical Investigation) 795
Dennis PA (abst) 240
Dennis PM (abst) 426
Dennis VW (abst) 160, 178, 356
Depriest D (abst) 265
Derderian R (abst) 164
Derkx FHM *See* Wenting GJ S-180
Desai H (abst) 294
Desanto NG (abst) 344
Descamps B (abst) 248
Deschodt G (abst) 245
Desjeux J-F (abst) 302
Deslarzes C (abst) 204
Devarajan P (abst) 366
Devney P (abst) 456
DeVore KW *See* Leypoldt JK 855
Dewitt C (abst) 452
Dhaene M (abst) 382
Di Bona GF (abst) 300
Di Fabio B (abst) 308
Di Micco JA (abst) 311
Di Pette D (abst) 311
Diamandopoulos A (abst) 871
Diamond BA (abst) 336
Diamond JR (abst) 379, 383
Diamond S (abst) 231
Diavidovitch-Consta H (abst) 864
Diaz JB (abst) 344
Diaz-Buxo JA (abst) 229
Dibona GF (abst) 285, 425
Dickman K (abst) 163

Dicorleto P (abst) 158, 175, 182
Diderich PhPNM (abst) 1046
Diethelm AG (abst) 266
Dietrick J (abst) 242
Digenis G (abst) 378
Digenis GF (abst) 862
Digenis G (abst) 864
Diiorio B (abst) 344
Dilillo D (abst) 409
Dillingham MA (abst) 257, 445
Dimitriadis A (abst) 861, 865, 866
Dimitriadou-Vafiadou A (abst) 871
Dimopoulos C (abst) 871
Dinarello CA (abst) 237, 238, 242, 245
Ding G (abst) 164
Ding G *See* Hays RM 530
Dinh N (abst) 234
Diraimondo CR (abst) 197
Dirks JH (abst) 360
Disbrow MR (abst) 380
Discala VA (abst) 447
Divincenzo C (abst) 339
Dixon BS (abst) 164
Dixon TE (abst) 164
Dobbie J (abst) 250
Dobrota M *See* Andersen K-J 886
Dolson GM (abst) 31
Dombros N (abst) 861
Dominguez JH (abst) 284, 345
Don BR (abst) 267
Donadio JV Jr (abst) 197
Donadio JV *See* Torres VE 1383
Donga J *See* Bakker WW 704
Donker AbJM: Nephrotoxicity of angiotensin converting enzyme inhibition S-132
Donker AJM (abst) 197, 255, 1044, 1046, 1050
Donker AJM *See* Navis G 815
Donoso V (abst) 383
Donoso VS *See* Birenboim N 85
Dorhout Mees EJ (abst) 349, 430, 433, 437, 1048, 1049
Doroshow J (abst) 220
Dosa S (abst) 297
Dougan CS *See* Delmez JA 795
Doulouridis E (abst) 865
Douma S (abst) 869
Doumas L (abst) 865, 868
Dourakis S (abst) 866
Dousa TP (abst) 183, 188, 270, 273, 358, 359
Downer G (abst) 317
Downing MR (abst) 198
Dratwa M (abst) 21
Dreuke T (abst) 308
Drew H (abst) 224
Drewnowska K (abst) 164
Drezner MK (abst) 356
Drif M (abst) 207
Drueke T (abst) 248, 302, 303, 345, 352, 1418
Druet P (abst) 328
Druml W (abst) 383
Dubb J (abst) 367
Dubinsky WP (abst) 186
Dubose TD Jr (abst) 407
Dubyak GR (abst) 175, 258, 267
Duckworth WC (abst) 398
Dudley H (abst) 225
Dudley MA (abst) 440
Duipmans J (abst) 1050
Duley I (abst) 197, 297
Dumler F (abst) 229, 238, 396, 397
Duncan RL (abst) 268
Dunn BR *See* Zatz R S-123
Dunn MJ (abst) 175, 258, 267, 273, 291, 308, 328
Dunn MJ, Scharschmidt LA: Prostaglandins modulate the glomerular actions of angiotensin II S-95
Dunn MJ *See* Rahman MA 1317
Dunn S (abst) 251
Durand L (abst) 1418
Durham B (abst) 467
Durr J (abst) 295
Durr JA (abst) 189, 195, 198
Durrant J (abst) 255
Dusing R (abst) 171, 268, 391
Dussaule J-C *See* Michel J-B S-168
Dusso A (abst) 345
Duursma SA (abst) 349, 1048
Dweinberg JM (abst) 449
Dworkin L (abst) 379, 383
Dworkin LD, Feiner HD, Randazzo J: Glomerular hypertension and injury in desoxycorticosterone-salt rats on antihypertensive therapy (Laboratory Investigation) 718
Dytko G (abst) 275
Dzau VJ (abst) 268
Dzau VJ *See* Levenson DJ S-173
Dzau VJ: Renal and circulatory mechanisms in congestive heart failure (Nephrology Forum) 1402
Dzau VJ: Renin-angiotensin system and renal circulation in clinical congestive heart failure S-203
Eastwood JB (abst) 865
Ebihara I (abst) 165, 171
Eby B (abst) 310, 346
Eby SR (abst) 398
Ecelman A (abst) 413
Echard T (abst) 227
Eckrich W (abst) 242
Economidou J (abst) 862, 863
Eddy A (abst) 317
Edelman A (abst) 442
Edipidis K (abst) 863, 864
Edwards BR *See* Valtin H 634
Edwards BS (abst) 268, 280, 286, 293
Edwards RM (abst) 270, 422
Eggena P (abst) 303
Egnor R (abst) 433
Egrie JC (abst) 198
Ehmann U (abst) 187
Ehrich JHH (abst) 1047
Eisner GM (abst) 286
Ekaterini D (abst) 864
Ekaterini E (abst) 864
El Kaki A (abst) 379
Elalouf J-M *See* de Rouffignac C 611
Elan I (abst) 251
Eldor A (abst) 400
Eldredge C (abst) 318, 333
Eleftherieadis E (abst) 867
Elema JD (abst) 1043
El-Housseini F *See* Sobh MA 1006
Elliot SJ (abst) 165, 172
Elliott WC (abst) 366, 369

Ellis D (abst) 159, 165
Ellis K (abst) 205
Ellison DH (abst) 432
Ellison KE (abst) 268
Elseviers MM (abst) 196
Elzinga L (abst) 193, 211, 367
Emancipator S (abst) 180
Emancipator SN (abst) 324, 328, 331
Emancipator SN *See* Rahman MA 1317
Emmanouel D (abst) 870
Endres DB *See* Andress DL 1244
Engbretson BG (abst) 32
English J (abst) 367, 368
Epley M (abst) 344
Epstein A (abst) 165
Epstein FH (abst) 367, 374, 376
Epstein M (abst) 269, 277
Ercolani L (abst) 166
Erduos EG *See* Skidgel RA S-45
Erik A (abst) 420, 421
Erikson M (abst) 338
Erlij D (abst) 451
Ernest M (abst) 204
Eschbach JW (abst) 198
Espidel J (abst) 444
Etcheverry J (abst) 443
Evan AP (abst) 383, 384, 385
Evan AP *See* Grantham JJ 1145
Evans D (abst) 234
Evans G (abst) 393
Evans M (abst) 235
Eveloff J (abst) 432
Fabiani F (abst) 238
Fabiani F *See* London GM 873
Fadda G (abst) 384
Fain P (abst) 206
Fakhry I (abst) 218
Falardeau P (abst) 269
Falcao H (abst) 231
Falck JR (abst) 269, 289
Falk RJ (abst) 318, 327, 337
Falk SA (abst) 381
Faller DV (abst) 312
Faltsis S (abst) 865
Famiglio M (abst) 373
Fanestil DD (abst) 278
Fanti P (abst) 246, 346, 353
Fardin R (abst) 230
Farmer CD (abst) 229
Farquhar MG (abst) 170
Farraggiana T (abst) 269
Faugere MC (abst) 246, 346, 353
Faure M (abst) 440
Favus M (abst) 351, 360
Favus MJ (abst) 352
Fawzy A (abst) 453
Feduska N (abst) 453
Feduska NJ (abst) 456
Feguson CW (abst) 231
Feig PU (abst) 296
Feiglin D (abst) 468
Feiner H (abst) 383
Feiner HD (abst) 198
Feiner HD *See* Dworkin LD 718
Feiner HD *See* Baldwin DS 790
Feingold R (abst) 378
Fejes-Toth G (abst) 166, 281
Feld LG (abst) 297
Felder C (abst) 166, 175
Felder RA (abst) 432
Feldman GM (abst) 407
Felicetta J (abst) 294
Fellin G (abst) 339
Fellner SK (abst) 227, 346
Felsen D (abst) 292, 394
Felsenfeld AJ *See* Rodriguez M 766
Felts J *See* Kaysen GA 1368
Fennell SA (abst) 305
Ferguson RK *See* Fruncillo RJ S-117
Ferguson RM (abst) 465
Fernandes G (abst) 318
Fernandez-Repollet E (abst) 422, 449
Ferrari C (abst) 395
Ferraro J (abst) 311
Ferrier C *See* Bianchetti MG 956
Ferriozzi S (abst) 283
Ferris TF (abst) 466
Fertman S (abst) 465
Fiallo A (abst) 261
Fiegel P (abst) 244
Field JB (abst) 179
Figueroa CD *See* Vaio CP 1327
Filburn CR (abst) 346
Fildes RD (abst) 422
Fillastre J-P *See* Marche P 59
Filly RA (abst) 470
Finch JL *See* Martin KJ 937
Finco D (abst) 380
Fine A (abst) 422
Fine BP (abst) 271
Fine LG (abst) 177, 180, 198, 428
Fine M (abst) 428
Fine RN (abst) 213, 251, 255, 357
Fink M (abst) 372
First M (abst) 455
Fischmann G (abst) 177
Fish AJ (abst) 206, 319
Fisher DA (abst) 259
Fisher JW (abst) 290
Fisher RS (abst) 373
Fitz A (abst) 301
Fitzsimmons E (abst) 244
Fivush BA (abst) 373
Flanigan MJ *See* Lim VS 808
Fleischer B (abst) 436
Fleischer S (abst) 436
Fleischmann LR (abst) 302
Fleming JT *See* Steinhausen M S-64
Fletcher AP *See* Alkjaersig N 772
Fleuren GJ (abst) 1043, 1047
Fliger FD, Wieslander J, Brentijens JR, Andres GA, Butkowski RJ: Identification of a target antigen in human anti-tubular basement membrane nephritis (Clinical Investigation) 800
Flora S (abst) 864
Floyd-Gimon D (abst) 294
Foegh ML (abst) 453, 457
Foellmer HG (abst) 318
Fogo A (abst) 384, 394, 424
Foidar JM (abst) 1047

Foidart J *See* Davin J-C . . . 1132
Foidart JB *See* Davin J-C . . . 32
Foidart J-M *See* Davin J-C . . . 32
Foley J (abst) . . . 357
Fonk T (abst) . . . 1050
Fonteyne E (abst) . . . 1417
Forman SJ (abst) . . . 297
Fornasieri A (abst) . . . 337, 339
Forrest JN Jr (abst) . . . 185, 274
Forshey K (abst) . . . 331
Foster SJ (abst) . . . 319
Fotino M (abst) . . . 455
Foulks CJ (abst) . . . 344
Fournier A (abst) . . . 1417
Fouser LS (abst) . . . 319
Fowler B (abst) . . . 193
Fracasso A (abst) . . . 250, 447
Fracasso AR (abst) . . . 338
Franco M (abst) . . . 423
Francos GC (abst) . . . 233
Frank B (abst) . . . 187
Franki N (abst) . . . 164
Franki N *See* Hays RM . . . 530
Franklin JO (abst) . . . 248
Fraser C (abst) . . . 347
Fraser CL (abst) . . . 190
Fredericks M (abst) . . . 367, 448
Freeman RH (abst) . . . 291
Freeman RM *See* Lim VS . . . 808
Freiberg JM (abst) . . . 219
Freitag JJ (abst) . . . 270
Fried TA (abst) . . . 261
Friedenberg D (abst) . . . 389
Friedenberg DS (abst) . . . 423
Friedlaender MM (abst) . . . 347
Friedlander G (abst) . . . 166, 418
Friedler RM (abst) . . . 353, 354
Friedman AL (abst) . . . 384
Friedman EA (abst) . . . 199, 214, 238, 466
Fries JWU (abst) . . . 312, 319, 392
Frigon R (abst) . . . 448
Frigon RP (abst) . . . 249
Frigon RP *See* Leypoldt JK . . . 855
Frock J (abst) . . . 250
Frohnert PP *See* Torres VE . . . 1383
Fruncillo RJ, Rocci ML Jr, Vlasses PH, Mojaverian P, Shepley K, Clementi RA, Oren A, Smith RD, Till AE, Riley LJ Jr, Krishna G, Narins RG, Ferguson RK: Disposition of enalapril and enalaprilat in renal insufficiency . . . S-117
Fry B (abst) . . . 416
Fryd D (abst) . . . 458
Frymoyer PA (abst) . . . 319
Fuchs E (abst) . . . 294
Fujihara CK (abst) . . . 395, 423
Fujiwara Y (abst) . . . 275
Fukatsu A (abst) . . . 320, 338
Fukuhara Y (abst) . . . 368, 399
Fusco MJ (abst) . . . 446
Gabbai F (abst) . . . 295
Gabbai FB *See* Blantz RC . . . S-108
Gabbai FB, Gushwa LC, Wilson CB, Blantz RC: An evaluation of the development of experimental membranous nephropathy (Laboratory Investigation) . . . 1267
Gabow P (abst) . . . 186, 197, 204, 206, 295
Gabow PA (abst) . . . 203, 297
Gabow P *See* Sedman A . . . 1000
Gafter U (abst) . . . 194, 347, 388
Gagnon R (abst) . . . 320
Gagnon RF (abst) . . . 320
Gaillard C (abst) . . . 433, 1049
Gaines JP (abst) . . . 401
Galicka-Piskorska G (abst) . . . 367
Galla JH (abst) . . . 337, 417, 433
Gallet B (abst) . . . 1416
Gallimore B (abst) . . . 320
Galvao MM (abst) . . . 459
Gambertoglio JG (abst) . . . 423
Gambertoglio J *See* Kaysen GA . . . 1368
Gamboa E (abst) . . . 467
Gandhi VC (abst) . . . 237, 243, 250
Ganz M (abst) . . . 161
Gapstur S (abst) . . . 273
Gapstur SM (abst) . . . 270
Garber J (abst) . . . 250
Garbis S (abst) . . . 865
Garcia DL (abst) . . . 385
Garcia JC (abst) . . . 260
Garcia JF *See* Walle AJ . . . 1205
Garcia-Robles R (abst) . . . 309
Gardenswartz MH (abst) . . . 221, 232
Gardikas V (abst) . . . 454
Gardin J-P *See* Patron P . . . 1174
Gardner J (abst) . . . 234
Gardner KD (abst) . . . 383, 395
Gardner P (abst) . . . 247
Gardner PW (abst) . . . 245, 245
Garg LC (abst) . . . 299, 413, 433
Garg LC, Narang N: Effects of hydrochlorothiazide on Na-K-ATPase activity along the rat nephron (Laboratory Investigation) . . . 918
Garovoy M (abst) . . . 453, 456
Garovoy MR (abst) . . . 232, 457
Garrell D (abst) . . . 219
Garretson LT (abst) . . . 170
Garrett BM (abst) . . . 297
Garvin J (abst) . . . 408
Garvin P (abst) . . . 454
Gattone VH (abst) . . . 385
Gaudio K (abst) . . . 376, 402
Gaughan W (abst) . . . 247
Gault H (abst) . . . 347
Gault MH (abst) . . . 240
Gauthier B (abst) . . . 199, 220
Gavellas G (abst) . . . 380
Gavin JR III (abst) . . . 169
Gearing BK *See* Delmez JA . . . 795
Geary DF (abst) . . . 385
Gee DC *See* Hooke DH . . . 964
Gee W (abst) . . . 167
Geer P (abst) . . . 270
Geering K (abst) . . . 186
Geiser JL (abst) . . . 384
Geiser JL *See* Grantham JJ . . . 1145
Gejyo F (abst) . . . 227
Gellai M (abst) . . . 270
Gemsa D (abst) . . . 228, 320
Genatious M (abst) . . . 868
George GL (abst) . . . 463

Georgiou T (abst) 868
Gerali S (abst) 865
Geratz D (abst) 318
Germann PJ (abst) 289
Geronemus R (abst) 232
Gersh BJ (abst) 286
Gertner J (abst) 354
Geven WB, Monnens LA, Willems HL, Buijs WC, ter Haar BG: Renal magnesium wasting in two families with autosomal dominant inheritance (Clinical Investigation) 1140
Ghandi VC (abst) 234
Gheerbrand JD (abst) 1417
Ghiggeri GM (abst) 199, 200, 321
Ghoniem MA *See* Sobh MA 1006
Gianella-Neto D (abst) 395
Giangrande A (abst) 348
Giannopoulos A (abst) 871
Gibbons R (abst) 232
Giebel J (abst) 408
Giebisch G (abst) 408, 436, 438, 441, 446, 447
Gifford JD (abst) 199
Gilbert D (abst) 211
Gilbert P *See* Minuth WW 1104
Gill J (abst) 200
Gill JC (abst) 217
Gilli P (abst) 226
Gilligan JM *See* Goodman WG 923
Gillis K (abst) 167
Gillum D (abst) 463
Gimenez LF, Solez K, Walker WG: Relation between renal calcium content and renal impairment in 246 human renal biopsies (Clinical Investigation) 93
Ginalski JM (abst) 204
Ginevri (abst) 199, 200, 321
Giocondi MC (abst) 166
Giordano C (abst) 193
Giordano D (abst) 365
Girard A *See* Marche P 59
Gitelman HJ (abst) 356
Gittlen S (abst) 233
Giuliano RA (abst) 377
Givens G (abst) 417
Givner ML *See* Crocker JFS 1088
Glas-Greenwalt P (abst) 222, 337
Glassock RJ (abst) 158
Glebova LP (abst) 335
Gleich GJ (abst) 339
Gleim GW (abst) 221, 232
Glennie J (abst) 458
Glick A (abst) 384, 394, 424
Glicklich D (abst) 200
Glickman JL (abst) 189
Gluck M (abst) 198
Gluck M *See* Baldwin DS 790
Gluck S (abst) 162, 167, 169
Glurich I (abst) 315, 321
Go R (abst) 468
Goddu KJ (abst) 448
Goetz CG (abst) 219
Goetz KL (abst) 260, 270
Gogelein H (abst) 435
Guogelein H *See* Greger R 1055
Golchini K (abst) 408, 414
Goldberg M (abst) 471
Goldfarb D (abst) 434
Goldfarb DS (abst) 433
Goldfarb S (abst) 387
Goldfinger JM (abst) 445
Goldstein SJ (abst) 236, 253
Goldstein SJ *See* Caruana RJ 1351
Goldszer R (abst) 300
Goligorsky MS (abst) 167, 356
Golper T (abst) 211, 226, 233, 255, 256
Golper TA (abst) 193, 200
Gomez RA (abst) 421
Gonzalez F (abst) 461
Gonzalez MF (abst) 215
Good DW (abst) 408
Goodman AI (abst) 175, 315
Goodman HM (abst) 166
Goodman R (abst) 387
Goodman WG (abst) 357
Goodman WG, Gilligan JM: Thyroparathyroidectomy modifies the skeletal response to aluminum loading in the rat (Laboratory Investigation) 923
Goodyer C (abst) 167
Goodyer PR (abst) 167
Goranfio G (abst) 279
Gordon B (abst) 340
Gordon JA (abst) 457
Gordon WG (abst) 222
Gorfien J (abst) 327
Gotch F (abst) 232, 235
Gotloib L (abst) 253
Gottschalk CW: History of the urinary concentrating mechanism (Introduction) 507
Gougoux A (abst) 403
Gougoux A *See* Vinay P 1194
Gougoux A *See* Vinay P 946
Gougoux A, Vinay P, Zizian L, Tejedor A, Noel J: Effect of acetazolamide on renal metabolism and ammoniagenesis in the dog (Laboratory Investigation) 1279
Gould R *See* Jaschke W 1038
Gourgiotis D (abst) 863
Goyal S (abst) 233
Graber M (abst) 409, 413
Grace M (abst) 250
Grady RW (abst) 281
Graf H (abst) 233
Granger JP (abst) 434
Granger JP *See* Ruilope LM 992
Granholm NA (abst) 321
Granolleras C (abst) 245, 1418
Grantham J (abst) 385
Grantham JA (abst) 184
Grantham JJ (abst) 163, 184, 383, 384
Grantham JJ *See* Birenboim N 85
Grantham JJ, Geiser JL, Evan AP: Cyst formation and growth in autosomal dominant polycystic kidney disease (Clinical Investigation) 1145
Grassl SM (abst) 409
Gratton C (abst) 250
Graves K (abst) 321
Gray RW (abst) 353
Green BJ (abst) 219
Green J (abst) 273
Green R (abst) 357, 446
Green T (abst) 233

Green W (abst) 465
Green WF (abst) 457
Greenberg A (abst) 302
Greene ER (abst) 419
Greger R (abst) 174, 435
Greger R, Guogelein H: Role of K^{pr} conductive pathways in the nephron (Editorial Review) 1055
Greger R, Velázquez H: The cortical thick ascending limb and early distal convoluted tubule in the urinary concentrating mechanism 590
Grekas D (abst) 863, 868, 871
Grennan D (abst) 337
Gresser I (abst) 463
Griffiths S (abst) 347
Griffiths SM (abst) 240
Grillo C (abst) 298
Griswold WR (abst) 467
Groene E (abst) 168
Groene HJ (abst) 168
Groggel GC (abst) 321, 389
Grond J (abst) 1043
Grooms P (abst) 382
Gross P *See* Minuth WW 1104
Grosse B *See* Lieberherr M 736
Grosser M (abst) 383
Grossman EB (abst) 434
Groszmann RJ (abst) 420
Gruber S (abst) 458
Grupp C (abst) 402
Grushkin C (abst) 470
Gruskin AB (abst) 302
Gruson M (abst) 354
Grynoch R (abst) 250
Grzyboski C (abst) 281
Gubler M-C *See* Mounier F 121
Guerin A (abst) 238
Guerin AP *See* London GM 873
Guggino SE (abst) 348, 431
Guggino WB (abst) 431, 434
Gugliotta J-E *See* Robert A 830
Guidi E (abst) 298
Guittierez A (abst) 189
Gullans SR (abst) 406
Gung A (abst) 363
Gunning M (abst) 271
Gunther J (abst) 322
Gunther RD (abst) 168
Guntupalli J (abst) 341, 348
Gupta SK (abst) 272
Gurich RW (abst) 168
Gushwa LC (abst) 386
Gushwa LC *See* Gabbai FB 1267
Gusmano R (abst) 199, 200
Gutierrez ML (abst) 221
Gutjahr E (abst) 372
Gutterman C (abst) 230, 454
Guzman NJ *See* Wilcox CS 135
Guzzetta P (abst) 233
Gyftaki H (abst) 865
Haakenstad AO (abst) 322
Haas J (abst) 300
Haas JA (abst) 212, 434
Haas M (abst) 171
Hackenthal E, Metz R, Bührle CP, Taugner R: Intrarenal and intracellular distribution of renin and angiotensin S-4
Haddad A (abst) 445
Hadeed A *See* Siegel SR 1181
Hadjiagapiou C (abst) 457
Hadjigeorgiou G (abst) 870
Haga H-J *See* Andersen K-J 886
Hagen K (abst) 186
Haggerty JG (abst) 168
Hainline B (abst) 341
Hakia RM (abst) 234, 239
Hakim R (abst) 245
Halasz NA (abst) 467
Hall CE (abst) 370
Hall J (abst) 427
Hall TL (abst) 251
Halperin ML (abst) 209, 224, 396, 443
Halperin R (abst) 224
Halstenson CE (abst) 189, 212
Halttunen J *See* Leszczynski D 1311
Hamm L (abst) 394, 398, 409, 444
Hamm LL (abst) 416
Hammerman MR (abst) 169, 396
Hammond WS *See* Harris DCH 41
Hamrick RM III (abst) 239
Han DC (abst) 248, 388
Hanai H (abst) 348
Hancock W (abst) 322
Handler JS (abst) 169
Handwerger BS (abst) 471
Hanlon S (abst) 298, 310
Hanna D (abst) 264
Hanna J (abst) 200
Hano J (abst) 190, 339, 388
Hansch GM (abst) 228, 322
Hansen G (abst) 235
Hansen VA (abst) 396
Hara Y (abst) 386
Haramati A (abst) 355
Haramti A (abst) 349
Hardisty RM *See* Vermylen CG 1396
Hardonk MJ (abst) 1045
Hardonk MJ *See* Bakker WW 704
Hardy MA (abst) 454, 456
Hardy MJ (abst) 201
Hariprasad MK (abst) 201
Harley F (abst) 250
Harnett J (abst) 347
Harnett JD (abst) 240
Harp RJ (abst) 370
Harper P (abst) 172
Harrah J (abst) 202
Harrington R (abst) 227, 413
Harris DCH (abst) 381, 391, 398
Harris DCH, Hammond WS, Burke TJ, Schrier RW: Verapamil protects against progression of experimental chronic renal failure (Laboratory Investigation) 41
Harris HW Jr (abst) 169
Harris RC (abst) 435, 439
Harrison S (abst) 346
Hartley B (abst) 335
Hartley B *See* Nolasco FEB 1160
Hartwig J (abst) 162
Harvey JA (abst) 362
Hasbargen JA *See* Molitoris BA 986

Haschemeyer RH (abst) 458, 467
Haschmeyer R (abst) 296, 469
Haskell L (abst) 414
Hatori N (abst) 271
Hatseras S (abst) 407
Hatton D (abst) 298, 304
Hatziconstantinou V (abst) 867, 868
Hatzidimitriou C (abst) 861
Hatzidimitriou H (abst) 868
Hauck D (abst) 331
Haupert GT (abst) 435
Hawkins E (abst) 336
Hawkins R (abst) 213, 255
Hawthorne VM (abst) 231, 242
Hayashi M (abst) 271
Hayes JM (abst) 458
Huayry P *See* Leszczynski D 1311
Hays RM (abst) 164, 450
Hays RM, Franki N, Ding G: Effects of antidiuretic hormone on the collecting duct 530
Hays SR (abst) 435
Hayslett JP (abst) 435
Hayslett JP *See* Panese S 1377
Hazelrig JB *See* Carmines PK S-229
Healey J (abst) 341
Heard E (abst) 197, 295, 297
Heard EO *See* Sedman A 1000
Hebel JR (abst) 234
Hebert L (abst) 201
Hebert LA (abst) 210, 227, 465
Hebert LA, Cosio FG: The erythrocyte-immune complex-glomerulonephritis connection in man (Editorial Review) 877
Hebert RL (abst) 271, 283
Hebert SC (abst) 434, 446
Hebert SC, Reeves WB, Molony DA, Andreoli TE: The medullary thick limb: Function and modulation of the single-effect multiplier 580
Heeg JE (abst) 1044
Heidenreich S (abst) 398
Heidland A (abst) 375
Heifets M (abst) 386
Heineguard D *See* Bygren P 25
Helderman J (abst) 458, 468
Helderman JH (abst) 459
Helfrich GB (abst) 453, 457, 459
Hellman RN (abst) 368
Helmchen U (abst) 168
Helmstadter K (abst) 385
Henderson L (abst) 448
Henderson LW (abst) 249
Henderson LW *See* Leypoldt JK 855
Hendler ED, Solomon L: Androgen therapy in hemodialysis patients: I. Effects on red cell oxygen transport (Clinical Investigation) 100
Henae RJ (abst) 1048, 349
Henrich W (abst) 231, 263, 272
Henry MA *See* Ogawa K 760
Henry ML (abst) 465
Hensley GT (abst) 213
Hercz G (abst) 349
Hering-Smith K (abst) 394, 398, 409, 444
Herlitz H (abst) 333
Hermann J (abst) 222, 224
Hermann-Erlee MPM *See* Lieberherr M 736
Hermle M (abst) 380
Hernandez J (abst) 458
Hernandez RE, Schamblelan M, Cogan MG, Colman J, Morris RC Jr, Sebastian A: Dietary NaCl determines severity of potassium depletion-induced metabolic alkalosis (Clinical Investigation) 1356
Hernando L (abst) 211, 291
Herrera-Acosta J (abst) 295
Hertel J (abst) 191, 208
Heublein DM (abst) 286, 293
Heyeraas KJ, Aukland K: Interlobular arterial resistance: Influence of renal arterial pressure and angiotensin II (Laboratory Investigation) 1291
Hiemstra PS (abst) 1047
Higgins JT (abst) 272
Hildebrand DA (abst) 272
Hilden S (abst) 409
Hildreth G (abst) 335
Hildreth G *See* Nolasco FEB 1160
Hill L (abst) 336
Hill S (abst) 223
Himmelfarb J (abst) 234
Himmelstein SI (abst) 272
Hines WH (abst) 322
Hinglais N *See* Mounier F 121
Hinkle DK (abst) 380
Hirsch DJ (abst) 446
Hirsch S (abst) 167, 169
Hirschberg R (abst) 201, 226
Hirsh Y (abst) 194
Hirszel P (abst) 252
Hirtle RWM (abst) 446
Hise MK (abst) 399
Hishida A *See* Honda N 1233
Hizon ML (abst) 202
Ho C (abst) 404
Ho P (abst) 395
Hoch BS (abst) 446
Hodge E (abst) 468
Hoechst AG (abst) 180
Hoedemaeker PhJ (abst) 1043
Hoedemaeker PJ (abst) 314
Hoeldtke R (abst) 206
Hogendoorn PCW (abst) 1043
Hogg RJ (abst) 202
Hogg RJ *See* Malagon M 981
Hoitsma AJ (abst) 1044
Hoitsma A (abst) 1047
Holdsworth SR *See* Boyce NW 8
Hollenberg NK (abst) 436
Holley KE (abst) 197, 212, 339
Holliday M (abst) 202, 214
Holmes T (abst) 245
Holohan PD (abst) 186, 409
Holtz H (abst) 298
Holtzman E (abst) 436
Homatas I (abst) 865, 869
Homma S (abst) 270, 273
Homma T (abst) 436
Honda N, Hishida A, Ikuma K, Yonemura K: Acquired resistance to acute renal failure (Editorial Review) 1233
Hong JH (abst) 466
Honma N (abst) 227
Honrath U *See* Sonnenberg H 1121
Hood VL (abst) 410

Hooke DH, Gee DC, Atkins RC: Leukocyte analysis using monoclonal antibodies in human glomerulonephritis (Clinical Investigation) 964
Hoover RL (abst) 323
Hopper J Jr *See* Alpers CE 781
Hori M (abst) 323
Horikoshi S (abst) 325
Horio M (abst) 368, 399
Horisberger JD (abst) 447
Horl WH (abst) 223
Horlait S (abst) 353
Horsley J (abst) 202
Horton C (abst) 277
Hoshi T (abst) 279
Hosoda S (abst) 359
Hossack K (abst) 295
Hossack KF (abst) 203
Hostetter TH (abst) 215, 392
Houghton D (abst) 364, 367
Houghton DC (abst) 368
Houser MT (abst) 203
Hoy W (abst) 203, 209
Hoyer J (abst) 424
Hrenluk D (abst) 394
Hricik DE (abst) 273
Hropot M (abst) 180
Hruska K (abst) 167
Hruska KA (abst) 215, 349, 356, 399
Hruska K *See* Martin KJ 937
Hruska KA *See* Reid IR 1113
Hsiung CK (abst) 338
Hsu C (abst) 263, 306, 350, 362
Huang W-C *See* Navar G S-81
Hudson EC *See* Wyatt RJ 1019
Hughson M (abst) 203
Huisman RM (abst) 299
Hull A (abst) 458, 468
Hull AR (abst) 459
Hulstaert CE *See* Bakker WW 704
Humes HD (abst) 323, 366, 371, 372, 404, 460
Humpierres J (abst) 264
Hunley T (abst) 436
Hunsicker L (abst) 201, 213
Hunsicker LG (abst) 319
Hunsicker LG *See* Bertolatus JA 1257
Hunter M (abst) 436, 438
Huntsberger T (abst) 203, 214
Hura C (abst) 423
Hurault de Ligny B (abst) 1416
Hurtado H (abst) 204
Hurwitz R (abst) 471
Huseman RA *See* Birenboim N 85
Hutchison FN *See* Kaysen GA 1368
Huysmans FThM (abst) 1049
Hwang KH (abst) 380
Hwang SD (abst) 248, 388
Hymes L (abst) 251
Hyver S (abst) 241
Ianhez LE (abst) 455, 459
Iatrou CHR (abst) 869, 870
Ichikawa I (abst) 293, 334, 363, 384, 394, 424
Ichikawa I, Kon V, Pfeffer MA, Pfeffer JM, Brenner BM: Role of angiotensin II in the altered renal function of heart failure S-213
Idrissi A (abst) 1417
Ikuma K *See* Honda N 1233
Ilia M (abst) 866
Illingworth R (abst) 200
Illsley NP (abst) 437
Ilno Y (abst) 237, 273, 289
Ilstrup DM (abst) 197
Ilstrup K (abst) 235
Imai H (abst) 323
Imai M, Taniguchi J, Tabei K: Function of thin loops of Henle 565
Imbert-Teboul M *See* Morel F 512
Inagami T (abst) 269
Ing TS (abst) 234, 237, 243, 250
Ingelfinger JR (abst) 268
Innes D (abst) 204
Isales CM (abst) 260
Ischenko EM (abst) 335
Iseki K (abst) 295
Ishibashi K (abst) 415, 437
Ishibashi K, Sasaki S, Yoshiyama N, Shiigai T, Takeuchi J: Generation of pH gradient across the rabbit collecting duct segments perfused in vitro (Laboratory Investigation) 930
Ishigami T (abst) 278
Ito K (abst) 160, 235
Ito Y (abst) 334, 386
Ivanovich PT (abst) 243
Iversen BM (abst) 329, 387, 390
Ives HE (abst) 169, 414
Iwai J (abst) 310
Izzo JL Jr (abst) 212, 216
Jabs K (abst) 293
Jackson B *See* Johnston CI S-154
Jackson K (abst) 203, 214
Jackson NM (abst) 404, 460
Jackson TE (abst) 428
Jacobs M (abst) 464
Jacobs WR (abst) 350
Jacobson H (abst) 225, 436
Jacobson HR (abst) 266, 269, 323
Jacoby M (abst) 446, 448
Jaeger P (abst) 204
Jaffe DJ (abst) 213
Jaffe DJ *See* Pardo V 1167
Jahan S (abst) 368
Jain R (abst) 217
Jamison RL (abst) 280, 290
Jamison RL *See* de Rouffignac C 501
Jamison RL: Tribute to Robert Berliner (Introduction) 502
Jamison RL: Short and long loop nephrons 597
Jamison RL *See* Zimmerhackl BL 641
Jamison RL: Potassium recycling (Editorial Review) 695
Janssen WMT (abst) 273, 1049
Jarskog F (abst) 223
Jaschke W, Cogan MG, Sievers R, Gould R, Lipton MJ: Measurement of renal blood flow by cine computed tomography (Technical Note) 1038
Jeffries WB *See* Pettinger WA S-191
Jenkins PG (abst) 234
Jennette JC (abst) 318, 337
Jensen M (abst) 325
Jensen PK, Christiansen JS, Steven K, Parving H-H: Strict metabolic control and renal function in the streptozotocin diabetic rat (Laboratory Investigation) 47

Jensen R (abst) 447
Jessen RH (abst) 324
Jo OD (abst) 309, 343, 358
Joeris B (abst) 371
Joh K (abst) 330
Johns C (abst) 409
Johnson C (abst) 363
Johnson CA (abst) 257
Johnson GC (abst) 375
Johnson HK (abst) 457
Johnson K (abst) 366, 460, 465
Johnson M (abst) 447
Johnson MA (abst) 298, 310
Johnson R (abst) 313, 329
Johnston CI, Jackson B: Overview: Angiotensin converting enzyme inhibition in renovascular hypertension S-154
Johnston CI *See* Ogawa K 760
Jojima K (abst) 469
Joles JA (abst) 1049, 437
Jones CE (abst) 421
Jones DB (abst) 366, 369
Jones ER (abst) 228
Jones J (abst) 363
Jones K (abst) 224
Jones KL (abst) 467
Jones P (abst) 266
Jones Q (abst) 254
Jones S (abst) 275
Jonker GJ (abst) 299
Jordan SC (abst) 340
Jorkasky D (abst) 462
Juorning PJG (abst) 1050
Jose P (abst) 166, 175
Jose PA (abst) 286, 310, 425
Josepovtiz C (abst) 369, 374
Josselson J (abst) 217, 234
Josselson J *See* Welik RA 1210
Julian BA (abst) 337
Julian BA *See* Wyatt RJ 1019
Jumeau Y (abst) 283
Jungas RL (abst) 396
Juster R (abst) 457
Justrabo E (abst) 1416
Kablitz C (abst) 261, 274
Kabot V (abst) 294
Kachadorian WA (abst) 447
Kachel HG (abst) 242
Kachra Z (abst) 167
Kad SK (abst) 299
Kaehney WD *See* Molitoris BA 986
Kaehny W (abst) 197, 204, 297
Kageyama Y (abst) 274
Kahn AM (abst) 299
Kahn CR (abst) 388
Kahn T (abst) 205, 387, 410
Kahng M (abst) 375
Kaiser B (abst) 460
Kaiser D (abst) 189, 204
Kaissling B (abst) 437
Kaji D (abst) 387
Kakavas J (abst) 864
Kakayas N (abst) 866
Kalekou H (abst) 871
Kalicharan D *See* Bakker WW 704
Kalil JE (abst) 455
Kallivretakis N (abst) 867
Kalogeropoulou C (abst) 868
Kaloheretis P (abst) 863
Kaloyanides GJ (abst) 370, 374
Kalpakoglou S (abst) 865
Kalycakis G (abst) 865, 867, 868
Kamada T (abst) 275, 368, 399
Kamidou C (abst) 861
Kanalas JJ (abst) 174, 324
Kanayama Y *See* Wyatt RJ 1019
Kangarloo H (abst) 213
Kant KS (abst) 222
Kant SK (abst) 337
Kanthanatana S (abst) 208
Kanwar Y (abst) 326
Kanwar YS (abst) 170, 173, 392
Kanwar YS *See* Lelongt B 1299
Kaplan B (abst) 167
Kapoulas S (abst) 871
Kapsimalakou G (abst) 869
Kapturczaak M (abst) 299
Karagiannis A (abst) 869
Karamouzis M (abst) 871
Karavasilis I (abst) 865
Karayanakos P (abst) 871
Karayannakis S (abst) 868
Karnaky KJ (abst) 170
Karniski LP (abst) 438
Karnovsky MJ (abst) 379, 393, 424
Karow AM (abst) 370
Kashgarian M (abst) 318, 376, 441
Kashgarian M *See* Minuth WW 1104
Kashtan C (abst) 205, 206
Kasinath BS (abst) 170, 182
Kasiske BL (abst) 300, 365, 387, 390, 462
Kasiske BL: Relationship between vascular disease and age-associated changes in the human kidney (Clinical Investigation) 1153
Kaskel FJ (abst) 366
Kathpalia SC (abst) 350
Katirtzoglou A (abst) 861, 864, 866
Kato K (abst) 359
Katz A (abst) 313
Katz AI (abst) 271
Katz L (abst) 226
Kaufman AM (abst) 410
Kaufman B (abst) 283
Kaugh YC (abst) 233
Kauker ML, Baer PG, Nasjletti A: Augmentation by aprotinin of the renal response to vasopression (Laboratory Investigation) 1092
Kaw D (abst) 205
Kawahara K (abst) 438
Kawai T (abst) 220
Kawano Y (abst) 235
Kay NE (abst) 235
Kaysen GA (abst) 267
Kaysen GA, Gambertoglio J, Felts J, Hutchison FN: Albumin synthesis, albuminuria and hyperlipemia in nephrotic patients (Clinical Investigation) 1368
Keane WF (abst) 189, 212, 310, 365, 387, 390, 462
Keen H *See* Wiseman MJ 1012
Keen M (abst) 232, 235
Kelekis L (abst) 869

Kelepouris E (abst) 444
Kelleher S (abst) 205, 243
Kelleher SP, Robinette JB, Miller F, Conger JD: Effect of hemorrhagic reduction in blood pressure on recovery from acute renal failure (Laboratory Investigation) 725
Kelley GG (abst) 274
Kelley V (abst) 367
Kelley VE (abst) 257, 324
Kellner D (abst) 162, 170
Kelly C (abst) 300
Kelly R (abst) 300, 383, 386, 389
Kelly RA *See* Wilcox CS 135
Kempson S (abst) 350
Kenney RE (abst) 391
Kennley R (abst) 250
Kenyon J (abst) 206
Kephart GM (abst) 339
Kerjaschki D (abst) 170
Kern EO (abst) 387
Kerr DNS *See* Papiha SS 130
Kert CJ (abst) 351
Keshaviah P (abst) 235
Kesse-Elia M (abst) 865
Khanna R (abst) 248, 250, 252, 253
Khanna R *See* Levin TN 731
Khawar M (abst) 461
Khawar MR (abst) 205, 469
Kiesel G (abst) 378
Kikuchi T (abst) 384, 394
Kilintzis V (abst) 861
Killen P (abst) 320, 338
Killen PD (abst) 165, 171
Kim JK (abst) 274
Kim S (abst) 222, 337
Kim Y (abst) 185, 205
Kimberling W (abst) 206
Kimburis J (abst) 865
Kimmel PL (abst) 241, 351, 358
Kimoto A (abst) 237
Kimura G (abst) 235
Kindermans C (abst) 266, 424
King A (abst) 239, 242
Kingma PJ (abst) 1050
Kinne R (abst) 402
Kinne RKH (abst) 171, 187
Kinne-Saffran E (abst) 171
Kinter LB (abst) 275
Kipnowski J (abst) 171, 391
Kirchner K (abst) 438
Kirchner KA, Brandon S, Mueller RA, Smith MJ, Bower JD: Mechanism of attenuated hydrochlorothiazide response during indomethacin administration (Laboratory Investigation) 1097
Kirk KL (abst) 275
Kirschbaum B (abst) 236
Kirschenbaum MA (abst) 163, 264, 275
Kitamura E (abst) 275
Kitchen L (abst) 236
Kittaka M (abst) 351
Kjellstrand C (abst) 196, 236, 239, 243
Klag M (abst) 311
Klahr S (abst) 386, 394, 409, 444
Klassen D (abst) 220, 224, 275
Klautky R (abst) 377
Kleeman C (abst) 188, 351, 355
Kleesattel A (abst) 331
Klein DJ (abst) 171, 178
Klein M (abst) 247
Klein MD (abst) 302
Klein MH (abst) 342
Kleinman H (abst) 320
Kleppel M (abst) 319
Kleppel MM (abst) 206
Klose R *See* Bank N 897
Klotman P (abst) 395
Klotman PE (abst) 272, 456
Knauss T (abst) 325
Knauss TC (abst) 184
Knepper M (abst) 408, 416
Knepper MA (abst) 450
Knepper MA, Roch-Ramel F: Pathways of urea transport in the mammalian kidney 629
Kniaz D (abst) 275
Knibloe K (abst) 351
Knippenberg LJ (abst) 196
Knowler WC (abst) 388
Knox FG (abst) 359, 434
Knutson DW (abst) 326, 330
Kobrin SM (abst) 236, 253
Koch KM (abst) 237, 238, 245, 296, 300, 372
Koene RAP (abst) 1043, 1044, 1049
Koepke JP (abst) 275
Koeppen B (abst) 410, 441
Koffman BM (abst) 460
Kofina A (abst) 862
Kohan DE (abst) 172
Kohaut EC (abst) 222
Kohen J (abst) 196
Kohler H (abst) 340
Koide H (abst) 325
Kojima I (abst) 282
Kojima S (abst) 235
Kokko JP (abst) 222, 265, 435, 445, 458
Kokko JP: The role of the collecting duct in urinary concentration 606
Komanicky P (abst) 362
Kon V (abst) 424
Kon V *See* Ichikawa I S-213
Kone B (abst) 223
Kone BC (abst) 373
Kontessis P (abst) 867
Kontich DA (abst) 396
Koomans H (abst) 433
Koomans HA (abst) 192, 430, 437
Koomans H (abst) 1049
Koomans HA (abst) 1048, 1049
Koopman MG (abst) 1048
Kootstra G (abst) 1047, 1050
Kopecky RT (abst) 277
Kopelman R (abst) 192
Kopito RR (abst) 159
Kopp UC (abst) 300
Kopple J (abst) 226, 246, 248
Kopple JD (abst) 201
Korbet S (abst) 254
Korbet SM (abst) 206, 223
Korkor AB (abst) 352
Kormendi F (abst) 453
Kornbluth J (abst) 462

Kornhaus J (abst) ... 184
Kortas C (abst) ... 190, 191
Kortlandt W (abst) ... 437, 1049
Korzets Z (abst) ... 251
Koshy V, Avasthi PS: The anionic sites at luminal surface of peritubular capillaries in rats (Laboratory Investigation) ... 52
Kosmas V (abst) ... 867
Kostakis A (abst) ... 869
Kostoyianni G (abst) ... 865
Kostoyianni-Papagalani G (abst) ... 867
Kotas RV (abst) ... 174
Kotchen TA (abst) ... 308
Kotler J (abst) ... 233
Koulouridis E (abst) ... 867, 868
Koutmos S (abst) ... 867, 868
Koutoulidis C (abst) ... 868
Koutsikos D (abst) ... 870
Kouttos C (abst) ... 864
Kovarik J (abst) ... 233
Kowaleska J (abst) ... 250
Kozeny G (abst) ... 190, 339, 388
Kracke MJ (abst) ... 186
Kraft N *See* Thomson NM ... 1186
Krall K (abst) ... 382
Kramer HJ (abst) ... 171, 268, 391, 398
Kramer MS (abst) ... 236, 253
Kramer MS *See* Caruana RJ ... 1351
Kramer P (abst) ... 1046
Krapf R (abst) ... 411
Kraut JA (abst) ... 442
Kravaritis A (abst) ... 864
Krediet RT (abst) ... 1048
Kreisberg J (abst) ... 184, 403
Kreisberg JI (abst) ... 277
Kremer S (abst) ... 172
Krensky A (abst) ... 461
Krevolin LE (abst) ... 194
Krishna GG (abst) ... 206
Krishna G *See* Fruncillo RJ ... S-117
Kriz W (abst) ... 371
Kriz W: A periarterial pathway for intrarenal distribution of renin ... S-51
Kriz W *See* Lemley KV ... 538
Kriz W *See* Trinh-Trang-Tan M-M ... 549
Kroborth P (abst) ... 255
Krolewski AS (abst) ... 207, 388
Krothapalli R (abst) ... 190, 207
Krouri A (abst) ... 207
Krumlovsky F (abst) ... 244
Kuhn K (abst) ... 296, 300
Kühn R *See* Steinhausen M ... S-64
Kumar P (abst) ... 461
Kumar S (abst) ... 325
Kunau R (abst) ... 411, 423
Kuntz D (abst) ... 1417, 1418
Kuriyama R (abst) ... 237
Kuriyama S (abst) ... 301
Kurokawa K (abst) ... 279, 282, 289, 431
Kurschel E (abst) ... 207, 304
Kurtin P (abst) ... 226
Kurtz I (abst) ... 408, 411, 414, 416
Kurtz TW (abst) ... 301
Kurtzberg D (abst) ... 225
Kurtzman NA (abst) ... 179, 211, 250, 292, 352, 414, 447
Kuwahara M (abst) ... 438
Kuwahara T (abst) ... 237
Kuzniak S (abst) ... 342
Kwok C (abst) ... 467
Kylander JE (abst) ... 337
Kyriakides G (abst) ... 467
Kyriakides S (abst) ... 865
Kyriasis I (abst) ... 862
Kyriazis J (abst) ... 378, 869
La France N (abst) ... 224
La Pointe M (abst) ... 302
Laborde K (abst) ... 266, 424
Laborde NP (abst) ... 259
Lacave R (abst) ... 172
Lachant NA (abst) ... 158
Lachin J (abst) ... 201, 208
Lacoste M *See* Mounier F ... 121
Lacour B (abst) ... 352
Ladisa N (abst) ... 338
Laederach K, Weidmann P: Plasma and urinary catecholamines as related to renal function in man (Clinical Investigation) ... 107
Laffel LMB (abst) ... 207
Lagoudaki-Keklikian P (abst) ... 866
Lagouranis A (abst) ... 867, 868
Lagrange BM (abst) ... 410
Lagrone L (abst) ... 262, 420
Lagrue G (abst) ... 1416, 1419
Lahorra MAG (abst) ... 259
Laidlaw S (abst) ... 246
Lakassa G (abst) ... 866
Lakassas G (abst) ... 861, 866
Lal SM (abst) ... 461, 462
Lalonde L *See* Vinay P ... 946
Lam C (abst) ... 246
Lambermon E (abst) ... 1044
Lamberts LV (abst) ... 196
Lambrey G (abst) ... 1417
Lamoureux C (abst) ... 283
Lamphiear DE (abst) ... 231
Lan S-P (abst) ... 217
Lancman I (abst) ... 461
Landman E (abst) ... 212
Landsverk J (abst) ... 253
Landwehr DM (abst) ... 382
Lane B (abst) ... 369, 374
Lang R (abst) ... 346
Lang RE (abst) ... 278
Lang RE *See* Tulassay T ... 1391
Lange J (abst) ... 310
Lange K (abst) ... 317
Lange MA (abst) ... 172
Langlois R (abst) ... 190
Langman C (abst) ... 351, 360
Langman CB (abst) ... 351, 352, 358
Langman CB *See* Bourdeau JE ... 913
Lanham JG *See* Vermylen CG ... 1396
Lapierre L *See* Vinay P ... 1194
Lapointe JY (abst) ... 440
Lapointe M (abst) ... 454
Laradi A (abst) ... 207
Laragh JH (abst) ... 282, 308
Larsen A (abst) ... 325
Larson TS (abst) ... 280
Larsson L (abst) ... 417

Larsson S (abst) 173
Lasaridis A (abst) 868, 869
Laska D (abst) 186
Laski ME (abst) 414
Laszczynska M *See* Leszczynski D 1311
Lau K (abst) 298, 310, 346, 350
Laurent J (abst) 1416, 1419
Lawlor M (abst) 208, 213
Lawson L (abst) 397
Lawton A (abst) 185, 397
Lawton W (abst) 301
Lazarides DP (abst) 867
Lazarus JM (abst) 234, 239
Leadley RJ Jr (abst) 260, 270
Lear S (abst) 367
Leary JF (abst) 326
Leavitt S (abst) 311
Lebel M (abst) 190
Lechago J (abst) 259
Lechene C (abst) 165, 173, 178, 435, 439
Lechleider R (abst) 343
Leddy CL (abst) 203
Lederer EJ (abst) 463
Ledingham JGG: Introduction S-1
Ledingham JGG: Effects of angiotensin II and of angiotensin converting enzyme inhibition in chronic renal failure S-112
Ledingham JGG: Overview: Physiology I S-49
Lee C (abst) 390
Lee DBN (abst) 303, 309, 382, 449
Lee HB (abst) 248, 388
Lee HM (abst) 239, 242
Lee J (abst) 251
Lee K (abst) 267
Lee P (abst) 400
Lee SH (abst) 388
Lee SM (abst) 369, 373
Leech S (abst) 461
Leehey DJ (abst) 250
Leeney DJ (abst) 237
Lefevre A (abst) 353
Lefkowith J (abst) 329
Lefkowitz M (abst) 462
Lefkowitz RJ (abst) 178
Legrimellec C (abst) 166
Leichter H (abst) 200, 217
Leichter HE (abst) 251
Leinfelder J (abst) 222
Lelongt B (abst) 173, 326
Lelongt B, Makino H, Kanwar YS: Status of glomerular proteoglycans in aminonucleoside nephrosis (Laboratory Investigation) 1299
Lemaitre V (abst) 1418
Lemann J Jr (abst) 353
Lemley KV, Kriz W: Cycles and separations: The histotopography of the urinary concentrating process 538
Lemoniatou H (abst) 863
Lenclud C (abst) 231
Leon V (abst) 444
Leone DR (abst) 275, 288
Leoporrier M (abst) 1416
Lerner GR (abst) 302
Lesniak MA (abst) 163
Leszczynski D, Laszczynska M, Halttunen J, Huayry P: Renal target structures in acute allograft rejection: A histochemical study (Laboratory Investigation) 1311
Leung G (abst) 262
Leunissen KML (abst) 1047, 1050
Leuther M (abst) 227
Levaltier B (abst) 1416
Leveille M *See* Vinay P 1194
Levenson DJ, Dzau VJ: Effects of angiotensin converting enzyme inhibition on renal hemodynamics in renal artery stenosis S-173
Lever AF *See* Tillman DM S-184
Levi J (abst) 194, 312, 353
Leviel F (abst) 405
Levin M *See* Vermylen CG 1396
Levin NW (abst) 229, 231, 238, 396
Levin TN, Rigden LB, Nielsen LH, Moore HL, Twardowski ZJ, Khanna R, Nolph KD: Maximum ultrafiltration rates during peritoneal dialysis in rats (Laboratory Investigation) 731
Levine BS (abst) 211, 351
Levine SD (abst) 446, 448
Levinson M (abst) 202
Levi-setti R (abst) 343
Levy E (abst) 205
Levy M (abst) 465
Lew S (abst) 191, 208
Lewis E (abst) 201, 208, 254
Lewis EJ (abst) 170, 206, 223
Lewis EJ: Glomerular abnormalities in patients receiving angiotensin converting enzyme inhibitor therapy S-138
Lewis SL, Van Epps DE, Chenoweth DE: Leukocyte C5a receptor modulation during hemodialysis (Clinical Investigation) 112
Lewis-Finch J (abst) 342
Leypoldt J (abst) 448
Leypoldt JK (abst) 249
Leypoldt JK, Frigon RP, DeVore KW, Henderson LW: A rapid renal clearance methodology for dextran (Technical Note) 855
Li JS (abst) 178
Liamos O (abst) 861, 870
Liang CT (abst) 348
Lianos EA (abst) 277, 293
Liboro RK (abst) 194
Libresco SM (abst) 159
Lieberherr M, Grosse B, Cournot-Witmer G, Hermann-Erlee MPM, Balsan S: Aluminum action on mouse bone cell metabolism and response to PTH and 1, 25$(OH)_2D_3$ (Laboratory Investigation) 736
Lieberknecht H-M *See* Rauterberg EW 820
Lieberman E (abst) 470
Lieberthal W (abst) 208
Lief P (abst) 414
Lifschitz M (abst) 411
Lilien TV (abst) 251
Lim CH (abst) 340
Lim HK (abst) 292
Lim LK (abst) 457
Lim V (abst) 232
Lim VS, Zavala DC, Flanigan MJ, Freeman RM: Blunted peripheral tissue responsiveness to thyroid hormone in uremic patients (Clinical Investigation) 808
Lin H (abst) 424
Linas SL (abst) 369, 377
Linas SL *See* Benedetti RG 906

Linberg J (abst) 344
Lindheimer M (abst) 209
Lindner J (abst) 177
Lindop GBM: Morphological aspects of renin synthesis, processing, storage, and secretion S-18
Linehan W (abst) 224
Linkowski G (abst) 470
Linshaw MA (abst) 173, 429
Lipkowitz GS (abst) 466
Lipkowitz MS (abst) 389, 429, 439
Lipman RD (abst) 439
Lipsky PE (abst) 332
Lipson L (abst) 384
Lipton J (abst) 263
Lipton MJ *See* Jaschke W 1038
Litardo M *See* Panese S 1377
Little A (abst) 294
Liu CN (abst) 328
Liu FY (abst) 412
Liu K (abst) 230
Livio M *See* Bertani T 1248
Llach F (abst) 238, 345, 354
Llach F *See* Rodriguez M 766
Llach F *See* London GM 873
Llibre J (abst) 302
Lo L (abst) 314
Lockette W (abst) 309
Lockhart P (abst) 376
Lodish HF (abst) 159
Loftus D (abst) 167
Logan A (abst) 162
Logan G (abst) 236
Logan JL (abst) 373, 462
Loghman-Adham M (abst) 359
Lomri A (abst) 354
London G (abst) 345
London GM (abst) 238
London GM, Fabiani F, Marchais SJ, de Vernejoul M-C, Guerin AP, Safar ME, Metivier F, Llach F: Uremic cardiomyopathy: An inadequate left ventricular hypertrophy (Clinical Investigation) 873
London RD (abst) 389
Lonnemann G (abst) 238
Loon NR (abst) 208
Loon NR *See* Wilcox CS 135
Lopes AG (abst) 434
Lopez-Hilker S (abst) 345
Lopez-Novoa JM (abst) 211
Lornoy W (abst) 1417
Louridas G (abst) 867
Loutzenhiser R (abst) 269
Louzenhiser R (abst) 277
Lovett D (abst) 314, 320, 325
Lovett DH (abst) 228
Lowder GM (abst) 238
Lowe A (abst) 443
Lowe AG (abst) 389
Lowery P (abst) 196
Lowry OH *See* Bastin J 1239
Lubiewski A (abst) 390
Lucas PA (abst) 302, 345, 352
Ludwig D (abst) 461
Luft FC (abst) 311
Luger AM (abst) 461, 462
Lukas PH (abst) 303
Luke DR (abst) 462
Luke RG (abst) 266, 417, 433
Luke RG: Hypertension in renal transplant recipients (Nephrology Forum) 1024
Lukeman DS (abst) 278
Lundberg U (abst) 173, 355
Lupinacci L (abst) 302
Lupini C (abst) 283
Luscher TF (abst) 307
Lustig S (abst) 303
Lyman N (abst) 464
Maack T (abst) 257, 288
Maastricht RUL (abst) 1050
Macconi D (abst) 267
Macconi D *See* Bertani T 1248
MacDonald JS, Bagdon WJ, Peter CP, Sina JF, Robertson RT, Ulm EH, Bokelman DL: Renal effects of enalapril in dogs S1-48
MacDonell R (abst) 465
MacDonell RC (abst) 457
MacDougall ML (abst) 427, 448
MacIntyre WJ (abst) 469
MacKay K (abst) 163
MacTier RA (abst) 252, 253
Madaio MP (abst) 326
Madias N (abst) 192, 409
Madsen K (abst) 417
Madsen KM *See* Clapp WL 1080
Maesake JK (abst) 195
Magner PO (abst) 209
Magnusson MD (abst) 469
Maguire JE (abst) 463
Mahajan S (abst) 294, 361, 463
Mahan J (abst) 326
Mahan JD (abst) 465
Maher JF (abst) 252
Mahieu P *See* Davin J-C 1132
Mahieu PR *See* Davin J-C 32
Mahncke HW (abst) 370
Mahoney C (abst) 399
Maidannik VG (abst) 335
Maikranz P (abst) 209, 359
Maki S (abst) 334
Makino H (abst) 173, 326
Makino H *See* Lelongt B 1299
Makker SP (abst) 174, 324
Malacarne F (abst) 226
Malachi T (abst) 347
Malagon M, Hogg RJ: Renal transplantation after prolonged dwell dialysis in children (Clinical Investigation) 981
Malaise M *See* Davin J-C 1132
Malamitsi J (abst) 868
Malatino LS *See* Tillman DM S-184
Malcolm A (abst) 465
Maldifassi P (abst) 339
Malhotra S (abst) 217
Malis CD (abst) 370
Malluche HH (abst) 246, 346
Man int'd Veld AJ *See* Wenting GJ S-180
Man NK (abst) 248
Manco-Johnson M (abst) 197
Manco-Johnson M *See* Sedman A 1009
Mandal AK (abst) 303, 370
Mandard JC (abst) 1416

Mandel IJ (abst) 163, 350
Mangili R *See* Wiseman MJ 1012
Manillier C *See* Vinay P 946
Manion BA (abst) 228
Manis T (abst) 466
Mann H (abst) 303
Mann JFE (abst) 278
Mann KW (abst) 424
Manning R (abst) 218
Manns M (abst) 340
Mansour AB (abst) 302
Mantyh CR (abst) 198
Mantyh PW (abst) 198
Maoui R (abst) 207
Marc-Aurele J (abst) 191
Marchais J (abst) 345
Marchais S (abst) 238
Marchais SJ *See* London GM 873
Marche P, Olier B, Girard A, Fillastre J-P, Morin J-P: Aminoglycoside-induced alterations of phosphoinositide metabolism (Laboratory Investigation) 59
Marchetti J, Roseau S, Alhenc-Gelas F: Angiotensin I converting enzyme and kinin-hydrolyzing enzymes along the rabbit nephron (Laboratory Investigation) .. 744
Marclano D (abst) 255
Marconi J (abst) 353
Marcus DC (abst) 174
Marcus NY (abst) 174
Marder HK (abst) 270
Margolin K (abst) 220
Margolis B (abst) 224
Marie A (abst) 1417
Marie PJ (abst) 354
Marinides GN (abst) 389
Marion D (abst) 394
Marion RM (abst) 308
Mark A (abst) 301
Markert M (abst) 237
Markovitz I (abst) 194
Marom S (abst) 174
Maroni BJ *See* Wilcox CS 135
Marsh DJ (abst) 421
Marsh DJ: Functional transitions in the renal countercurrent system 668
Martin A (abst) 398
Martin C (abst) 350
Martin D (abst) 364, 461
Martin G (abst) 320, 338
Martin GR (abst) 165, 171
Martin J (abst) 463
Martin KJ, Finch JL, Hruska K, Slatopolsky E: Effect of biological activity of PTH on its peripheral metabolism in the rat (Laboratory Investigation) 937
Maartin RS *See* Panese S 1377
Martineau A (abst) 269
Martinez A (abst) 309
Martinez O (abst) 232
Martinez-Maldonado M (abst) 260, 422, 449
Marumo F (abst) 278, 285
Maruyama Y (abst) 279
Marver D (abst) 265, 278, 436
Maschio G (abst) 184
Mason J (abst) 371
Mason J, Welsch J, Torhorst J: The contribution of vascular obstruction to the functional defect that follows renal ischemia (Laboratory Investigation) 65
Mason R (abst) 245
Massad TC (abst) 412
Massardo S (abst) 174
Massry SG (abst) 295, 342, 384, 393
Mastrolitti G (abst) 338
Masur SK (abst) 174
Masurel N (abst) 1046
Mathew M (abst) 463
Matson M (abst) 239
Matsunaga H (abst) 279
Matsuo S (abst) 338
Matsuzaki K (abst) 439
Matthews C (abst) 354
Mattioli C (abst) 332
Matzke GR (abst) 212, 462
Mauer SM (abst) 192
Maurette JM (abst) 424
Mavrikakis G (abst) 283
Mavrikakis M (abst) 864
Mavrokephalos P (abst) 867
May R (abst) 383, 386, 389
Mayer G (abst) 233
Mayer PR (abst) 395
Mayopoulou-Symvoulidis D (abst) 864
Mayopoulou-Symvoulidou D (abst) 866
Mayrer AR *See* Schachner MS 77
McAdams AJ (abst) 338
McAlister C (abst) 326
McAlister E (abst) 263, 272
McAteer J (abst) 184
McBride D (abst) 279
McCallister T (abst) 367
McCarron D (abst) 298, 304, 308
McCarron DA (abst) 209, 304, 307, 343
McCarthy SC *See* Crocker JFS 1088
McCluskey R (abst) 338
McCormick CP (abst) 303
McCroarty M (abst) 227
McCrory W (abst) 354
McCurdy R (abst) 309
McDaniel HG (abst) 199
McDermott RG (abst) 267
McDonald F (abst) 294, 361
McDonald FD (abst) 162, 170
McDonald JW (abst) 316
McDonald MA (abst) 463
McEnery P (abst) 455
McEnery PT (abst) 338
McGrath M (abst) 252
McKay C (abst) 354
McKelvey T (abst) 175
McKenna BA (abst) 212, 216
McKeowm JW (abst) 279
McKinney TD (abst) 412, 450
McLeish KR (abst) 365
McNamara ER (abst) 405
McNeely EZ, Pallone TL, Deen WM, Robertson CR: Models of the medullary microcirculation 662
McNeill P (abst) 239, 242
McNerney R (abst) 426
McRoy C (abst) 217, 377
Meaney TF (abst) 469
Medline A (abst) 862

Mees EJD (abst) 192
Megaloconomo K (abst) 865
Meggs LG (abst) 175, 315
Megill D (abst) 209
Mehta RL (abst) 326, 330
Mehta V (abst) 226
Meijer JH (abst) 1046
Mejia G (abst) 464
Mejia R (abst) 416
Mela-Riker L (abst) 364
Melias J (abst) 169
Melvin D (abst) 455
MelvinT (abst) 205
Melzer J (abst) 453, 456, 457
Memmos D (abst) 868
Ménard J *See* Michel J-B S-168
Ménard J: Overview: Anatomy S-2
Mendelsohn FAO, Millan M, Quirion R, Aguilera G, Chou S-T, Catt KJ: Localization of angiotensin II receptors in rat and monkey kidney by in vitro autoradiography S-40
Mendez RE (abst) 279
Mendez-Picon G (abst) 239, 242
Mendoza SA (abst) 467
Mendrick DL (abst) 175, 312, 319, 392
Mene P (abst) 175, 267
Meneses R (abst) 213
Meneses R *See* Pardo V 1167
Mengrelli C (abst) 864
Mento P (abst) 390
Menzel D (abst) 1044
Mercier O (abst) 405, 407
Merke J (abst) 303, 352
Merli C (abst) 416
Messana JM (abst) 371
Mestdagh J (abst) 1417
Mestecky J (abst) 337
Metaxas P (abst) 869
Metaxatos G (abst) 862, 871
Metivier F (abst) 238
Metivier F *See* London GM 873
Metska K (abst) 861
Metz J (abst) 298, 304
Metz R *See* Hackenthal E S-4
Metz-Kurschel U (abst) 207, 304
Meyer TW (abst) 328, 393, 426
Meyer TW *See* Zatz R S-123
Meyer TW, Anderson S, Rennke HG, Brenner BM: Reversing glomerular hypertension stabilizes established glomerular injury (Laboratory Investigation) 752
Meyer-Lehnert H (abst) 309, 464
Meyrier A (abst) 210
Mezger M (abst) 305
Miale A (abst) 232
Michael A (abst) 317
Michael AF (abst) 185, 206, 319
Michael S (abst) 862, 869, 870, 871
Michael UF (abst) 373
Michaels S (abst) 287
Michel J-B, Dussaule J-C, Choudat L, Nochy D, Corvol P, Ménard J: Renal damage induced in the clipped kidney of one-clip, two-kidney hypertensive rats during normalization of blood pressure by converting enzyme inhibition S-168
Michelis MF (abst) 221, 232
Middendorf DF (abst) 210, 227
Miettinen A (abst) 170
Migdal S (abst) 361, 463
Migliorini P (abst) 326
Mignon F (abst) 258, 284, 1418
Mihatsch M (abst) 280
Milanes CL (abst) 173, 355
Milford EL (abst) 466, 467
Milgrom M (abst) 467
Milhoan KA (abst) 364
Millan M *See* Mendelsohn FAO S-40
Millan V (abst) 192
Miller E (abst) 206
Miller F *See* Kelleher SP 725
Miller J (abst) 462, 467
Miller JH (abst) 241, 245, 247
Miller L (abst) 210, 348
Miller N (abst) 189, 198
Miller NL *See* Molitoris BA 986
Miller WL (abst) 280
Mills S (abst) 464
Mimran A, Casellas D: The renin-angiotensin system and nephron function heterogeneity S-57
Minetti L (abst) 298
Miniter PM *See* Schachner MS 77
Mintz E (abst) 442
Minuth WW, Gross P, Gilbert P, Kashgarian M: Expression of the α-subunit of Na/K-ATPase in renal collecting duct epithelium during development (Laboratory Investigation) 1104
Miranda B (abst) 215, 309
Miranda B *See* Ruilope LM 992
Mishell J (abst) 247
Misler S (abst) 167
Mitch W (abst) 300, 383, 386, 389
Mitch WE (abst) 210
Mitch WE *See* Wilcox CS 135
Mitchell C (abst) 251
Mitchell KD (abst) 280
Mitchell KD *See* Navar G S-81
Mitchell M (abst) 281
Mitchell P (abst) 413
Miyahara T (abst) 330
Miyamoto H (abst) 334
Miyamoto M (abst) 280
Mizelle HL (abst) 427
Mogensen CE: Microalbuminuria as a predictor of clinical diabetic nephropathy (Nephrology Forum) 673
Mohrmann M (abst) 280
Mojaverian P *See* Fruncillo RJ S-117
Mok H (abst) 324
Molenaar JC (abst) 1045
Moles K (abst) 254
Molitoris BA (abst) 371
Molitoris BA, Alfrey PS, Miller NL, Hasbargen JA, Kaehney WD, Alfrey AC, Smith BJ: Efficacy of intramuscular and intraperitoneal deferoxamine for aluminum chelation (Clinical Investigation) 986
Molony DA (abst) 439
Molony DA *See* Hebert SC 580
Monnens L (abst) 1044
Monnens LA *See* Geven WB 1140
Montanari A (abst) 304
Monteon F (abst) 246

Moore H (abst) ... 253
Moore HL *See* Levin TN ... 731
Moore LC (abst) ... 366, 425
Moorthy AV (abst) ... 464
Morales JM (abst) ... 215
Moran A (abst) ... 176
Morel F (abst) ... 262, 440
Morel F, Imbert-Teboul M, Chabardges D: Receptors to vasopressin and other hormones in the mammalian kidney ... 512
Morelle V (abst) ... 1417
Moret F (abst) ... 413, 441
Morford D (abst) ... 254
Morgan J (abst) ... 347
Morgunov NS (abst) ... 281
Morigi M *See* Bertani T ... 1248
Morin J-P *See* Marche P ... 59
Morinier P (abst) ... 1417
Morita I (abst) ... 273
Moriyama T (abst) ... 368, 399
Morley AR *See* Papiha SS ... 130
Morris CD (abst) ... 209, 304
Morris RC (abst) ... 301
Morris RC Jr *See* Hernandez RE ... 1356
Morrison A (abst) ... 354
Morrison AR (abst) ... 178
Morrissey J (abst) ... 176, 354
Morse GD (abst) ... 252, 256
Morsing P (abst) ... 421
Mortzos G (abst) ... 867
Mosimann R (abst) ... 470
Moskowitz DW (abst) ... 399
Moss AH (abst) ... 239
Moss NG (abst) ... 327
Mougenot B (abst) ... 1418
Mounier F, Hinglais N, Brehier A, Thomasset M, Lacoste M, Sich M, Gubler M-C: Ontogenesis of 28 kDa vitamin D-induced calcium-binding protein in human kidney (Clinical Investigation) ... 121
Mountokalakis T (abst) ... 861, 864, 866
Mousson C (abst) ... 1416
Moustafa FE *See* Sobh MA ... 1006
Muallem S (abst) ... 188, 351, 355, 442
Mueller RA *See* Kirchner KA ... 1097
Mujais S (abst) ... 266, 429
Mujais SK (abst) ... 390
Mulder C (abst) ... 1050
Mulgaonkar S (abst) ... 464
Muller E (abst) ... 185
Muller J (abst) ... 447
Mulliez N (abst) ... 327
Mulroney S (abst) ... 349
Mulroney SE (abst) ... 355
Mundy GR: The hypercalcemia of malignancy (Nephrology Forum) ... 142
Munger K (abst) ... 281, 367
Muntzel M (abst) ... 298, 304
Murota S (abst) ... 273
Murphy HR (abst) ... 169
Murphy TF (abst) ... 252
Murray BM (abst) ... 425
Myers BD (abst) ... 381
Nadel AS (abst) ... 281
Nagami GT (abst) ... 400
Nahman NS Jr (abst) ... 227, 465
Nakagawa Y (abst) ... 176, 359, 361
Nakahama H (abst) ... 368, 399
Nakamoto M (abst) ... 371, 464
Nakamura A (abst) ... 305
Nakamura K (abst) ... 175
Nakamura KT (abst) ... 45
Nakanishi T (abst) ... 176
Nakhoul NL (abst) ... 412
Nakopoulou L (abst) ... 863
Narang N (abst) ... 413, 433
Narang N *See* Garg LC ... 918
Narayanan M *See* Alkjaersig N ... 772
Naray-Fejes-Toth A (abst) ... 166, 281
Narins RG *See* Fruncillo RJ ... S-117
Nascimento L (abst) ... 201
Nasjletti A *See* Kauker ML ... 1092
Nasr LB (abst) ... 345
Nassar V (abst) ... 210
Nassar VH (abst) ... 219
Natscheh T (abst) ... 865
Navar G, Carmines PK, Huang W-C, Mitchell KD: The tubular effects of angiotensin II ... S-81
Navar LG (abst) ... 280, 423
Navar LG *See* Carmines PK ... S-229
Navarro JM (abst) ... 211
Navis G, de Jon PE, Donker AJM, van der Hem GK, de Zeeuw D: Moderate sodium restriction in hypertensive subjects: Renal effects of ACE-inhibition (Clinical Investigation) ... 815
Nebeker HG *See* Andress DL ... 1244
Necker H (abst) ... 413
Nedrud JG (abst) ... 324
Negley C (abst) ... 310
Negoro N *See* Wyatt RJ ... 1019
Nehme D (abst) ... 465
Neilson E (abst) ... 183, 324
Neilson EG (abst) ... 316, 322, 330
Nelson E (abst) ... 452
Nemery R (abst) ... 354
Neto ED (abst) ... 459
Neugarten J (abst) ... 198, 305, 379
Neugarten J *See* Baldwin DS ... 790
Neuman A (abst) ... 346
Neuman J (abst) ... 455
Neumayer HH (abst) ... 465
Neuwirth R (abst) ... 327
Newsom G (abst) ... 211
Neylan JF (abst) ... 239
Ng TC (abst) ... 469
Nguyen D *See* Bank N ... 897
Nguyen HH (abst) ... 313
Nguyen VD (abst) ... 371, 372
Nhoung S (abst) ... 381
Niblack G (abst) ... 460, 465
Niblack GD (abst) ... 457
Nicastri A (abst) ... 205
Nicastri AD (abst) ... 199
Nicholls MG: Overview: Angiotensin, angiotensin converting enzyme inhibition, and the kidney—Congestive heart failure ... S-200
Nicolakakis N (abst) ... 867, 868
Nicolopoulou N (abst) ... 867
Niederle N (abst) ... 207
Niedermayer W *See* Walle AJ ... 1205
Nielsen E (abst) ... 201

Nielsen LH *See* Levin TN 731
Nikolaides P (abst) 863
Nikolaidis P (abst) 863, 868
Nikolopoulou N (abst) 864
Nikolou C (abst) 867
Nikou S (abst) 868
Niles J (abst) 338
Nissenson AR (abst) 253, 255
Nissim I (abst) 400
Nitenberg A (abst) 418
Noble B (abst) 277, 327, 393, 445
Nochy D *See* Michel J-B S-168
Noel J (abst) 403, 430
Noel J *See* Gougoux A 1279
Nuoel LH (abst) 1418, 322
Nolasco F (abst) 335
Nolasco FEB, Cameron JS, Hartley B, Coelho A, Hildreth G, Reuben R: Intraglomerular T cells and monocytes in nephritis: Study with monoclonal antibodies (Clinical Investigation) 1160
Nolph K (abst) 250
Nolph KD (abst) 252, 253
Nolph KD *See* Levin TN 731
Nonoguchi H (abst) 450
Noonan H (abst) 211
Noordhoek GT (abst) 1046
Nord EP (abst) 180, 282, 434
Nordio M (abst) 226
Norman J (abst) 177, 180
Noronha A (abst) 325
Norris KC (abst) 211, 214, 349
Norusio MJ (abst) 195
Nouwen EJ (abst) 344
Novarini A (abst) 304
Novick A (abst) 468
Novick AC (abst) 458, 469
Novoa JML (abst) 291
Novogrodsky A (abst) 188, 340
Nunley R (abst) 321
Nussberger J *See* Brunner HR S-104
Nuzzi F (abst) 193
Nylander W (abst) 465
O'Brien M (abst) 257
O'Connell MP (abst) 300
O'Connor DT (abst) 305, 306
O'Connor RP (abst) 323, 366, 372, 404
O'Connor SF (abst) 177
O'Donnell J (abst) 468
O'Donnell MP (abst) 365, 387, 390
O'Hagan KP (abst) 305
O'Hara D (abst) 300
O'Neil RG (abst) 170, 452
Oates PJ (abst) 448
Ochi R (abst) 329
Ochi RF (abst) 313
Ochi S (abst) 172
Oe PL (abst) 255, 1046
Oegema TR (abst) 171, 178
Oemar BS (abst) 1047
Oettinger CW (abst) 240
Offerman JJG (abst) 1046
Offord KP *See* Torres VE 1383
Ofstad J (abst) 329, 387, 390
Ogata E (abst) 282
Ogawa K, Henry MA, Tange J, Woodcock EA, Johnston CI: Atrial natriuretic peptide in dehydrated Long-Evans rats and Brattleboro rats (Laboratory Investigation) 760
Ogawa M (abst) 223
Ogborn MR (abst) 316
Oh MS (abst) 212
Ohara K (abst) 227
Okamura M (abst) 212
Okuda T (abst) 282
Olbricht CJ (abst) 372
Oleggini R (abst) 200
Olier B *See* Marche P 59
Oliver JC (abst) 240
Olmer M *See* Robert A 830
Olsen DB (abst) 202, 261, 274
Olson P (abst) 196
Omae T (abst) 235
Onorato J (abst) 240
Onsgard M (abst) 359
Ooi BS (abst) 334
Opava-Stitzer S (abst) 449
Opsahl JA (abst) 189, 212
Oren A *See* Fruncillo RJ S-117
Oreopolous DG (abst) 246
Oreopoulos DG (abst) 253, 862
Orita Y (abst) 275, 368, 399
Ornt DB (abst) 216
Ortola F (abst) 171
Ortola FV (abst) 279, 282
Osborn JL (abst) 306
Osgood RW (abst) 261
Ossa L *See* Pardo V 1167
Ota K (abst) 216, 220
Ott SM *See* Andress DL 1244
Oudinet J-P (abst) 287
Oulges R (abst) 1418
Owada A (abst) 289
Oyasu R (abst) 392
Ozere CO (abst) 316
Ozone S (abst) 392
Pabico RC (abst) 212, 216
Pacholski M (abst) 261
Pachoula-Papasteriades C (abst) 863
Padavese P (abst) 226
Paddock J (abst) 372
Paddock JK (abst) 372
Paielli DL (abst) 396
Paillard F (abst) 465
Paillard M (abst) 405, 407
Paillard M *See* Patron P 1174
Pak CYC (abst) 362
Pakunka V (abst) 190
Palant CE (abst) 449
Paller MS (abst) 373, 466
Pallone TL (abst) 240
Pallone TL *See* McNeely EZ 662
Palmer J (abst) 321
Palmer M (abst) 391
Palmisano J (abst) 413
Palomino C (abst) 302
Palti Y (abst) 174
Pan G (abst) 338
Pandey GL (abst) 190
Paneblanco R (abst) 184
Panese S, Maartin RS, Virginillo M, Litardo M, Siga E,

Arrizurieta E, Hayslett JP: Mechanism of enhanced transcellular potassium-secretion in man with chronic renal failure (Clinical Investigation) 1377
Pankewycz O (abst) 326
Panourgias P (abst) 864
Papadakis G (abst) 861, 863, 864
Papadakis JT (abst) 870
Papadimitriou M (abst) 861, 863, 865, 867, 868, 869, 870
Papadoyannakis NJ (abst) 870
Papagalanis N (abst) 865, 867, 868
Papageorgioy K (abst) 864
Papanikolaou M (abst) 862
Papatheofanis I (abst) 869
Papiha SS, Pareek SK, Rodger RSC, Morley AR, Wilkinson R, Roberts DF, Kerr DNS: HLA-A, B, DR and Bf allotypes in patients with idiopathic membranous nephropathy (IMN) (Clinical Investigation) 130
Pappas A (abst) 867, 868
Pappas MV (abst) 867
Paptheofanis I (abst) 865
Pararas B (abst) 861
Parbtani A (abst) 316
Pardo V (abst) 213
Pardo V, Meneses R, Ossa L, Jaffe DJ, Strauss J, Roth D, Bourgoignie JJ: AIDS-related glomerulopathy: Occurrence in specific risk groups (Clinical Investigation) 1167
Pareek SK *See* Papiha SS 130
Parent L (abst) 440
Parfrey P (abst) 347
Parfrey PS (abst) 240
Parham P (abst) 461
Park CH (abst) 449
Park CH *See* Wingo CS 1225
Parker CJ (abst) 230, 241
Parker M (abst) 383
Parks J (abst) 209
Parmer RJ (abst) 306
Parrish AE (abst) 391
Parthasarathy S (abst) 364
Parving H-H *See* Jensen PK 47
Paschalidou E (abst) 867
Pashalidou E (abst) 863
Pasko MT (abst) 249
Pasquier R (abst) 328
Pastore A (abst) 338
Pastoriza E (abst) 409, 413
Patchin D (abst) 277, 366
Patel PY (abst) 277
Patel S (abst) 306, 350, 362
Patel Y (abst) 403
Patrikarea A (abst) 870
Patron P, Gardin J-P, Paillard M: Renal mass and reserve of vitamin D: Determinants in primary hyperparathyroidism (Clinical Investigation) 1174
Patrono C (abst) 283
Patrono C *See* Bertani T 1248
Pattison ME (abst) 369, 373
Pattyn VM (abst) 377
Patzold U (abst) 300
Paul LC (abst) 1047
Paul M (abst) 347
Pavlitou A (abst) 861
Pavlou SN (abst) 177
Pawlowska D (abst) 434
Pawlowski I (abst) 314
Pazianas M (abst) 865
Paz-Martinez V (abst) 173, 355
Pearson J (abst) 461
Pecci G (abst) 283
Pechan BW (abst) 459
Pecker MS (abst) 282
Pedram A (abst) 264
Pelayo JC (abst) 391
Pelletier L (abst) 328
Peppler R (abst) 377, 471
Perakis K (abst) 870
Peraldi MN (abst) 465
Perfetto M (abst) 318
Perfumo F (abst) 199, 200
Perico N (abst) 267, 283
Perin N (abst) 241
Perkins HA (abst) 456
Perkinson D (abst) 329
Pernalete N (abst) 173, 355
Perras ST (abst) 256
Perri NA (abst) 238, 466
Perrinjaquet C (abst) 195
Perrone R (abst) 208, 213, 279
Perry MD *See* Carmines PK S-229
Perschel W (abst) 244
Persson G (abst) 420
Persson GE (abst) 421
Pesce A (abst) 455
Pescovitz M (abst) 458
Peset R (abst) 1050
Pesigan M (abst) 310, 346
Peter CP *See* MacDonald JS S-148
Peters P (abst) 455
Petersen J (abst) 240, 241
Peterson O (abst) 213
Peterson OW (abst) 386
Petrasek D (abst) 303
Petry F (abst) 380
Pettinger WA, Jeffries WB, Tam L-T: Renal α_2-adrenoceptors as potential targets for converting enzyme inhibitors S-191
Pfeffer JM (abst) 279
Pfeffer MA *See* Ichikawa I S-213
Pfeffer JM *See* Ichikawa I S-213
Pham MA (abst) 208
Phan S (abst) 317
Philippart Y (abst) 382
Philips TM (abst) 241
Phillips EA (abst) 241
Phillips LS (abst) 341
Phillips ME (abst) 865
Phung V (abst) 332
Picarello N (abst) 251
Piccoli A (abst) 226
Pickard LL (abst) 468
Pierroutsakos I (abst) 863
Pierucci A (abst) 283
Pietsch R (abst) 268
Piette Y *See* Vinay P 1194
Pifarre R (abst) 237
Pimentel C (abst) 354
Pineda AA (abst) 368
Pinnick RV (abst) 392

Pion I (abst) 287, 378
Piper C (abst) 283
Piraino B (abst) 355
Piskorska G (abst) 393
Pitcher D (abst) 231
Pittius C (abst) 251
Pityer R (abst) 384
Plachot J-J *See* Bourdeau AM 15
Planch A (abst) 254
Planelles G (abst) 413, 442
Plant S (abst) 343
Plante GE (abst) 271, 283
Plantilla M (abst) 382
Platsakis K (abst) 861, 866
Platt JL (abst) 178
Pleuss JA (abst) 353
Ploth DW (abst) 306
Pohl M (abst) 201
Pointillart A *See* Bourdeau AM 15
Polevsky PM (abst) 177
Polinsky M (abst) 460
Polio J (abst) 420
Pollak VE (abst) 222, 334, 337, 386
Pollock DM (abst) 284
Pollock M (abst) 242
Pollok M (abst) 242
Polymenidis Z (abst) 870
Pomerantz A (abst) 251
Pomrantz A (abst) 205, 461
Ponce P (abst) 192
Popick A (abst) 213
Popli S (abst) 237, 250
Popovtzer MM (abst) 347, 357, 373, 400, 415, 442
Poppe-Snijders C (abst) 255
Popp-Snijders C (abst) 1050
Poptic E (abst) 158
Port FK (abst) 231, 242
Portilla D (abst) 178
Porush JG (abst) 264
Posner MP (abst) 239, 242
Potempa LD (abst) 234, 243
Poujeol P (abst) 445
Powell SL (abst) 327
Prabhakaran V (abst) 347
Pramanik B (abst) 269
Pratz J (abst) 445
Predel HG (abst) 391
Preisig PA (abst) 414
Pressley MS (abst) 307
Preston R (abst) 269
Pretorius D (abst) 297
Price J (abst) 284, 345
Primdas F (abst) 384
Pritzl P (abst) 288, 315
Pritzl PM (abst) 265, 312
Pritzl PM *See* Stahl RAK 1126
Provoost AP (abst) 1045
Prowant B (abst) 250
Prud'homme M *See* Vinay P 1194
Pruszczynski W (abst) 258, 284
Psarra A (abst) 862
Psarra E (abst) 861
Psimmaras T (abst) 864
Puri VN (abst) 356
Puschett J (abst) 355
Puschett JB (abst) 264, 302
Puttney C (abst) 414
Pyrpasopoulos M (abst) 871
Quamme G (abst) 356
Quamme GA (abst) 362
Quarles LD (abst) 356
Queirolo C (abst) 200
Queirolo J (abst) 199
Querfeld U (abst) 213
Queriolo C (abst) 321
Quigg RJ (abst) 317, 328
Quinless F (abst) 224
Quintanilla AP (abst) 391
Quirion R *See* Mendelsohn FAO S-40
Rabinovich S (abst) 862
Rabinowitz L (abst) 440
Rabkin R (abst) 187, 399
Rabon EC (abst) 168
Raciti A (abst) 205, 243
Racusen LC (abst) 373
Radke KJ (abst) 216
Ragalevsky CA (abst) 328
Ragbeer SS (abst) 201
Ragheb N (abst) 242
Rahman MA (abst) 328
Rahman MA, Emancipator SN, Dunn MJ: Immune complex effects on glomerular eicosanoid production and renal hemodynamics (Laboratory Investigation). 1317
Raij L (abst) 215, 235, 307, 377
Rainfray M (abst) 210, 258
Raja RM (abst) 236, 253
Raja RM *See* Caruana RJ 1351
Rajan T (abst) 449
Rajerison RM (abst) 440
Ramee MP (abst) 218
Ramentol M (abst) 1047
Ramos EL (abst) 466
Ramsammy L (abst) 369, 374
Rand LI (abst) 207, 388
Randazzo J (abst) 383
Randazzo J *See* Dworkin LD 718
Rane S (abst) 178
Rao KV (abst) 466
Rao TKS (abst) 199, 214
Rapin I (abst) 225
Rapoport J (abst) 450
Rapp N *See* Delmez JA 795
Rascher W *See* Tulassay T 1391
Rashad A (abst) 193, 256
Raskin P (abst) 225
Rasmussen H (abst) 260
Rauch AL (abst) 303, 307
Rauch J (abst) 320
Rauterberg EW (abst) 228, 243
Rauterberg EW, Lieberknecht H-M, Wingen A-M, Ritz E: Complement membrane attack (MAC) in idiopathic IgA-glomerulonephritis (Clinical Investigation) 820
Ray P (abst) 202, 214
Raymakers JA (abst) 349, 1048
Rayment CM *See* Wilcox CS 135
Raymond JR (abst) 160, 178
Raymond KH (abst) 374
Razi M (abst) 190, 191
Reams GP (abst) 295

Rebelo MA (abst) 231
Recinos G (abst) 221
Rector F (abst) 411
Rector F Jr (abst) 438
Rector FC Jr (abst) 414
Reddy SR (abst) 308
Reed WR (abst) 385
Reed WR *See* Welik RA 1210
Reems GP (abst) 307
Reeves WB (abst) 440
Reeves WB *See* Hebert SC 580
Regan JW (abst) 178
Reid GM (abst) 308
Reid IR (abst) 356
Reid IR, Civitelli R, Westbrook SL, Avioli LV, Hruska KA: Cytoplasmic pH regulation in canine renal proximal tubule cells (Laboratory Investigation) 1113
Reilly A (abst) 315
Reiser IW (abst) 264
Reisner RK (abst) 368
Reitsma WD (abst) 1044
Remuzzi G (abst) 267, 283, 321
Remuzzi G *See* Bertani T 1248
Remuzzi G *See* Zoja C 1335
Renaud H (abst) 1417
Rennke HG (abst) 175, 312, 319, 328, 385, 392
Rennke HG *See* Meyer TW 752
Rennke HG *See* Alpers CE 781
Rennke HG *See* Zatz R S-123
Repine JE (abst) 369, 377
Resch K (abst) 320
Resnick L (abst) 304
Resnick LM (abst) 292, 308
Reuben A (abst) 420
Reuben R *See* Nolasco FEB 1160
Reznik VM (abst) 467
Ribeiro C (abst) 179
Ribeiro-Neto F (abst) 179
Rich A (abst) 425
Richards AM *See* Robertson JIS S-216
Richards G (abst) 420
Richards GK (abst) 320
Richards RM (abst) 428
Richards S (abst) 161
Richardson WP (abst) 392
Richie R (abst) 465
Richie RE (abst) 457
Ridderstrale Y (abst) 441
Riebman J (abst) 261, 274
Riegger GAJ: Experimental models of heart failure: Implications for renin and the kidney S-210
Rifai A (abst) 323
Rifai A: Experimental models for IgA-associated nephritis (Editorial Review) 1
Rifle G (abst) 1416
Rigden LB *See* Levin TN 731
Riggio R (abst) 455, 469
Riggio RR (abst) 296, 458, 467
Riley LJ Jr *See* Fruncillo RJ S-117
Ringoir S (abst) 221, 1045
Ritsios N (abst) 868
Ritter C (abst) 354
Ritz E (abst) 228, 278, 303, 352
Ritz E *See* Rauterberg EW 820
Robert A, Olmer M, Sampol J, Gugliotta J-E, Casanova P: Clinical correlation between hypercoagulability and thrombo-embolic phenomena (Clinical Investigation) 830
Robert M (abst) 349
Roberts DF *See* Papiha SS 130
Roberts JM (abst) 243
Robertson CR *See* Zimmerhackl BL 641
Robertson CR *See* McNeely EZ 662
Robertson JA (abst) 214
Robertson JIS *See* Tillman DM S-184
Robertson JIS: Overview: Renal disease and ACE inhibition S-130
Robertson JIS, Richards AM: Converting enzyme inhibitors and renal function in cardiac failure S-216
Robertson JIS: Concluding remarks S-233
Robertson RT *See* MacDonald JS S-148
Robertson W (abst) 347
Robillard J (abst) 175
Robillard JE (abst) 425
Robinette J (abst) 374
Robinette JB *See* Kelleher SP 725
Robinson AG (abst) 221
Robinson L (abst) 224
Robles RG *See* Ruilope LM 992
Robson AM *See* Alkjaersig N 772
Rocci ML Jr *See* Fruncillo RJ S-117
Rocco V (abst) 404
Roch-Ramel F *See* Knepper MA 629
Rockel A (abst) 244
Rodby R (abst) 254
Rodella H (abst) 246, 253, 862
Rodger RSC *See* Papiha SS 130
Rodicio JL (abst) 215, 309
Rodicio J *See* Ruilope LM 992
Rodrigues H (abst) 455
Rodriguez A (abst) 414
Rodriguez M, Felsenfeld AJ, Llach F: The role of aluminum in the development of hypercalcemia in the rat (Laboratory Investigation) 766
Rodriguez P (abst) 298
Roe B (abst) 231
Rohrbach R *See* Batsford SR 710
Roinel N *See* de Rouffignac C 611
Rolin HA (abst) 469
Rollier A (abst) 1417
Romao JE Jr (abst) 459
Romero JC (abst) 197, 212, 215, 420, 434
Romero JC *See* Ruilope LM 992
Romero L (abst) 295
Ronco P (abst) 327, 328, 329, 401, 1418
Ronco P *See* Zoja C 1335
Rondeau E (abst) 172, 465, 1418
Ropers HH (abst) 1044
Rosansky SJ (abst) 203, 214
Roseau S *See* Marchetti J 744
Rosen S (abst) 367, 374, 376
Rosenberg ME (abst) 215, 392
Rosenberg S (abst) 224
Rosenfeld SI (abst) 330
Rosenzweig PN (abst) 215
Ross CR (abst) 186, 409
Ross E (abst) 471
Rossi NF (abst) 284
Rota S (abst) 1418
Roth D (abst) 467

Roth D *See* Pardo V 1167
Roth J (abst) 163
Rother KO (abst) 243, 322
Rothstein DM (abst) 467
Rothstein M (abst) 215
Rothstein M *See* Delmez JA 795
Rottembourg J (abst) 354
Rouleau JL (abst) 191
Roullet C (abst) 308
Roumeliotis D (abst) 869
Rourke L (abst) 222
Roux C (abst) 327
Rowinski CA (abst) 252
Roxe D (abst) 244
Royal H (abst) 213
Royer J (abst) 461
Rspoport J (abst) 249
Rubin A (abst) 296, 455
Rubin AL (abst) 467, 470
Rubin J (abst) 254
Rubin JE (abst) 244
Rubinger D (abst) 357
Rubinger DI (abst) 400
Rufolo A (abst) 365
Ruilope LM (abst) 215, 309
Ruilope LM, Rodicio J, Robles RG, Sancho J, Miranda B, Granger JP, Romero JC: Influence of a low sodium diet on the renal response to amino acid infusions in humans (Clinical Investigation) 992
Ruley E (abst) 233
Russi JB (abst) 381
Rustemeijer C (abst) 255
Rustemeyer C (abst) 1050
Rutherford WE (abst) 230
Rutledge JC (abst) 440
Rutsky EA (abst) 199
Ryan MP (abst) 398
Ryckelynck JPh (abst) 1416
Rye D (abst) 361
Sabadini E (abst) 337
Sabatini S (abst) 179, 211, 250, 292, 352, 414, 447
Sabbaga E (abst) 455, 459
Sablay LB *See* Bank N 897
Sabnis S (abst) 334, 453
Sabolic I (abst) 406
Sachin A (abst) 869, 870
Sachs C (abst) 266, 424
Sachs C *See* Bourdeau AM 15
Sackett DI (abst) 230
Sacktor B (abst) 348, 349
Sadjadi SA (abst) 216, 221
Sadler J (abst) 217
Sadler JH (abst) 234
Sadler JH *See* Welik RA 1210
Sadovnic MJ (abst) 179
Safar ME *See* London GM 873
Safirstein R (abst) 375, 378
Sagalowsky A (abst) 459, 468
Sage C (abst) 424
Sahai A (abst) 400
Sahali D (abst) 327, 401
Sainte-Laudy J (abst) 1416
Saito F (abst) 235
Sakal R (abst) 340
Sakamoto H (abst) 278, 285
Sakelariou P (abst) 867
Sakellariou E (abst) 870
Sakellariou G (abst) 863, 867
Saklaridis J (abst) 867
Sala C (abst) 282
Salaita K (abst) 311
Salant DJ (abst) 317, 328, 334
Salcedo J (abst) 233
Salcedo JR (abst) 244
Salemans J (abst) 1047
Salido EC (abst) 259, 285
Salinas-Madrigal L (abst) 393
Salomon DR (abst) 468
Salusky IB (abst) 214, 251, 255, 357
Salvatierra O (abst) 453, 456, 457
Salvi D (abst) 298
Samels K (abst) 194
Samma S (abst) 392
Sampol J *See* Robert A 830
Samuelsson B (abst) 286
Sanaka T (abst) 216, 220
Sancho J (abst) 309
Sancho J *See* Ruilope LM 992
Sandroni S (abst) 236, 254
Sands JM (abst) 450
Sandstrom DJ (abst) 328
Sani E (abst) 304
Sansom S (abst) 441
Santiago A (abst) 245
Santos G (abst) 223
Sanz E (abst) 291
Saral R (abst) 223
Sarnacki P (abst) 347
Sartain J (abst) 230
Sasaki S (abst) 415, 437
Sasaki S *See* Ishibashi K 930
Satani M (abst) 235
Satriano JA (abst) 285
Sauer B (abst) 371
Saunders C (abst) 184
Saunders R (abst) 314
Sauve R (abst) 440
Savin VJ (abst) 392, 426, 427, 435
Savory J (abst) 205, 243
Saxinger WC (abst) 461
Sayheed M (abst) 388
Sbyrakis S (abst) 864
Scalamogna A (abst) 461
Scandling JD (abst) 212, 216
Scarpa A (abst) 175, 267
Schaap GH (abst) 197
Schachner MS, Miniter PM, Mayrer AR, Andriole VT: Interaction of Tamm-Horsfall protein with bacterial extracts (Laboratory Investigation) 77
Schacht RG (abst) 305, 379
Schaefer K (abst) 357
Schaefer RM (abst) 375
Schafer JA (abst) 285, 441
Schalekamp MADH (abst) 1048
Schalekamp MADH *See* Wenting GJ S-180
Schambelan M (abst) 267
Schamblelan M *See* Hernandez RE 1356
Schuarer K *See* Tulassay T 1391
Scharschmidt L (abst) 260
Scharschmidt LA *See* Dunn MJ S-95

Schaumann D (abst) ... 161
Schechter N (abst) ... 455
Scheinman SJ (abst) ... 179, 343
Schena FP (abst) ... 338
Scherf H (abst) ... 268
Scherzer P (abst) ... 442
Schianchi P (abst) ... 304
Schidlovsky G (abst) ... 224
Schilb T (abst) ... 196
Schirger JS (abst) ... 293
Schlatter E (abst) ... 441
Schlondorff D (abst) ... 259, 260, 285, 327
Schloonik G (abst) ... 461
Schlosser J (abst) ... 180
Schmidt-Nielsen B: The renal pelvis ... 621
Schmitz JM (abst) ... 278
Schneeberger E (abst) ... 338
Schneider H (abst) ... 1046
Schneider N (abst) ... 232
Schnermann J (abst) ... 430
Schoelermann B (abst) ... 171
Schoeppe W (abst) ... 242
Scholey JW (abst) ... 393, 426
Schollmeyer P (abst) ... 223, 289
Scholz W (abst) ... 180
Schoolwerth A (abst) ... 401
Schoolwerth AC (abst) ... 402
Schouten JA (abst) ... 1050
Schreiner G (abst) ... 329, 363
Schreiner GE (abst) ... 459
Schreiner GF (abst) ... 172
Schrier R (abst) ... 186, 295, 197, 295, 297
Schrier RW (abst) ... 198, 203, 274, 284, 309, 371, 374, 381, 391, 398, 464
Schrier R *See* Sedman A ... 1000
Schrier RW *See* Harris DCH ... 41
Schrier RW *See* Burke TJ ... S-143
Schrijver G (abst) ... 1043
Schruoder C (abst) ... 1044
Schroeder ET (abst) ... 277
Schroeder T (abst) ... 455
Schryver SM (abst) ... 420
Schubert C (abst) ... 401
Schueler VJ (abst) ... 269
Schuetz H (abst) ... 171
Schulman ES (abst) ... 233
Schulman G (abst) ... 205, 245
Schulz W (abst) ... 416
Schulz WW *See* Skidgel RA ... S-45
Schulze H (abst) ... 243
Schulze M (abst) ... 313, 329
Schuster VL (abst) ... 439, 443
Schwab SJ (abst) ... 216, 228, 240
Schwab TR (abst) ... 286
Schwartz AB (abst) ... 194
Schwartz AG (abst) ... 242
Schwartz GJ (abst) ... 415
Schwartz JH (abst) ... 180, 181, 405
Schwartz MM (abst) ... 206, 217, 223, 314, 336
Schwartz S (abst) ... 330
Schwarz HP (abst) ... 233
Schwertschiag US (abst) ... 426
Scicli AG (abst) ... 263, 419
Scoble J (abst) ... 405
Scrogin K (abst) ... 298, 304
Sdrakas L (abst) ... 864
Sealey J (abst) ... 304
Sebastian A *See* Hernandez RE ... 1356
Sebert JL (abst) ... 1417
Sedman A, Bell P, Manco-Johnson M, Schrier R, Warady BA, Heard EO, Butler-Simon N, Gabow P: Autosomal dominant polycystic kidney disease in childhood: A longitudinal study (Clinical Investigation) ... 1000
Sedor J (abst) ... 180, 325
Segal GM, Stueve T, Adamson JW: Spermine and spermidine are non-specific inhibitors of in vitro hematopoiesis (Laboratory Investigation) ... 72
Segal S (abst) ... 400
Segre G (abst) ... 355
Seidel D (abst) ... 168
Seidler A (abst) ... 311
Seifter J (abst) ... 293
Seifter JL (abst) ... 161, 182, 401
Seijer S (abst) ... 1044, 1046
Seikaly MG (abst) ... 286
Sekse I (abst) ... 329, 387, 390
Seligson G (abst) ... 317
Sell LL (abst) ... 302
Selvaggio AM (abst) ... 180, 181
Seney FD (abst) ... 420
Seniuk S (abst) ... 292
Serhan CN (abst) ... 286
Seri I (abst) ... 258
Serkes K (abst) ... 250
Servilla K (abst) ... 254, 452
Seshan V (abst) ... 269
Sethi K (abst) ... 217
Sewell DL (abst) ... 255
Seyberth HW *See* Tulassay T ... 1391
Shafik IM (abst) ... 357
Shah RM (abst) ... 216, 221
Shah SV (abst) ... 177, 313, 330
Shaldon S (abst) ... 237, 238, 245
Shanley P (abst) ... 371
Shanley PF (abst) ... 375
Shannon B (abst) ... 326
Shany E (abst) ... 249
Shapiro J (abst) ... 375
Shapiro JI (abst) ... 247, 371, 401, 464
Shapiro RJ (abst) ... 181, 362
Shaver TS (abst) ... 385
Shayman JA (abst) ... 181
Sheikhamad D (abst) ... 309
Shen H (abst) ... 239
Shen SY (abst) ... 217, 460
Shen SY *See* Welik RA ... 1210
Shenolikar S (abst) ... 181, 186
Shepley K *See* Fruncillo RJ ... S-117
Sherman RA (abst) ... 247
Sherrard DJ (abst) ... 341, 349
Sherrard DJ *See* Andress DL ... 1244
Sheth KJ (abst) ... 200, 217
Shiba K (abst) ... 160
Shibasaki T (abst) ... 330
Shiffman R (abst) ... 426
Shih WY (abst) ... 330
Shiigai T (abst) ... 289, 415, 437
Shiigai T *See* Ishibashi K ... 930
Shimizu A (abst) ... 218

Shimizu AG (abst) 230
Shinaberger JH (abst) 241, 245, 247, 349
Shiraga H (abst) 424
Shirahama T (abst) 1417
Showalter CJ (abst) 286
Shultz P (abst) 158, 182
Shvil Y (abst) 415
Siakotos M (abst) 862, 863, 864, 867, 868
Siamopoulos KC (abst) 867
Sibley R (abst) 192
Sica D (abst) 218, 239, 242
Sica DA (abst) 222
Sich M *See* Mounier F 121
Siddhanta AS (abst) 289
Siddhanta AW (abst) 269
Siebens AW (abst) 415
Siegal FP (abst) 195
Siegel N (abst) 376, 402
Siegel SR, Hadeed A: Renal handling of calcium in the early newborn period (Clinical Investigation) 1181
Sievers R *See* Jaschke W 1038
Siga E *See* Panese S 1377
Sigler MH (abst) 246
Sillix D (abst) 361, 463
Silva ACP (abst) 459
Silva F (abst) 339, 416
Silva FG (abst) 202
Silva P (abst) 271, 293, 367, 374, 376
Silver B (abst) 158
Silver MR (abst) 255
Silverman M (abst) 313, 427
Simenhoff M (abst) 251
Simmons D (abst) 287
Simmons R (abst) 399, 458
Simon E (abst) 364
Simon EE (abst) 416
Simon P (abst) 210, 218, 229
Simonetti BM (abst) 283
Simonson MS (abst) 273
Simplaceanu V (abst) 404
Simpson R (abst) 350, 362
Sina JF *See* MacDonald JS S-148
Singh AK (abst) 170, 182, 314
Singhal P (abst) 327
Singhellakis P (abst) 867, 868
Sinico RA (abst) 337, 339
Sinkey C (abst) 301
Sirivongs D (abst) 176, 359
Sirois P (abst) 271, 283
Sirota R (abst) 362
Sirota RA (abst) 225, 247
Sis J (abst) 278
Sisson-Ross S (abst) 332
Sissons JP (abst) 337
Skidgel RA, Schulz WW, Tam L-T, Erduos EG: Human renal angiotensin I converting enzyme and neutral endopeptidase S-45
Skorecki KL (abst) 172, 262
Skorecki KL *See* Ausiello DA 521
Skott O (abst) 287
Slatoplosky E (abst) 351
Slatopolsky E (abst) 342, 345, 349, 354, 357, 382
Slatopolsky E *See* Delmez JA 795
Slatopolsky E: The interaction of parathyroid hormone and aluminum in renal osteodystrophy (Nephrology Forum) 842
Slatopolsky E *See* Martin KJ 937
Slatopolsky EA *See* Andress DL 1244
Slayman CW (abst) 168
Sleifer DTh (abst) 1046
Sloand JA (abst) 326, 330
Slomowitz L (abst) 246
Slooff M (abst) 1050
Slotowski A (abst) 303
Sluiter HE (abst) 1049
Smardo FL Jr (abst) 163
Smetana O (abst) 251
Smit AJ (abst) 1044
Smith AJ (abst) 246, 346
Smith BC (abst) 402
Smith BJ *See* Molitoris BA 986
Smith CL (abst) 218
Smith CR (abst) 244
Smith DM (abst) 175
Smith JA (abst) 166
Smith LA (abst) 300
Smith MJ Jr (abst) 428
Smith MJ *See* Kirchner KA 1097
Smith P (abst) 263, 272
Smith R (abst) 273
Smith RD (abst) 286
Smith RD *See* Funcillo RJ S-117
Smith S (abst) 309, 397
Smith T (abst) 300
Smith WL (abst) 287
Smorgorzewski M (abst) 393
Soares V (abst) 331, 333
Sobh MA, Moustafa FE, El-Housseini F, Basta MT, Deelder AM, Ghoniem MA: Schistosomal specific nephropathy leading to end-stage renal failure (Clinical Investigation) 1006
Soffer O (abst) 210, 219
Solbiati L (abst) 348
Soleimani M (abst) 416
Solez K (abst) 373
Solez K *See* Gimenez LF 93
Solinger HW (abst) 464
Sollinger H (abst) 454
Sollott S (abst) 287
Solomon H (abst) 300
Solomon L *See* Hendler ED 100
Solomon RJ *See* Weinberg M 836
Sombolos K (abst) 246, 253
Son YK (abst) 195
Sondheimer J (abst) 294
Sonnenberg H, Honrath U, Wilson DR: Effects of amiloride in the medullary collecting duct of rat kidney (Laboratory Investigation) 1121
Sophocles A (abst) 195
Sorkin MI (abst) 255
Sosa RE (abst) 292
Sotsiou F (abst) 863
Souney PF *See* Wilcox CS 135
Spanos PK (abst) 867
Spar B (abst) 375
Spector AA (abst) 457
Spector D (abst) 219
Speeg KV (abst) 450
Spiegel J (abst) 192
Spielman WS (abst) 259, 406

Spilman P (abst) 220, 275
Spilman PS (abst) 196, 224
Spinowitz B (abst) 198
Spinowitz B *See* Baldwin DS 790
Spirito A (abst) 252
Spiro A (abst) 225
Spital A (abst) 468
Spitzer A (abst) 225
Spokes K (abst) 367, 374, 376
Sprague SM (abst) 195, 219
Spring KR (abst) 450
Springate JE (abst) 297, 422
Spry L (abst) 393, 454
Sraer J (abst) 287
Sraer J-D (abst) 172, 287, 465
Sraer J *See* Ardaillou R S-74
Sraer J-D *See* Ardaillou R S-74
Stahl RAK (abst) 265, 288, 289, 312, 313, 315, 329
Stahl RAK, Adler S, Baker PJ, Chen YP, Pritzl PM, Couser WG: Enhanced glomerular prostaglandin formation in experimental membranous nephropathy (Laboratory Investigation) 1126
Staiger C (abst) 283
Stalia K (abst) 229
Stamatiadis D (abst) 862, 869, 871
Stamatopoulou D (abst) 861
Stamler J (abst) 344
Stanton B (abst) 437, 441
Stanton RC (abst) 161, 182
Star R (abst) 416
States B (abst) 400
Stathakis CH (abst) 870
Stathakis OH (abst) 869
Stauffer JC (abst) 470
Stavropoulou A (abst) 862, 870
Stears J (abst) 204
Steele TH (abst) 288
Steele TH, Challoner-Hue L: Response of isolated Dahl rat kidney to calcium antagonists (Laboratory Investigation) 941
Stefanidis CJ (abst) 866, 870
Stefanou J (abst) 871
Steigerwalt SP (abst) 309
Steigmeier K (abst) 283
Stein H (abst) 362
Stein HD (abst) 225, 247
Stein JH (abst) 261, 374
Stein P (abst) 215
Steinhardt G (abst) 393
Steinhausen M, Sterzel RB, Fleming JT, Kuuhn R, Weis S: Acute and chronic effects of angiotensin II on the vessels of the split hydronephrotic kidney S-64
Steinhilber D (abst) 468
Steinman T (abst) 213, 300
Steinman TI (abst) 210
Steinmetz PR (abst) 413
Steinmuller D (abst) 468
Steinmuller DR (abst) 458
Stejskal-Lorenz E (abst) 452
Stella A, Zanchetti A: Control of renal renin release S-89
Stenberg A (abst) 421
Stenzel K (abst) 289
Stenzel KH (abst) 188, 296, 340, 455, 458, 467, 469, 470
Stephan TR (abst) 435
Stephenson JL: Models of the urinary concentrating mechanism 648
Stephenson R (abst) 407
Stern N (abst) 303
Sterns R (abst) 219
Sterzel RB (abst) 161, 318, 420
Sterzel RB *See* Steinhausen M S-64
Stetler DA (abst) 331
Steven K *See* Jensen PK 47
Stewart C (abst) 310
Stickel D (abst) 228
Stier CT Jr (abst) 310
Stinson M (abst) 215, 321
St-Louis G *See* Vinay P 1194
Stoff JS (abst) 275, 288
Stokes JB (abst) 402, 439, 443
Stone DK (abst) 183, 187, 416, 417
Stone WJ (abst) 177, 197
Stoner LC (abst) 418, 432
Stork JE (abst) 331
Stote R (abst) 267
Stout R (abst) 275
Stout RL (abst) 196, 220, 224
Stover J (abst) 460
Stowe NT (abst) 469
Strange K (abst) 450
Stratigea G (abst) 865
Straub SG *See* Wingo CS 1225
Strauss J *See* Pardo V 1167
Streem S (abst) 468
Streicher HZ (abst) 461
Strevey J (abst) 160, 182
Strife CF (abst) 331
Striker GE (abst) 163, 165, 172
Striker LJ (abst) 163, 165, 172
Strom TB (abst) 324, 335
Stromski M (abst) 402
Struck A (abst) 268
Strzelecki T (abst) 401
Stubenbord WT (abst) 455
Stueve T *See* Segal GM 72
Sturgill B (abst) 204
Sturgill BC (abst) 189, 332
Sugimoto S *See* Wyatt RJ 1019
Sugino N (abst) 216, 220
Suh J (abst) 336
Sujansky E (abst) 206
Suki WN (abst) 179
Sullivan J (abst) 341
Summer SN (abst) 274
Sun C (abst) 331
Sun MJ (abst) 316
Sun SZ (abst) 183
Susic D (abst) 303
Suthanthiran M (abst) 188, 340, 455, 467, 469, 470
Sutter PM (abst) 376
Suzuki M (abst) 257, 288, 358
Svalander C (abst) 333
Swales JD: Overview: Angiotensin converting enzyme inhibition and renal disease S-102
Swanson JE (abst) 215
Swanson R (abst) 367
Sweeney K (abst) 227
Sweeney WE (abst) 159
Swift C (abst) 468
Symvoulidis A (abst) 864

Syrganis C (abst) 868, 869
Szczepanska-Konkel M (abst) 183, 188, 358, 359
Szerlip H (abst) 183, 186
Tabei K *See* Imai M 565
Tachibana K (abst) 273
Tagliaferri M (abst) 267
Taitelbaum SL (abst) 342
Takaichi K (abst) 289
Takemura T (abst) 334
Takeuchi J (abst) 237, 273, 289, 415, 437
Takeuchi J *See* Ishibashi K 930
Taki S (abst) 359
Talor Z (abst) 407, 418
Talwalkar R (abst) 308
Tam L-T *See* Pettinger WA S-191
Tam L-T *See* Skidgel RA S-45
Tamaki T (abst) 423
Tamura T (abst) 359
Tan S (abst) 298, 310, 350
Tang MJ (abst) 185, 402, 449
Tange J *See* Ogawa K 760
Taniguchi J *See* Imai M 565
Tannen RL (abst) 400, 402
Tanner CM (abst) 219
Tanter Y (abst) 1416
Tan-Tjion LH *See* Wenting GJ S-180
Tapia L (abst) 296, 458
Tapia LA (abst) 467, 469
Tapper ML (abst) 221
Tarkowski A (abst) 333
Tatoian D (abst) 267
Tatum AH (abst) 319
Tauc M (abst) 329
Taugner R *See* Hackenthal E S-4
Tavella M (abst) 379
Tayback M (abst) 311
Taylor DW (abst) 230
Taylor N (abst) 316
Teehan BP (abst) 246
Tegos C (abst) 864
Tegzess A (abst) 1050
Teixeira RC (abst) 423
Tejani A (abst) 205, 461, 469
Tejani N (abst) 426
Tejedor A (abst) 403, 439
Tejedor A *See* Gougoux A 1279
Teller EB (abst) 351, 358
Ten RM (abst) 339
ter Haar BG *See* Geven WB 1140
Teraternoka S (abst) 216, 220
Terreros DA (abst) 376
Teschner M (abst) 375
Tessitore N (abst) 184
Teulon J (abst) 413, 442
Textor SC (abst) 220, 297
Thaiss F (abst) 289
Thanos A (abst) 867
The TH (abst) 1050
Theisen L *See* Bourdeau JE 913
Theodorides T (abst) 863
Theodoropoulos P (abst) 871
Theodoulou G (abst) 866
Thibault G *See* Vinay P 946
Thiel G (abst) 380
Thienpondt L (abst) 1417
Thies HL (abst) 195
Thiruvengadam R (abst) 238
Thomas BL (abst) 215
Thomas D (abst) 219, 346
Thomas K (abst) 255
Thomas SR (abst) 442
Thomasset M *See* Mounier F 121
Thomasson K (abst) 405
Thompson AM (abst) 297
Thompson JR (abst) 376
Thompson M *See* Bastin J 1239
Thomson NM, Kraft N: Normal human serum also contains the lymphotoxin found in minimal change nephropathy (Clinical Investigation) 1186
Thorner P (abst) 385
Thulin G (abst) 476, 402
Tidwell R (abst) 318
Tieleman C (abst) 231
Tijvra M (abst) 861
Till AE *See* Fruncillo RJ S-117
Tillis T (abst) 867
Tillman DM, Malatino LS, Lever AF, Robertson JIS: Transrenal changes in active and inactive renin and angiotensin II in renal artery stenosis: Effects of converting enzyme inhibition S-184
Tindira CA (abst) 382
Tisher CC (abst) 417
Tisher CC *See* Clapp WL 1080
Tobian I (abst) 298
Tobian L (abst) 310
Tobin J (abst) 219
Tochimaru H (abst) 332
Tolins JP (abst) 377
Tomaselli C (abst) 391
Tomaszewski J (abst) 462
Tomita K (abst) 237, 273, 289
Tomlanovich S (abst) 453, 456
Tomlanovich SJ (abst) 453, 456
Torbohm I (abst) 322
Torhorst J *See* Mason J 65
Torres F (abst) 247
Torres VE (abst) 212, 339
Torres VE, Offord KP, Anderson CF, Velosa JA, Frohnert PP, Donadio JV, Wilson DM: Blood pressure determinants in living-related renal allograft donors and their recipients (Clinical Investigation) .. 1383
Toto R (abst) 458, 459, 468
Toto RD (abst) 289
Toumpouras M (abst) 867
Tourkantonis A (abst) 863, 868, 869, 871
Tourtellotte WW (abst) 211
Townsend R (abst) 311
Trachtman H (abst) 199, 220, 290
Traindl D (abst) 233
Trakatrellis A (abst) 871
Tran SD (abst) 165
Trapp GA (abst) 225
Travis LB (abst) 420
Treat RC (abst) 370
Trebbin W *See* Weinberg M 836
Treser G (abst) 335
Trevino-Becerra A (abst) 221
Trifillis A (abst) 375
Trigg D (abst) 364, 405
Trimble ME (abst) 186, 451

Trinh MM (abst) ... 379, 430
Trinh-Trang-Tan MM (abst) ... 403
Trinh-Trang-Tan M-M *See* Bankir L ... S-25
Trinh-Trang-Tan M-M, Bouby N, Kriz W, Bankir L: Functional adaptation of thick ascending limb and internephron heterogeneity to urine concentration ... 549
Troussard X (abst) ... 1416
Troutman SL (abst) ... 285
Troy JL (abst) ... 281, 328
Troyer D (abst) ... 184, 318
Troyer DA (abst) ... 277
Truong KV (abst) ... 221
Truong L (abst) ... 332
Tsai P (abst) ... 309
Tsai SJ (abst) ... 187, 417
Tsivitae P (abst) ... 184
Tsobanelis T (abst) ... 867
Tsolas O (abst) ... 867
Tsomi K (abst) ... 866
Tsoukas A (abst) ... 864
Tsukamoto Y (abst) ... 359
Tuck ML (abst) ... 382
Tuerlings J (abst) ... 1044
Tulassay T, Rascher W, Lang RE, Seyberth HW, Schuarer K: Atrial natriuretic peptide and other vasoactive hormones in nephrotic syndrome (Clinical Investigation) ... 1391
Turka LA (abst) ... 466
Turnbull DI (abst) ... 316
Turner MC (abst) ... 336, 470
Turner RJ (abst) ... 176
Turrini F (abst) ... 406
Twardowski Z (abst) ... 250, 252
Twardowski ZJ (abst) ... 248, 253
Twardowski ZJ *See* Levin TN ... 731
Tykocinski M (abst) ... 180
Tyler K (abst) ... 454
Tyll FC (abst) ... 231
Tyson T (abst) ... 332
Uchic M (abst) ... 184
Uchida S (abst) ... 185
Uebis V (abst) ... 283
Ueno M (abst) ... 290
Ulan R (abst) ... 250
Ullian M (abst) ... 383
Ulm EH *See* MacDonald JS ... S-148
Ulm K (abst) ... 310
Umegaki K (abst) ... 287
Umetani N (abst) ... 278
Ura N (abst) ... 263
Urbaitis BK (abst) ... 377, 396
Urena P (abst) ... 248
Uribarri J (abst) ... 212
Urizar RE (abst) ... 315
Uzan M (abst) ... 248
Vafiadis S (abst) ... 864, 868
Vafiadou E (abst) ... 865
Valentich JD (abst) ... 185
Valenzuela R (abst) ... 458
Valles A (abst) ... 454
Valtin H, Edwards BR: GFR and the concentration of urine in the absence of vasopressin ... 634
van Acker BAC (abst) ... 255, 1050
van Bennekom C (abst) ... 1044
van Bronsijk H (abst) ... 1046
van Bronswijk H (abst) ... 255, 1046, 1050
Van De Stolpe A (abst) ... 290
Van De Vyver FL (abst) ... 1963, 44
Van Der Hem GK (abst) ... 185, 273, 296, 299, 1044, 1046, 1049
van der Hem GK *See* Navis G ... 815
van der Mark Th (abst) ... 1050
Van Der Meer R (abst) ... 311
Van Der Meer W (abst) ... 353
van der Meulen J (abst) ... 1046
van der Voort EAM (abst) ... 1047
Van Der Woude FJ (abst) ... 185
Van Doren K (abst) ... 172
Van Driessche W (abst) ... 451
Van Epps DE *See* Lewis SL ... 112
van Es LA (abst) ... 1047
Van Goor H (abst) ... 1043
van Hooff JP (abst) ... 1047, 1050
van Lier HJJ (abst) ... 1044
Van Liew JB (abst) ... 297, 393
Van Putten V (abst) ... 375
Van Scoy M (abst) ... 359
van Seyen AJ *See* Wenting GJ ... S-180
van Son WJ (abst) ... 1050
Van Steenberge R (abst) ... 1417
Van Valkenburg D (abst) ... 246
Vandewalle A (abst) ... 401
Vanherweghem JL (abst) ... 382
Vanhille Ph (abst) ... 1418
Vanholder R (abst) ... 221, 1045
Vanhoutte PM (abst) ... 307, 420
Vanhoutte V (abst) ... 420
Vanliew J (abst) ... 327
Vanscoy M (abst) ... 358
Vargas J (abst) ... 213
Vargemezis V (abst) ... 861
Varghese Z (abst) ... 868
Vari RC (abst) ... 291
Varla M (abst) ... 863
Vasilakakis D (abst) ... 864
Vasiliou S (abst) ... 868
Vaughan ED Jr (abst) ... 292, 394
Vaughan H (abst) ... 225
Vaughn E (abst) ... 224
Vaughn W (abst) ... 460
Vayonas G (abst) ... 865
vd Berg-Loonen RM (abst) ... 1050
vd Linden C (abst) ... 1050
Vehaskari VH (abst) ... 394
Vehaskari VM (abst) ... 409
Veis J (abst) ... 247
Velazquez H (abst) ... 432
Velaazquez H *See* Greger R ... 590
Velazquez J (abst) ... 221
Veldkamp PJ (abst) ... 299
Velentzas C (abst) ... 867
Velo M (abst) ... 291
Velosa JA *See* Torres VE ... 1383
Venezio F (abst) ... 339
Venkatachalam M (abst) ... 184, 374, 403
Venkatachalam MA (abst) ... 277
Venuto RC (abst) ... 262, 290
Verani R (abst) ... 339
Verbrugh HA (abst) ... 1046
Verbueken AH (abst) ... 344
Verburg KM (abst) ... 291

Vergemezis V (abst) ... 861
Verhoef J (abst) ... 1046
Verkman AS (abst) ... 437, 444, 451
Verkman AS *See* Ausiello DA ... 521
Verlander J (abst) ... 417
Verlander JW *See* Clapp WL ... 1080
Verma U (abst) ... 426
Vermylen CG, Levin M, Lanham JG, Hardisty RM, Barratt TM: Decreased sensitivity to heparin in vitro in steroid-responsive nephrotic syndrome (Clinical Investigation) ... 1396
Vernier R (abst) ... 294
Vernier RL (abst) ... 192, 319, 332
Verpooten GA (abst) ... 377
Verroust P (abst) ... 327, 328, 329, 401, 1418
Verroust P *See* Zoja C ... 1335
Versluis DJ (abst) ... 1046
Vertuno L (abst) ... 190, 388
Vial W (abst) ... 231
Viberti G *See* Wiseman MJ ... 1012
Villamediana LM (abst) ... 291
Villarreal D (abst) ... 291
Vinay P (abst) ... 194, 403, 430
Vinay P, Prud'homme M, Vinet B, Cournoyer G, Degoulet P, Leveille M, Gougoux A, St-Louis G, Lapierre L, Piette Y: Acetate metabolism and bicarbonate generation during hemodialysis: 10 years of observation (Clinical Investigation) ... 1194
Vinay P, Manillier C, Lalonde L, Thibault G, Boulanger Y, Gougoux A, Cantin M: Comparative effect of ANF and various diuretics on isolated nephron segments (Laboratory Investigation) ... 946
Vinay P *See* Gougoux A ... 1279
Vincent HH (abst) ... 1048
Vincenti F (abst) ... 453, 456, 470
Vinet B *See* Vinay P ... 1194
Vaio CP, Figueroa CD: Evidence for a stimulatory effect of high potassium diet on renal kallikrein (Laboratory Investigation) ... 1327
Virginillo M *See* Panese S ... 1377
Viron B (abst) ... 258, 284
Viscuso R (abst) ... 464
Vishny WK (abst) ... 176
Visser WJ (abst) ... 196, 349, 1048
Vitting KE (abst) ... 221, 232
Vlasses PH *See* Fruncillo RJ ... S-117
Vlassis T (abst) ... 865
Voekler JR (abst) ... 222
Vogt A *See* Batsford SR ... 710
Von Albertini B (abst) ... 245, 247
Von Herrath D (abst) ... 357
Von Lilien T (abst) ... 255
Von Niederhausern W (abst) ... 204
Vos J (abst) ... 349, 1048
Voscaki I (abst) ... 864, 871
Vosnides G (abst) ... 863, 864
Vosnides GR (abst) ... 862
Voudiklari S (abst) ... 867
Vouyiouglis N (abst) ... 867
Vreede PJ (abst) ... 319
Vrettos K (abst) ... 864
Wabner C (abst) ... 359, 361
Wacholtz MC (abst) ... 332
Wadhwa N (abst) ... 337, 455
Wadhwa NK (abst) ... 222
Waeber B *See* Brunner HR ... S-104
Wagner K (abst) ... 465
Wakabayashi T (abst) ... 273
Walb D (abst) ... 244
Wald H (abst) ... 347, 357, 373, 415, 442
Waldo FB (abst) ... 222, 337
Waligura A (abst) ... 171
Walker BR (abst) ... 270
Walker J (abst) ... 356
Walker K (abst) ... 411
Walker P (abst) ... 339
Walker PD (abst) ... 330
Walker PJ (abst) ... 229
Walker WG (abst) ... 311
Walker WG *See* Gimenez LF ... 93
Wall BM (abst) ... 417
Wall C III (abst) ... 255
Wall SM (abst) ... 442
Walle A (abst) ... 340
Walle AJ (abst) ... 470
Walle AJ, Wong GY, Clemons GK, Garcia JF, Niedermayer W: Erythropoietin-hematocrit feedback circuit in the anemia of end-stage renal disease (Clinical Investigation) ... 1205
Walli A (abst) ... 168
Walser M (abst) ... 223
Walshe JJ (abst) ... 252, 256
Wang BC (abst) ... 260, 270
Wang J (abst) ... 291, 296, 340
Wang T (abst) ... 291
Wanner C (abst) ... 223
Warady BA *See* Sedman A ... 1000
Ward H (abst) ... 331, 333
Warden DH (abst) ... 443
Warnock DG (abst) ... 168, 389, 404, 423, 432, 443
Warram JH (abst) ... 207, 388
Warren GV (abst) ... 223
Warshaw B (abst) ... 251
Warvariv V (abst) ... 470
Wasserman M (abst) ... 363
Watanabe N (abst) ... 330
Watanabe T (abst) ... 287
Watkins DW (abst) ... 351, 358
Watlington CO (abst) ... 268
Watson A (abst) ... 223
Watson AJ (abst) ... 220, 224
Wauters JP (abst) ... 470
Wauthers J-P (abst) ... 237
Wayman AL (abst) ... 230, 241
Wayman AL *See* Cheung AK ... 1072
Webb D (abst) ... 224
Weber E (abst) ... 311
Weber M (abst) ... 160, 340
Weber PC (abst) ... 158, 370
Webster SK (abst) ... 360
Wedeen RP (abst) ... 196, 224, 364, 365
Weening JJ (abst) ... 314, 1043
Weidmann P *See* Laederach K ... 107
Weidmann P *See* Bianchetti MG ... 956
Weimar W (abst) ... 1046, 1048
Weinberg JM (abst) ... 185, 397
Weinberg M, Belknap S, Trebbin W, Solomon RJ: Effects of changing salt and water balance on renal kallikrein, kininogen and kinin (Clinical Investigation) ... 836

Weinman E (abst) 181
Weinman EJ (abst) 186
Weinreich T (abst) 228
Weinstein R (abst) 193
Weinstein SW (abst) 451
Weir MR (abst) 234, 471
Weis S *See* Steinhausen M S-64
Weisberg L (abst) 183, 186
Weisenger J (abst) 248
Weisinger J (abst) 360
Weisinger JR (abst) 173
Weisman S (abst) 292
Weisman SM (abst) 394
Weiss M (abst) 222, 337, 386
Weiss MA (abst) 334
Weiss R (abst) 225
Welbourne TC (abst) 410, 417
Welch WJ (abst) 427
Welik RA, Josselson J, Shen SY, Reed WR, Sadler JH: Repeated low-dose streptokinase infusions into occluded permanent, central-venous hemodialysis catheters (Clinical Investigation) 1210
Welling PA (abst) 452
Wellisch DK (abst) 253
Welsch J *See* Mason J 65
Wenman W (abst) 250
Wens R (abst) 231
Wenting GJ, Derkx FHM, Tan-Tjion LH, van Seyen AJ, Man int'd Veld AJ, Schalekamp MADH: Risks of angiotensin converting enzyme inhibition in renal artery stenosis S-180
Werber H (abst) 180
Weshler Z (abst) 400
Wesseling H (abst) 1044
Wesson DE (abst) 418
West L (abst) 255, 256
West ML (abst) 224, 443
Westberg G (abst) 333
Westbrook S (abst) 399
Westbrook SL *See* Reid IR 1113
Westenfelder C (abst) 202, 261, 274, 292, 368, 389, 419
Wetzel JFM (abst) 1044
Wetzels JFM (abst) 1049
Wharton J (abst) 292
Whelton A (abst) 196, 220, 223, 224, 275
Whelton PK (abst) 311
White MD (abst) 371, 404
Whiteside C (abst) 427
Whittembury G (abst) 444
Whittenburg D (abst) 369, 377
Whittlesey GC (abst) 302
Whitworth JA: Mechanisms of glucocorticoid-induced hypertension (Nephrology Forum) 1213
Whorton AR (abst) 426
Wible JH (abst) 311
Wickner W (abst) 160
Wiegmann TB (abst) 427, 448
Wieslander J *See* Bygren P 25
Wieslander J *See* Fliger FD 800
Wigfall DR (abst) 340
Wiggins R (abst) 317
Wiggins RC (abst) 318, 333
Wilcox CS (abst) 208, 427
Wilcox CS, Guzman NJ, Mitch WE, Kelly RA, Maroni BJ, Souney PF, Rayment CM, Braun L, Colucci R, Loon NR: Na^+, K^+ and BP homeostasis in man during furosemide: Effects of prazosin and captopril (Clinical Investigation) 135
Wilder L (abst) 365
Wilke L (abst) 292
Wilke T (abst) 310
Wilkes B (abst) 287, 390
Wilkes BM (abst) 378
Wilkinson A (abst) 471
Wilkinson AH (abst) 195, 211
Wilkinson R *See* Papiha SS 130
Willems HL *See* Geven WB 1140
Williams AH (abst) 463
Williams GH (abst) 436
Williams JC Jr (abst) 452
Williams PD (abst) 186
Willingham MC (abst) 169
Wills M (abst) 205, 243
Wilson CB (abst) 333, 364, 386
Wilson CB *See* Gabbai FB 1267
Wilson DM *See* Torres VE 1383
Wilson DR *See* Sonnenberg H 1121
Wilson P (abst) 311, 312
Wilson PD (abst) 186
Wilson R (abst) 225
Wilson RS (abst) 219
Wilson SK: A comparison of the effects of angiotensin II and norepinephrine on intrarenal arteries in the rat. S-193
Winaver J (abst) 174
Windus D (abst) 382
Windus DW *See* Delmez JA 795
Winearls CG (abst) 337
Wineman R (abst) 196
Wingen AM (abst) 322
Wingen A-M *See* Rauterberg EW 820
Wingo C (abst) 417
Wingo CS, Bixler GB, Park CH, Straub SG: Picomole analysis of alkali metals by flameless atomic absorption spectrophotometry (Technical Note) 1225
Winner P (abst) 225
Winston J (abst) 378
Winter C (abst) 294
Wiseman MJ, Mangili R, Alberetto M, Keen H, Viberti G: Glomerular response mechanisms to glycemic changes in insulin-dependent diabetics (Clinical Investigation) 1012
Witsoe D (abst) 250
Witten D (abst) 462
Witters L (abst) 166
Wolcott DL (abst) 253
Wold L (abst) 310
Wold LE (abst) 268
Wolf C (abst) 287
Wolfe RA (abst) 231
Wolff NA (abst) 187
Wolfson M (abst) 226, 233, 248
Wolszczak EA (abst) 265
Womble D (abst) 458
Wombolt D (abst) 471
Wong GY (abst) 470
Wong GY *See* Walle AJ 1205
Wong KR (abst) 451
Wong NLM (abst) 360
Wong S (abst) 162
Wonigeit K (abst) 300

Woo David DL (abst) 187
Woo KT (abst) 340
Wood IG (abst) 466
Wood M (abst) 361, 463
Woodcock EA *See* Ogawa K 760
Woods LL (abst) 427
Woods RL *See* Anderson WP S-157
Woolverton V (abst) 306
Worcester E (abst) 361
Worley E (abst) 230
Wright FS (abst) 420, 432
Wright L (abst) 361
Wu G (abst) 862
Wu K (abst) 350
Wyatt RJ (abst) 202, 323, 337
Wyatt RJ, Kanayama Y, Julian BA, Negoro N, Sugimoto S, Hudson EC, Curd JG: Complement activation in IgA nephropathy (Clinical Investigation) 1019
Wylds AC (abst) 370
Xavier M (abst) 455
Xie SX (abst) 183
Xie XS (abst) 187, 416, 417
Xue H (abst) 343
Yagil C (abst) 187
Yamada Y (abst) 165
Yamaguchi D (abst) 351, 355
Yamaguchi DT (abst) 188
Yamamoto T (abst) 333
Yamashita N (abst) 279, 282, 431
Yamashita W (abst) 334, 386
Yan T (abst) 356
Yanagawa N (abst) 309, 343, 358, 361, 405
Yanase M (abst) 399
Yang C (abst) 263
Yang T (abst) 331
Yang WC (abst) 418, 443
Yankovitz N (abst) 249
Yap HK (abst) 340
Yared A (abst) 293, 334
Yarger WE (abst) 272, 426
Yee B (abst) 195, 198
Yeh I (abst) 241
Yeyati N (abst) 443
Yin D-P (abst) 222
Ying A (abst) 350
Yohay D (abst) 456
Yonemura K *See* Honda N 1233
Yong CKK (abst) 362
Yoo MH (abst) 388
Yoshida Y (abst) 384, 394, 424
Yoshikawa Y (abst) 332
Yoshioka K (abst) 334
Yoshioka T (abst) 293, 424
Yoshiyama N (abst) 237, 273, 289, 415, 437
Yoshiyama N *See* Ishibashi K 930
Youmans S (abst) 161
Youmans SJ (abst) 188, 406
Young DB (abst) 424, 428
Young E (abst) 306, 350, 362
Young L (abst) 222
Young S (abst) 202
Young SG (abst) 364
Yucha CB (abst) 418
Yudis M (abst) 225, 247, 362
Yudkoff M (abst) 400
Yuhas Y (abst) 251
Yusufi ANK (abst) 183, 188, 273, 358
Zabetakis PM (abst) 221, 232
Zackson D (abst) 341
Zager RA (abst) 378
Zamboulis C (abst) 869
Zambraski EJ (abst) 305
Zanchetti A *See* Stella A S-89
Zanglis A (abst) 293
Zappacosta AR (abst) 256
Zatz R (abst) 328, 395, 423
Zatz R, Anderson S, Meyer TW, Dunn BR, Rennke HG, Brenner BM: Lowering of arterial blood pressure limits glomerular sclerosis in rats with renal ablation and in experimental diabetes S-123
Zavala DC *See* Lim VS 808
Zawalich K (abst) 260
Zedalis J (abst) 385
Zeidel ML (abst) 271, 293
Zeis PM (abst) 863
Zelikovic BI (abst) 452
Zeller KR (abst) 225
Zerefos N (abst) 378, 869, 870
Zerwekh JE (abst) 362
Zettle R (abst) 209
Zettle RM (abst) 443
Zevin D (abst) 194
Zikria M (abst) 391
Zimmerhackl BL, Robertson CR, Jamison RL: The medullary microcirculation 641
Zimmerman C (abst) 265
Zimmerman RS (abst) 280, 286, 293
Zimmerman S (abst) 254
Zimmerman SW (abst) 257, 464
Zingraff J (abst) 248, 1417, 1418
Ziroyanis P (abst) 864
Ziroyanis PN (abst) 865
Ziroyannis P (abst) 870
Ziroyannis PN (abst) 870
Ziyadeh FN (abst) 444
Zizian L *See* Gougoux A 1279
Zoja C, Benigni A, Verroust P, Ronco P, Bertani T, Remuzzi G: Indomethacin reduces proteinuria in passive Heymann nephritis in rats (Laboratory Investigation) 1335
Zorn SL (abst) 461
Zoumbaridis N (abst) 865
Zuckerman A (abst) 188
Zuili I (abst) 249
Zuyderhoudt FMJ (abst) 1048

Subject Index For Volume 31

A-V fistulas in children (abst) 233
Abdominal pressure, CAPD (abst) 248
ACE inhibition
(abst) 212
captopril, inhibition (abst) 333
mechanisms in congestive heart failure 1390
Acetaminophen, nephropathy (abst) 192
Acetate
HCO_3 transport (abst) 408
metabolism, bicarbonate generation during HD 1194
to bicarbonate dialysis (abst) 227
Acetazolamide
on Na/HCO_3 cotransport (abst) 416
proteinuria (abst) 210
renal metabolism and ammoniagenesis 1279
Acid
CyA stimulates (abst) 414
dietary, effect on Mg (abst) 362
organic in Cl (abst) 439
phosphonoformic, mechanism of (abst) 359
Acid-base fluxes, determination (abst) 406
Acidic compartments in OMCD (abst) 417
Acidification
acute hypocapnia (abst) 405
glucagon inhibits urinary (abst) 407
intercalated cells of OMCD 1080
renal insufficiency (abst) 411
urine anion gap in evaluation (abst) 202
Acidosis
abnormal branched-chain amino acid metabolism (abst) 386
alkalosis, respiratory, regulate ketoacid production (abst) 410
chronic metabolic, increases glutamine transport (abst) 399
cytoprotection (abst) 375
glucocorticoids and glutamine production in (abst) 410
glucocorticoids on glutamine utilization (abst) 417
H^+ ATPase (abst) 407
hyperkalemia in hyperchloremic (abst) 209
insulin resistance in uremia (abst) 389
Na/H antiporter, $NaHCO_3$ cotransporter (abst) 404
pH gradient across CCD 930
recovery of cell pH from respiratory (abst) 409
TAL and internephron heterogeneity to urine concentration 549
Acquired renal cystic disease (abst) 210
Acute hypocapnia (abst) 405
Acute renal failure
acquire resistance to 1233
dietary protein (abst) 363
disposition of insulin (abst) 395
furosemide, renal blood flow (abst) 368
glycerol-induced, prostaglandin (abst) 378
hemorrhagic reduction in BP 725
human alpha 2b interferon (abst) 207
iron in ischemic and hemoglobinuric (abst) 373
ischemic, Ca and endothelium derived relaxing factor (abst) 374
K^+ loading, uranyl nitrate (abst) 376
nifedipine (abst) 865
open heart surgery (abst) 195
serum iron (abst) 865
Acute serum sickness
PAF mediates nephrotoxic nephritis 1248
Acute tubular necrosis
ACE inhibition S-143
furosemide no protection against ischemic (abst) 373
Adenine nucleotide concentration (abst) 396
nucleotide toxicity (abst) 374
Adenosine
modulates medullary injury (abst) 367
nucleotide, ATP (abst) 397
prostaglandin mediates 2-chloroadenosine (abst) 423
receptor regulation of erythropoietin secretion (abst) 290
receptors (DPX) (abst) 265
signal transduction, Ca (abst) 259
Adenosine triphosphate
acidosis (abst) 407
adriamycin nephrosis, proteinuria 704
exogenous (abst) 402
sensitivity of K^+ channels (abst) 436
Adenylate cyclase
activity, dietary protein (abst) 430
multi-hormonal control 512
ADH
PMA increase immunolabelling of toad bladder (abst) 174
proteins, permeability response to (abst) 169
Adrenergic agonists, Ca (abst) 284
Adrenergic receptor
stimulation mechanism (abst) 160
Adrenoceptor, beta, in sheep (abst) 175
Adriamycin nephrosis
ATPase activity independent of proteinuria 704
protein restriction and CEI (abst) 1043
proteinuria (abst) 393
Adsorbent, carbonaceous in CRF (abst) 216
Adult respiratory distress syndrome
Cya associated (abst) 464
Afferent arteriole
distribution of renin and angiotensin S-4
Age
PTH action on Na-Ca exchange (abst) 348
related, P reabsorption (abst) 349
transplant outcomes in (abst) 456
transplantation in (abst) 471
water excretion (abst) 219
Aggrephore, vesicular traffic (abst) 164
Agonist, dopamine SKF 38393 (abst) 310
AIDS
associated nephropathy (abst) 199
HTLVIII associated nephropathy (abst) 336
hyponatremia, hypoadrenalism, nonosmolar vasopressin (abst) 221

kidney transplantation (abst) ... 456
related glomerulopathy ... 1167
related glomerulopathy (abst) ... 213
tubular nephropathy (abst) ... 195
ultrastructural markers (abst) ... 335
AIgM.C1q probe for C1qR (abst) ... 330
Albumin
glomerulopathy (abst) ... 315
hyperlipemia in nephrotic patients ... 1367
isoelectric point, nephrosis (abst) ... 321
Albuminuria
BP, hydrala (abst) ... 395
granulocytes (abst) ... 1043
Aldosterone
α-subunit of Na/K-ATPase in CCD ... 1104
ANP inhibits secretion (abst) ... 260
apical K-H exchange in colon (abst) ... 279
Ba^{++} effects on apical cation selectivity (abst) ... 442
chronic chloride depletion metabolic alkalosis (abst) ... 417
cortical collecting cell monolayers (abst) ... 160
deficiency, papillary acidification parameters (abst) ... 407
induced proteins, localization to luminal surface (abst) ... 183
K^+ concentration (abst) ... 279
kallikrein, kininogen and kinin, changing salt and water ... 836
Alkali
picomole analysis of metals ... 1225
Alkalinization
IGF II induced (abst) ... 169
luminal and basolateral transport (abst) ... 415
Alkalosis
chloride depletion metabolic, aldosterone (abst) ... 417
chronic metabolic, acidification in PCT (abst) ... 412
citrate reabsorption (abst) ... 444
furosemide infusion (abst) ... 208
metabolic, sodium chloride determines severity ... 1355
new syndrome, lactic (abst) ... 191
Alkyldihydroxyacetone phosphate (abst) ... 293
Allergy, idiopathic nephrotic syndrome (abst) ... 1415
Allograft
blood pressure in donor, recipient ... 1382
Allotypes in IMN ... 130
Alpha 2 adrenoceptor
agonist, VP (abst) ... 270
CEI ... S-191
characterization in arterioles (abst) ... 422
receptors (abst) ... 178
Alport syndrome, X-linked (abst) ... 1044
Aluminum
absorption (abst) ... 214
antacid in dialysis (abst) ... 234
associated disease in chronic HD (abst) ... 341
bone cell response to PTH and vitamin D3 ... 736
bone uptake, PTH (abst) ... 354
cardiac abnormalities in HD (abst) ... 238
chelation, deferoxamine ... 986
collagen synthesis (abst) ... 342
deferoxamine in bone disease ... 1343
deferoxamine infusion test, neuropsychologic (abst) ... 219
desferioxamine test (abst) ... 345
histomorphometric correlation, bone disease (abst) ... 341
hypercalcemia ... 766
loading, thyroparathyroidectomy modifies skeleton ... 923
microcytic anemia in hemodialysis (abst) ... 225
neutron activation analysis (abst) ... 205
osteodystrophy, PTH ... 842
plasma levels in hemodialysis (abst) ... 229
PTH response to ... 15
removal is associated with vitamin D (abst) ... 346
subcellular localization in parathyroid glands (abst) ... 344
transfer during HD (abst) ... 243
vitamin D 3 (abst) ... 352
Amdinocillin, urinary kinetics (abst) ... 196
Amiloride
and analogues of retard MDCK cyst growth (abst) ... 184
bicarbonate handling (abst) ... 418
medullary collecting duct ... 1121
Na influx (abst) ... 178
Na transport (abst) ... 301
resistance, LLC-PK1 (abst) ... 168
Amines, monensin, nigericin (abst) ... 287
Amino acid
ANP in dehydrated rats ... 760
hyperalimentation (abst) ... 220
induced hyperfiltration (abst) ... 418
infusion, hemodynamics (abst) ... 427
infusions, low sodium diet ... 992
oral, GFR (abst) ... 382
polyol, methylamine solutes in renal inner medulla ... 562
TAL (abst) ... 403
Aminoglycoside
nephrotoxicity (abst) ... 370
metabolism ... 59
Aminohydroxypropylideenbishopsphonate
renal osteodystrophy (abst) ... 349
Aminonucleoside nephrosis
acute tubulointerstitial nephritis (abst) ... 317
status of glomerular proteoglycan ... 1298
Amlodipine monotherapy (abst) ... 295
Ammonia
determinants of entry along PCT (abst) ... 416
disequilibrium pH (abst) ... 416
secretion by tubule monolayers (abst) ... 405
Ammoniagenesis
ACZ on renal metabolism ... 1279
pathways and regulation (abst) ... 400
pH, 15N labelled glutamine and glutamate (abst) ... 400
phorbol esters (abst) ... 396
Amphotericin B, vasoconstriction (abst) ... 377
Amylase isoenzyme in hemodialysis (abst) ... 193
Amyloidosis
dialysis, tissular distribution (abst) ... 1416
fibrillary glomerulonephritis ... 781
hemodialysis (abst) ... 227
spohdylarthropathies of hemodialysis (abst) ... 1399
Analbuminemia, fluid partition (abst) ... 423
Analgesic abuse, interstitial nephritis ... 1416
Anaphylactic reaction in dialysis (abst) ... 243
Anaphylactoid purpura nephritis (abst) ... 192
Anatomy
nephron ... S-25
of Ang II site ... S-2

Ancillary conductance pathways (abst) 168
Androgen therapy in hemodialysis 100
Anemia
  Al induced in hemodialysis (abst) 225
  in ESRD, correction of (abst) 198
  of ESRD 1205
Angioplasty in hypertension (abst) 869
Angiotensin
  ANF (abst) 286
  binding sites correlate with ANP (abst) 278
  CEI, AII (abst0 390
  functional receptors on PCT (abst) 291
  mRNA expression in ontogeny (abst) 268
Angiotensin converting enzyme
  inhibition, artery stenosis (abst) 299
    acute tubular necrosis S-143
    Ang II in chronic renal failure S-112
    normal kidney S-104
    renal disease S-102
Angiotensin converting enzyme inhibitor
  enalapril, enalaprilat in renal insufficiency S-117
  not alike (abst) 307
Angiotensin I
  and II on glomerular function (abst) 280
  converting enzyme and kinin 744
  converting enzyme and neutral endopeptidase S-45
Angiotensin II
  binding studies in cirrhotic rats (abst) 291
  Ca^{++} activated Cl^- conductance (abst) 282
  captopril administration (abst) 262
  chronic partial ureteral obstruction (abst) 421
  control of renal renin release S-89
  converting enzyme, reduction of proteinuria (abst) 1044
  cytosolic pH (abst) 271
  dietary protein, vascular reactivity (abst) 425
  dihydropyridine calcium antagonist felodipine (abst) 1049
  heart failure, renal function and S-220
  hemodynamics and ultrafiltration coefficient (abst) 427
  interlobular arterial resistance 1291
  intracapillary volume (abst) 276
  isolated glomeruli and cultured glomerular cells S-74
  mechanism of decreased vascular response, hypertension 906
  modulates glomerular AII receptors (abst) 287
  periarterial pathway for renin S-51
  PGE_2 synthesis (abst) 285
  proximal tubular fluid reabsorption, Ca, lipoxygenase (abst) 279
  reabsorption dependent on Ca and lipoxygenase (abst) 279
  saline loading (abst) 419
  secretagogue of ANP (abst) 292
  thromboxane A_2, ureteral occlusion (abst) 394
  tubular effects S-81
  ultrafiltration coefficient (abst) 426
Anion
  current, NaCl transport (abst) 438
  exchangers, cDNAs encoding (abst) 159
  organic, cyst formation (abst) 159
Anionic
  proteins, tubular uptake of proteins (abst) 449
  sites in capillaries 52
  surface charges (abst) 159
Anoxia
  change in energy reserves during ischemia 1239
Antagonism, hydrochlorothiazide 1097
Antagonists
  Ca in Dahl 941
Anti-GBM nephritis
  terminal complement pathway (abst) 321
Anti-glomerular basement membrane
  antibody, intrarenal hemodynamic alterations 8
  human, induces glomerulonephritis in sheep 25
  epitopic specificity, antisera (abst) 322
Anti-viral factor in dialysate (abst) 251
Antibody
  anti-α-, immune complexes in children, IgAN, HS purpura 1132
  anti-tubular basement, interstitial nephritis (abst) 316
  anto-interleukin 2 receptor (abst) 324
  distribution of renin and angiotensin S-4
  Fc, uptake of macromolecules (abst) 327
  glomerular extracellular matrices (abst) 326
  identification of monoclonal (abst) 327
  membranous nephritis, glycoprotein (abst) 338
  mesangial cell injury (abst) 333
  monoclonal against laminin A chain and B chain (abst). 325
  monoclonal, leukocyte analysis in glomerulonephritis 964
  PG production mechanism (abst) 315
  RNA polymerase I (abst) 331
  solid phase C1q, membranous glomerulophritis (abst) 331
  specificity to streptococcus mutans (abst) 315
  trypanosomiasis-related glomerulonephritis (abst) 1047
Anticoagulation in hemodialysis (abst) 240
Antidiuretic hormone
  cellular response (abst) 447
  effect on collecting duct 530
  MTAL volume regulation (abst) 446
  receptor to vasopressin and other hormones 512
  stimulated water reabsorption (abst) 450
  TAL and internephron heterogeneity to urine concentration 549
  urinary acidification (abst) 405
  urine concentrating mechanism 549
Antidiuretic
  SK&F 101926 (abst) 267
Antigen
  anti-GP600 of Heymann nephritis (abst) 174
  cross reactivity of Heymann nephritis (abst) 324
  endostreptosin (abst) 317
  failure to induce IgA nephropathy (abst) 1046
  fibronectin binding (abst) 316
  Goodpasture target in GBM (abst) 340
  HLA-A, B, DR in Greek idiopathic GN patients (abst) 863
  interleukin 1, interferon gamma, endotoxin (abst) 322
  major histocompatibility complex, murine kidney (abst) 463
  monoclonal anti-DNA antibodies (abst) 326
  proteinuria in GN (abst) 333
  recognition complex, T cell activation (abst) 469
  target for immune deposits (abst) 329
  target in human anti-tubular basement membrane nephritis 800
  tubular damage in tubulointerstitial nephritis (abst) 335

Antihypertensive
mechanism of hydrochlorothiazide response, indomethacin ... 1097
therapy, DAHL rats ... 718
therapy, NSN (abst) ... 379
Antimycin A, ATP (abst) ... 162
Antiporter
Na-H activity and HCO_3 reabsorption (abst) ... 418
Na/H mediates bicarbonate absorption (abst) ... 414
Antithymocyte serum, CyA (abst) ... 455
Apical chloride channels, colon (abst) ... 435
Apical membrane
cAMP (abst) ... 181
Cl/base exchange (abst) ... 428
Aplastic bone disease (abst) ... 349
Apoferritin immune complex GN (abst) ... 319
Aprotinin, vasopressin ... 1092
Arachidonic acid
cAMP, LLC-PK1 (abst) ... 276
metabolism (abst) ... 395
metabolite (abst) ... 286
Arginine
indomethacin blocks rise (abst) ... 201
Arginine vasopressin
ANF on Ca^+ in vascular smooth muscle cells (abst) ... 309
cAMP, Ca-calmodulin (abst) ... 289
dimethyl sulfoxide, water flow (abst) ... 292
Na-K-ATPase in CCD (abst) ... 289
removal stimulates secretion (abst) ... 258
trifluperazine and napthalene-sulfonamide (abst) ... 284
Arterial resistance, interlobular ... 1291
Arterioles, α-adrenoceptor (abst) ... 422
Artery
contraction (abst) ... 420
evaluation of renal, DSA (abst) ... 867
renal, morphology of renin synthesis ... S-18
Ascending vasa recta, models ... 662
Ascites, transport (abst) ... 253
Aspirin, diabetic GN (abst) ... 194
Atherosclerosis, vascular disease ... 1153
percutaneous transluminal angioplasty (abst) ... 192
ATP
clathrin-coated vesicle proton pump (abst) ... 183
content in proximal cells (abst) ... 170
H_2O_2 injury (abst) ... 159
ATPase
adriamycin mediated by oxygen free radical species (abst) ... 1045
Ca_2^+, Mg_2^+ dependent (abst) ... 342
characterization of H^- (abst) ... 414
Cl^- channel inhibitors and diuretics on (abst) ... 409
H^+, immunocytochemical localization of (abst) ... 167
H^+, structural heterogeneity (abst) ... 169
mitochondria-rich cell plasma (abst) ... 162
Na-K activity, glucocorticoid receptors (abst) ... 165
vanadate sensitive activity (abst) ... 413
Atrial natriuretic factor
ADPKD (abst) ... 295
ammonucleoside-induced NS (abst) ... 272
cirrhosis with ascites, nephrotic syndrome (abst) ... 273
cisplatin nephrotoxicity (abst) ... 365
cytosolic free Ca (abst) ... 258
dose-response relationship (abst) ... 288
experimental nephrosis (abst) ... 283
failure to induce natriuresis (abst) ... 264
Goldblatt hypertension (abst) ... 295
hAND 102–126 in normals (abst) ... 270
ischemic ARF (abst) ... 371
Na excretion, tachycardia (abst) ... 280
Na retention, heart failure (abst) ... 291
natriuretic at physiologic concentrations (abst) ... 293
nucleotide accumulation in CCTC (abst) ... 281
receptors and response, low salt diet (abst) ... 257
renal, cardiovascular, endocrine actions (abst) ... 286
renin-angiotensin system (abst) ... 286
saline infusion in hypertensive, normotensive (abst) ... 282
various diuretics on isolated nephron segments ... 946
vasopressin in pulmonary edema (abst) ... 195
ventricular immunoreactive (abst) ... 268
Atrial natriuretic peptide
adenine nucleotide (abst) ... 397
aldosterone response to hypervolemia (abst) ... 274
angiotensin II a secretagogue (abst) ... 292
arginine vasopressin (abst) ... 274
artificial heart implantation (abst) ... 202
binding sites correlate with AII (abst) ... 278
cardiac changes obscure renal effects of (abst) ... 274
CEI and renal function in cardiac failure ... S-216
cGMP metabolism (abst) ... 397
characteristics in renal diseases (abst) ... 278
cirrhosis (abst) ... 262
concentrations, effect on release of renin (abst) ... 263
coronary sinus (abst) ... 261
CRF, cardiac denervation (abst) ... 284
dehydration ... 760
determination in microliter samples (abst) ... 259
dietary salt (abst) ... 288
essential hypertension (abst) ... 296
glomerular binding (abst) ... 198
inhibition of Ca_2^+ ATPase activity (abst) ... 266
inositol trisphosphate (abst) ... 277
mechanism of natriuretic action (abst) ... 1049
mechanism of renal natriuretic action (abst) ... 273
metabolism by membranes and tubules (abst) ... 271
myocardial infarction, Na (abst) ... 279
Na reabsorption (abst) ... 290
natriuresis after, in sodium restriction (abst) ... 1049
not dominant in natriuresis (abst) ... 270
papillary collecting duct transport (abst) ... 430
PGE_2, 6-keto-$PGF_{1\alpha}$ production (abst) ... 272
PTH (abst) ... 400
receptors along the nephron (abst) ... 262
renal effects (abst) ... 265
renal function and BP (abst) ... 391
specific receptors in medullar collecting duct (abst) ... 271
thromboxane-induced vasoconstriction (abst) ... 277
vasa recta blood flow (abst) ... 280
vasoactive hormones in nephrotic syndrome ... 1373
volume expansion and contraction in normal men (abst) ... 285
Atrial peptide
physiological regulator of pressures (abst) ... 260
Atriopeptin
resets tubuloglomerular feedback (abst) ... 284
Atriopeptin III, cGMP, renin (abst) ... 272
Attitudes towards kidney donation (abst) ... 468
Auto-immune glomerulonephritis
cell transfer (abst) ... 332
Autoantibody

against granulocyte cytoplasm (abst) 337
renal failure (abst) 320
Autologous immune complex nephritis
hybridoma model (abst) 313
Autonomic insufficiency in BP (abst) 297
Autoradiography, angiotensin receptor S-40
Autosomal dominant inheritance, Mg 1140
Autosomal dominant PKD
β_2 microglobulin in 85
cyst formation and growth 1145
renal structure and concentrating ability (abst) 197
Avian mesangial cell culture (abst) 179
Azathioprine
6-mercaptopurine (abst) 1047
Azotemia
B6 deficiency (abst) 248
cyclosporine induced (abst) 463
prerenal, GFR (abst) 293
A1 adensine receptors
chloride transport (abst) 274

Baboon GFR (abst) 380
Bacteria, Tamm-Horsfall protein 77
Baroreflexes, Ang II in stenosis S-157
Basolateral membrane
adrenergic receptor stimulation (abst) 160
non-selective cation channel (abst) 442
Benxyl alcohol, MDCK cells (abst) 166
Benzodiaxzepine binding site (abst) 278
Berliner tribute 502
Beta adrenergic blockade (abst) 428
Beta adrenoceptor
vasodilation (abst) 425
Beta receptor, cAMP (abst) 281
Beta $_2$ microglobulin
adsorption to highflux membranes (abst) 244
AIDS in allograft recipient (abst) 461
dialysis membranes (abst) 248
polycystic kidney disease 85
reprocessing dialyzers (abst) 238
uremics in hemodialysis (abst) 229
Beta-adrenoceptor
in sheep (abst) 175
peritoneal dialysis patients (abst) 197
vasodilation, norepinephrine (abst) 425
Bicarbonate
acidification in PCT inhibited during alkalosis (abst) ... 412
amiloride (abst) 418
ammonia transport (abst) 408
chronic load, K, Cl or KCL depletion (abst) 410
concentration (abst) 405
generation, acetate metabolism during HD 1194
high, dialysate for repletion (abst) 240
metabolic acidosis in SHR (abst) 302
Na-H antiporter activity and, in post-hypercapnic (abst) 418
Na/H antiporter mediates absorption (abst) 414
pHi regulation in S3 proximal tubule (abst) 412
phosphorus levels in hemodialysis (abst) 231
rapid high effeciency HD (abst) 235
sequential changes in during dialysis (abst) 236
transport (abst) 407
Binding properties, antibodies (abst) 326
Binding, C5a during hemodialysis 112
Biologic-HD dialysis machine (abst) 227

Biopsy
calcium content and renal impairment in 246 93
fibrillary glomerulonephritis 781
fine needle aspiration, ultrasonically guided (abst) 462
probe renal disease (abst) 198
rejection in intra-operative (abst) 453
Bisphosphate, 2,6 fructose (abst) 401
Blood
active and inactive renin, ACE inhibition S-184
coagulopathy in nephrotic children 772
flow measurement, cine computed tomography 1038
flow regulation, hypertonic urine formation 668
GFR, bradykinin antagonist infusion (abst) 419
HTLV-III in hemodialysis (abst) 227
immunoglobulin-secreting cells in, IgAN (abst) 338
indium-111-labeled white cell scan (abst) 468
ionized Ca in HD (abst) 346
lymphocytes and monocytes in peripheral (abst) 862
medullary flow 641
peripheral, mononuclear cell function, verapamil (abst) 471
pressure, hypertension in renal transplant recipients 1024
red cells, sodium lithium counter transport (abst) 190
split hydronephrotic kidney, angiotensin II S-64
transfusion, transplantation (abst) 455
transfusions, renal transplantation (abst) 459
tubings, C3a anaphylatoxin generation (abst) 1400
vasa recta flow, ANP (abst) 280
Blood flow
ACE inhibition and acute tubular necrosis S-143
physiology of intrarenal renin-angiotensin system S-49
Blood pressure
ACE inhibition and renal disease S-102
ACE inhibition in hypertensives 815
ANP effect on renal function (abst) 391
changes in bone marrow transplant (abst) 297
chronic renal failure progression (abst) 189
diabetic nephropathy 898
donor, recipient 1366
family history and hypertension (abst) 298
hemorrhagic reduction in ARF 725
K in elderly (abst) 311
lowering of arterial, diabetes S-123
Na^+ nitroprusside reduced, hypertension (abst) 306
norepinephrine vs. angiotensin II S-193
regulation, K, norepinephrine, Ang II mediated 956
renal damage, CEI S-168
renal function in insulin-dependent diabetes (abst) 207
vitamin D deprivation (abst) 310
Blycolysis
DCCD in suspensions of nephron segments (abst) 403
Body fluid compartments (abst) 283
Bone
aluminum
associated disease in HD (abst) 341
induced disease, PTH (abst) 356
trabecular vs. cortical in HD (abst) 353
cell metabolism, Al, PTH and vitamin D_3 736
deferoxamine in Al-related disease 1326
lead toxification (abst) 196
marrow transplant, hypomagnesemia (abst) 223
microprobe determination of cell function (abst) 343
renal mass and reserve of vitamin D, hyperparathyroidism 1174

single channel fluctuations from (abst) 348
thyroparathyroidectomy modifies response to Al loading 923
Bowman's space, crecentic neph. (abst) 333
Bradykinin
Ca from intracellular tubular stores (abst) 282
inhibits transport-dependent O_2 consumption (abst).... 293
MCDK cells (abst)..... 178
prostaglandin formation, renal function, renin (abst)... 426
Brain
catecholamines, P depletion (abst) 342
damage, symptomatic hyponatremia (abst)..... 190
dehydration, hyponatremia (abst) 219
Branched-chain ketoacids, CRF (abst) 223
Brush border membrane
gentamicin (abst) 368
Brush border vesicles
osmolarity influence on Na^+/H^+ exchanger (abst)..... 406
Bumetanide and furosemide (abst) 213

C-PTH(35–84PTH), CRF (abst) 871
Cadium, PTH-adenylate cyclase (abst) 173
Calcitonin degradation (abst) 399
Calcitriol
clearance in CRF (abst)..... 350
production in SHR (abst)..... 362
synthesis by P (abst) 352
therapy in children (abst)..... 220
Calcium
absorption in cTAL, PTH stimulated 913
activated K^+ channels in MTAL (abst) 431
adenosine signal transduction (abst) 259
adrenergic agonists increase (abst) 284
Al in hypercalcemia..... 766
antagonists and renin release (abst) 260
ATP-driven in BLMV (abst) 359
ATPase activity in RBC (abst) 236
ATPase in RBC in HD (abst) 236
AVP, ANF in vascular smooth muscle cells (abst) 309
binding protein, 28 kDa vitamin D 121
binding to membranes, aminoglycoside, phosphoinositide 59
BP sex difference in hypertension (abst)..... 298
bradykinin (abst) 282
calcitriol and PTH 795
calmodulin, AVP (abst) 289
channel blocking, cyclosporine nephrotoxicity (abst)... 454
channel in UMR-106 cells (abst)..... 188
citrate as a phosphate binder (abst) 239
Cl^- conductance, angiotensin II (abst)..... 282
CO_3 for Al-GELS, aplastic bone disease (abst)..... 349
cytosolic free Ca_2^+ concentration, PAF in mesangial (abst)..... 161
cytosolic free levels (abst)..... 172, 258, 361
cytosolic in single proximal tubule cells (abst)..... 167
diet in hypertension (abst)..... 298
dihydropyridine antagonist felodipine, Ang II (abst) .. 1049
early rise in cytosolic free (abst)..... 180
excretion, $KHCO_3$ (abst)..... 353
excretion, Mg (abst)..... 357
fluctuations modulate permeability (abst)..... 449
fluxes in enterocytes (abst) 345
free, FURA 2 measurements (abst)..... 350
FURA-2 measurements in hypertension (abst)..... 302
gender and acidification in stone former (abst)..... 347
gentamicin nephrotoxicity, PTH (abst)..... 366
glucose modulate renal responses (abst)..... 395
hypercalcemia and malignancy 142
hypertension, PGE_2 production (abst) 292
influx of SHR isolated enterocytes (abst)..... 308
intake, salt in hypertension (abst)..... 308
intracellular, essential hypertension (abst) 869
ionized, regulation by vitamin D_3 (abst) 360
lipid dependent kinase following nephron loss (abst)... 399
lipoxygenase, AII (abst) 279
Mg_2^+ dependent ATPase (abst) 342
Na^+,K^+-ATPase inhibition (abst)..... 295
nephrolithiasis, urinary glycosaminoglycans (abst)..... 864
newborn handling..... 1181
nitrendipine effect on gentamicin nephrotoxicity (abst) . 369
oxalate and carbonate supersaturations in pregnancy (abst)..... 209
oxalate crystal growth inhibition, nephrocalcin (abst) .. 361
oxalate crystal growth, pregnancy (abst) 359
oxygen free radical damage, marine lipids (abst) 370
platelet-derived growth factor modulates (abst) 175
prostaglandin (abst) 267
proton fluxes from calvariae (abst) 361
PTH activated, regulation by phorbol ester (abst) 351
PTH stimulation of cytosolic (abst)..... 346
regulation of vitamin D_3 (abst) 352
relation between content, and renal impairment 93
response of isolated Dahl kidney to antagonists..... 941
sodium exchange (abst)..... 345
stone former, uric acid (abst) 215
stone former, vitamin D_3 (abst)..... 1416
supplementation on blood lead and BP (abst)..... 209
sytosolic Ca_2^+ in LLC-PK1, exogenous nucleotide (abst)..... 185
therapeutic agent for renal osteodystrophy (abst) 344
transport in vitamin D-deprived SHR (abst)..... 350
uptake in HgCl2 injured tubules (abst) 365
uptake is early renal hypertrophy (abst)..... 399
vasopressin induced increases (abst)..... 449
zinc nutritional status (abst) 358
25,26–dihydroxyvitamin D_3 (abst)..... 362
Calmodulin antagoinists (abst) 347
cAMP
ANP inhibits aldosterone secretion (abst)..... 260
AVP, arachidonic acid, LLC-PK1 cell (abst)..... 276
binding proteins in medullary collecting tubule (abst) .. 270
Ca in cultured epithelia (abst) 162
Ca induced prostacyclin (abst) 264
dependent protein kinase, apical membrane (abst)..... 181
effect on phosphate transport, ^{32}P in ATP (abst) 184
forskolin and vasopressin on urinary bladder (abst).... 448
lithium, Ns mediates (abst) 258
mediated beta receptor response (abst)..... 281
mediated protein dephosphorylation (abst)..... 177
reconstitution of protein kinase, Na^+-H^+ exchanger (abst)..... 186
regulation in renal microvessels (abst) 163
vasopressin signalling 521
vasopressin-sensitive nephron segments..... 1065
Cancer
gentamicin and cisplatinum, renal function (abst) 215
hypercalcemia of malignancy 142
interleukin-2 therapy (abst) 224
regression of metastatic renal (abst) 340

CAPD
algae peritonitis misdiagnosed as fungal (abst) 256
cellular immunity (abst) 862
center city hospital (abst) 249
changes in peritoneal solute transport (abst) 248
clinical evaluation of program (abst) 861
CPK heart isoenzyme (abst) 871
deferoxamine for aluminum chelation 986
enhanced neuropsychological function (abst) 253
Greece (abst) 861
HD effect on renal patient cellular immunity (abst) 862
hepatis B vaccine (abst) 249
hepatitis B vaccine evaluation (abst) 249
iatrogenic complications of (abst) 861
kinetics of water and electrolytes in dialysate (abst) 866
left ventricular funtion, intra-abdominal pressure (abst) 248
long term survivors (abst) 257
lymphatic absorption in (abst) 252
management of multiple enteric organism peritonitis (abst) 254
media enrichment of infected bags (abst) 255
omega-3 polyunsaturated fatty acids (abst) 255, 1050
peritoneal membrane, ultrafiltration (abst) 866
peritonitis rate by UV-XD (abst) 256
peritonitis, ticarcillin-clavulanic acid (abst) 250
PTH, vitamin D_3 (abst) 354
secondary hyperparathyroidism, calcitriol, Ca and PTH 795
T-lymphocyte transformation (abst) 862
transplantation after prolonged dialysis 981
tunnel infection management (abst) 869
vancomycin in (abst) 255
$1,25(OH)_2D_3$ synthesis by peritoneal macrophages (abst) 249
Capillary barrier, proteinuria (abst) 314
Capillary solute flux (abst) 427
Captopril
ACE inhibition (abst) 333
ACE inhibitors not alike (abst) 307
acute tubular necrosis S-143
administration on vascular AII (abst) 262
bradykinin, prostanoid production (abst) 275
glomerular abnormalities, ACE inhibition S-138
nephrotoxicity of ACE inhibition S-132
prazosin during fruosemide 135
protein restriction, proteinuria (abst) 314
proteinuria in nephrotic syndrome (abst) 199
raises red cell flow in DVR (abst) 421
renal disease and ACE inhibition S-130
zinc, hypertension (abst) 294
Carbon dioxide
HCO_3- BLM, transport mechanisms (abst) 411
Carbonic anhydrase
beta (abst) 413
collecting duct heterogeneity (abst) 441
Cardiac
abnormalities in PKD (abst) 203
ANF during chronic Na retention (abst) 291
ANF in heart failure (abst) 268
ANP (abst) 274
congestive heart failure, ANF (abst) 286
denervation on ANP (abst) 284
failure, CEI S-216
nervous system in CyA hypertension (abst) 309
renal function, heart failure and Ang II S-220
sodium effect on enlargement (abst) 303
Cardiomyopathy, uremic (abst) 175
Cardiopulmonary hypertension 1072
Cardiovascular system, jaundice (abst) 398
Castration in rats (abst) 388
Catecholamine
β-adrenoceptor vasodilation (abst) 425
function, P (abst) 286
plasma and urinary, renal function in man 107
Catheter
dacron cuffed jugular venous dialysis (abst) 228
low-dose streptokinase infusions 1210
peritoneal, fungal peritonitis (abst) 861
peritoneal, survival in children (abst) 250
Seldinger technique for Tenckhoff (abst) 256
Catheterization, lithotripsy (abst) 204
Cation
apical, aldosterone and Ba^{++} effects on (abst) 442
channel, non-selective (abst) 442
flux, uremia (abst) 383
Cd-thionein, cortex lysosomes 886
cDNA encoding, anion exchanger (abst) 159
CD_3, T lymphocyte signalling (abst) 332
Ceftazidime in CAPD (abst) 863
Cell
counts in dialysis (abst) 250
culture, new model of human PKD (abst) 186
cytoplasmic pH regulation in renal proximal tubule 1113
dual pathway activation, PTH (abst) 356
function regulation, vasopressin 512
human red in uremia (abst) 389
intercalated, rat inner medullary collecting duct 1080
line, proximal tubule, hyperpolarization (abst) 431
MDCK, Na^+ cytoplasmic vs. external transport (abst) 434
measurement by ion-sensitive microelectrode (abst) 164
mesangial, norepinephrine (abst) 424
microprobe of bone, function (abst) 343
mitochondiral rich, immunodissection (abst) 406
papillary collecting duct, purification (abst) 402
plasma, mitochondria-rich is an H^+ATPase (abst) 162
proliferation, CyA induced (abst) 460
proximal tubular, Na^+/H^+ antiporter quantitation (abst) 428
proximal tubule, glycolytic (abst) 402
red, captopril (abst) 421
red, oxygen transport 100
transcellular fluid shift measurement during HD (abst) 1046
transfer, auto-immune GN (abst) 332
Central pontine myelinolysis (abst) 212
Charge barrier, lamina densa 710
Chemotherapy of malaria, Berliner 502
Children
ADPKD 1000
albumin induced natriuresis, ANP 1373
Ca handling in newborns 1181
chronic renal failure assessment (abst) 225
coagulopathy in nephrotic 772
coping skills in, on dialysis (abst) 252
decreased sensitivity to heparin 1395
dialysis regimen for CCPD (abst) 251
diffuse proliferative lupus nephritis (abst) 205
ECV and FPF, in MLNS and FSGS (abst) 336
growth and cardiac complications of A-V fistulas 233

haploidentical live related donor transplant (abst) 469
Henoch-Schönlein purpura, IgA nephropathy 1132
histogenesis of cysts in PKD (abst)..... 339
IgA nephropathy (abst) 202
infants, CRF, high essential amino acid/calorie diet (abst)..... 866
peritoneal catheter survival (abst)..... 251
proteinuria (abst) 203
regression of dense deposits in MPGN type II (abst)... 338
renal bone disease, CAPD/CCPD 357
steroid-dependent minimal change NS (abst) 205
Tc99m measurement of ultrafiltration (abst)..... 255
transplantation after prolonged dialysis 981
untreated hyponatremia in (abst)..... 190
Chloride
action on Na dependent taurine uptake (abst) 187
amiloride, Na/H antiporter (abst) 443
cell volume changes, vasopressin water flow (abst).... 261
dietary NaCl alters Cl reabsorption (abst) 433
intracellular activity (abst)..... 437
permeability in culture (abst)..... 439
stimulates proton pump, clathrin coated vesicle (abst) . 417
transport measured by fluorescent indicator (abst)..... 437
transport, anion exchange pathways (abst)..... 438
transport, A1 adensoine receptors (abst) 274
volume regulation of MTAL (abst)..... 440
Chlorine
base, apical membrane exchange (abst) 428
bicarbonate exchange in BLMV (abst)..... 409
channel inhibitors and diuretics on H ATPase (abst)... 409
HCO_3 exchange at BLM (abst)..... 415
K conductances, BLM (abst) 452
Cholesterol, glomerular injury (abst) 387
Chromosome 16, PKD (abst) 206
Chronic renal disease
glomerular structure and permselectivity (abst) 424
hyperfiltration theory (abst)..... 394
Chronic renal failure
anemia, spermine and spermidine in hematopoiesis..... 72
ANP, renal function and BP (abst)..... 391
blood pressure reduction on progress of (abst)..... 189
branched-chain ketoacids (abst) 223
C-PTH (35–84PTH) (abst)..... 871
calcitriol clearance (abst)..... 350
carbonaceous adsorbent (abst) 216
ceftazidine (abst) 863
CEI on uranyl nitrate induced (abst)..... 367
control of hypertension (abst)..... 215
drug protein binding (abst) 221
effects of Ang II, ACE inhibition..... S-112
enhanced transcellular potassium secretion 1376
estimation of parathyroid function (abst) 867
heparin free dialysis..... 1350
hypothalmic hypophyseal adrenal axis (abst)..... 867
infants, children assessment of CNS function (abst)..... 225
insulin release, PTH (abst) 384
lipoprotein density classes (abst)..... 379
low triiodothyronine syndrome (abst)..... 867
oxalate clearance (abst)..... 382
pancreas secretory trypsin (abst) 223
phosphate restriction (abst)..... 398
PTH and oxidation of fatty acids (abst) 393
serum bone alkaline phosphatase (abst) 868
serum osmolality (abst) 869
serum thyroid hormones (abst) 207
sulindac (abst) 217
thromboxane A2 receptor BM 13.177 (abst)..... 283
thyroidectomy (abst) 381
tissue response to thyroid hormone in uremics 808
vascular disease and age-associated kidney changes..... 1153
verapamil 41
verapamil (abst)..... 381
zinc (abst)..... 863
25(OH)D_3 effect on vitamin D_3 (abst)..... 345
Chronic renal impairment
ibuprofen, piroxicam and sulindac (abst) 224
Chronic renal injury
internephron heterogeneity (abst)..... 392
Chronic renal insufficiency
calcitriol therapy of refractory renal osteodystrophy (abst)..... 220
crescentic glomerulonephritis 790
high protein intake (abst)..... 197
Na-K-ATPase inhibitors in hypertension (abst) 300
protein restriction, phosphorus (abst)..... 384
PTH response to Al..... 15
sulindac and metabolites (abst)..... 220
Chronic serum sickness
proteinuria (abst) 327
Cimetadine, renal function (abst) 356
Cine computed tomography, blood flow 1038
Ciprofloxacin, cystic disease (abst) 193
Circadian rhythm, children (abst) 344
Circulating anodic antigen
schistosomal specific nephropathy 1006
Circulating immunocomplexes
estimation of in idiopathic and secondary GN (abst)... 863
Cirrhosis
ANF, nephrotic syndrome (abst) 273
angiotensin II binding (abst) 291
natriuresis to ANP (abst)..... 276
peritoneovenous shunting, ANP (abst)..... 262
plasma irANF dissociation from Na^+ handling (abst)..... 269
uric acid and endogenous lithium excretion (abst)..... 198
Cisplatin
nephrotoxicity, ANF (abst)..... 365
DNA (abst)..... 375
verampmil (abst) 1046
Citrate reabsorption, alkalosis (abst) 444
Clathrin-coated proton pump (abst) 416
Clathrin-coated vesicle pump (abst) 183
Clearance
method for rapid renal, dextran 855
middle molecule in CAVH (abst) 232
vancomycin (abst) 211
Clinoril, ARF (abst) 368
Clonidine suppression test (abst) 299
Cloning, pyruvate carboxylase (abst) 166
Clotting activators 830
Coagulopathy, nephrotic children 772
Cold storage, kidney (abst) 453
Collagen
formation in nephritis (abst) 317
synthesis, Al (abst) 342
type IV synthesis, C5b-9 (abst)..... 322
type IV, laminin, in human MGN (abst)..... 338
type IV, nephritogenicity (abst) 319

Collecting duct
cellular heterogeneity (abst) 415
papillary, Na/H exchange regulation (abst)..... 442
urinary concentration..... 606
Collecting tubule
potassium recycling..... 695
Colloid osmotic pressure
dialysis techniques, changes in red cell volume (abst).. 241
Colo-rectal cancer, ARF (abst) 207
Colon
aldosterone, K-H exchange (abst)..... 279
apical chloride channels (abst) 435
Compensatory renal growth, CyA (abst) 378
Complement
activation in IgA nephropathy..... 1019
activation, renal nerves, Na retention (abst) 327
binding C3 fragments to cuprophan (abst) 241
C5b-9 in membranous nephropathy (abst) 329
free hemodialysis (abst)..... 228
IgA immune complex, aggregates (abst)..... 323
membrane attack 820
nephritogenic antibody to Heymann nephritis (abst) ... 328
pathway, nephritis (abst)..... 321
role in IgA-associated nephritis 1
vasoconstriction in Heymann nephritis (abst)..... 329
Computerized tomography, PN (abst) 210
Concentration gradient, models 648
Conductive pathways, K^+ in nephron 1055
Conductive properties of BBMV (abst) 429
Conductivity, guanylate cyclase (abst) 445
Congestive heart failure
ACE, Ang II..... S-200
mechanisms, role of Ang II S-213
Pavp (abst)..... 191
renal and circulatory mechanisms..... 1401
renin-angiotensin system and renal circulation S-203
Continuous arteriovenous hemodialysis
Middle molecule clearance (abst) 232
transport in slow (abst) 246
Continuous arteriovenous hemofiltration
mathmatical and in vitro models (abst)..... 240
novel pump design (abst)..... 229
polysulfone capillary membrane (abst) 244
slow, solute transport (abst) 246
ultrafiltration characteristics of filters (abst)..... 242
Converting enzyme inhibition
α 2-adrenoceptors, targets for S-191
angiotensin, AII (abst)..... 390
renal damage induced in hypertensive rats S-168
uranyl nitrate-induced renal failure (abst)..... 367
Converting enzyme inhibitor
furosemide in congestive heart failure (abst) 211
glomerular sclerosis (abst)..... 389
injury (abst) 383
renal function in cardiac failure..... S-216
Coronary sinus, ANP (abst) 261
Cortex
heterogenity of endosomes (abst) 168
Cortical collecting duct
cell monolayers, aldosterone (abst)..... 160
generation of pH gradient 930
hydrochlorothiazide on Na-K-ATPase activity..... 918
Na/K-ATPase a-subunit in..... 1104
Cortical collecting tubule
metabolic support of transport in (abst) 398
Cortical interstitial fluid (abst) 452
Cortical mactophages, thromboxane (abst) 257
Cortical thick ascending limb
urinary concentrating mechanism 590
Corticosterone
PKD 1088
stimulation of Na^+ transport (abst)..... 268
Corticotropin releasing factor (abst) 867
Countercurrent
exchange
medullary microcirculation 641
K recycling..... 695
urea transport pathways in mammalian kidney..... 629
hypothesis, historical..... 507
medullary microcirculation 641
system, function transitions in 668
Creatinine
iothalamate clearances, HPLC (abst) 389
urine concentration in spinal cord injury patients (abst)..... 205
Crescent composition in GN (abst) 334
Crescentic glomerulonephritis
not so rapidly progressive (abst)..... 198
protracted course..... 790
Crescentic nephritis
Bowman's space (abst) 333
T cells (abst) 318
Cross-circulation technique, renin S-210
Cryoglobulinemia, kidney, nerve (abst) 864
Culture
matrix constituents (abst) 318
monolayers, S1 tubules (abst)..... 161
Cuprophan
binding of C3 fragments to (abst) 241
H binding, complement activation (abst) 243
induced pulmonary hypertension..... 1072
membranes, sodium hypochlorite (abst)..... 230
monocytes and glomerular epithelial cells (abst) 228
Cushing's syndrome
glucocorticoid induced hypertension..... 1213
Cycles and separations
histotopagraphy of renal medulla 538
Cyclic GMP, ANF (abst) 397
Cycloheximide, nicotinamide (abst) 350
Cyclosporine
acid secretion stimulation (abst) 414
act via receptors (abst) 460
adult respiratory distress syndrome (abst) 464
after transplantation, 3 years (abst)..... 470
antithymocyte serum (abst)..... 455
cadaver transplantation (abst)..... 467
compensatory renal hypertrophy (abst) 454
conversion to AZA after transplantation (abst) 1044
conversion to standard immunosuppression (abst)..... 454
fractional excretion of lithium, K in transplant (abst)..... 1048
hepatotoxicity in renal transplant (abst) 865
hypertension (abst) 464
hypertension: hyperreninemic hypoaldosteronism (abst)..... 303
hypoaldosteronism (abst)..... 266
impaired GFR after transplantation (abst) 471
induced cell proliferation (abst)..... 460
induced hypomagnesemia (abst) 360
inhibits PGE_2 formation (abst) 288

lack of renal Mg wasting in transplant (abst) 200
limits compensatory renal growth (abst) 462
liposome delivery (abst) 462
Mg transport (abst) 36
multiple sclerosis (abst) 211
natural killer activity in transplant (abst) 462
nephrotoxicity (abst) 461
nephrotoxicity, compensatory renal growth (abst) 378
nephrotoxicity, prostaglandins (abst) 365
new pharmacokinetic modeling method (abst) 455
NVA2, hemodynamic effects of (abst) 466
pediatric facial changes in transplantation (abst) 467
prednisone conversion, post-transplant (abst) 459
prednisone treated transplant recipients (abst) 463
prerenal azotemia (abst) 463
pretransplant ESRD (abst) 452
prostacyclin formation (abst) 457
refractory nephrotic syndrome (abst) 214
suppressor T cell induction (abst) 468
thromboembolism in diabetic allograft recipients (abst) . 458
thromboxane suppression in CyA nephrotoxicity (abst) 367
tubulointerstitial nephritis (abst) 330
volume regulation (abst) 376

Cyst
ADPKD, cardiac abnormalities (abst) 203
C-MYC in PKD (abst) 163
cellular basis of formation, growth in ADPKD (abst) .. 384
diagnosis in PKD (abst) 216
formation and growth in ADPKD 1145
functional changes (abst) 392
histogenesis in PKD (abst) 339
hypertension, renal structure in ADPKD (abst) 297
new human model culture in PKD (abst) 186
organic anion uptake in metanephric organ culture (abst) 159
PKD, basement membrane genes in murine congenital (abst) 165
renal excretion of B_2M in polycystic kidney disease 85
tubule basement membrane viscoelastic properties (abst) 383

Cysteine proteinases, GBM (abst) 177
Cytochrome, epoxygenase (abst) 269
Cytomegalovirus infection (abst) 1050
Cytoplasmic dilution, ADH (abst) 450
Cytoskeletal
disruption (abst) 429
volume control (abst) 173
Cytosolic Ca_2^+ in proximal cell (abst) 167
C3a
anaphylatoxin generation by blood tubings (abst) 1417
C5a receptor modulation, hemodialysis 112
C5b-9, type IV collagen (abst) 322

Dacron cuffed jugular catheter (abst) 228
Data, transplantation results (abst) 459
DCCD in suspensions of nephron (abst) 403
Death
choosing (abst) 243
CyA nephrotoxicity (abst) 373
Deferoxamine
Al infusion test, neuropsychologic abnormalities (abst). 219
aluminum chelation 986
bone histologic response in Al-related bone disease... 1343
infusion and iron dialysance in HD (abst) 244
PTH and Al in renal osteodystrophy 842
therapy in HD (abst) 246
Dehydration
ANP in rats 760
diabetes, nitrogen (abst) 194
GFR, urine concentration in absence of vasopressin... 634
Delta alkalinity (abst) 406
Denervated kidneys, hyperperfusion(abst) 419
Deoxycorticosterone acetate, K (abst) 443
Deoxyribonucleic acid, cisplatin (abst) 375
Dephosphorylation, protein, cAMP (abst) 177
Descending vasa recta, models 662
Desferioxamine
bone aluminum and lestion (abst) 345
infusion test in HD (abst) 868
infusion test (abst) 226
yersinia enterocolitica in serum (abst) 247
Desoxycorticosterone, hypertension 718
Detergent, PT-40K-ADPr (abst) 179
Dextran
fractional clearances (abst) 448
platelet activating factor (abst) 331
renal clearance methodology 855
Dextrose
relation to ultrafiltration rate (abst) 252
Diabetes
aprotinin augmentation by vasopressin 1092
blood pressure impact on renal function (abst) 207
CAPD-transplantation program (abst) 1415
change in rates of nephropathy (abst) 222
dehydration, low blood urea nitrogen (abst) 194
diastolic pressure, kidney size, GFR (abst) 204
dietary protein modification (abst) 225
glomerular and mesangial PGE2 (abst) 260
glucocorticoid-induced hypertension 1213
hemodialysis (abst) 238
hemodynamics in captopril and indomethacin treated (abst) 208
hyperfiltration associated with ANP (abst) 282
inositol (abst) 387
insulin dependent, glycemic changes 1012
lowering of arterial BP, glomerular sclerosis S-123
mellitus, insulin and capillary pressure (abst) 426
microalbuminuria as predictor of diabetic nephropathy . 673
mortality, long term outcome (abst) 239
mRNA levels, laminin and collagen IV chains (abst)... 171
nephrogenic, plasma arginine vasopressin (abst) 190
nephropathy, CyA in transplantation (abst) 459
nephropathy, increased glomerular pressure 898
non-diabetic renal disease in (abst) 189
preferential injury, hypertension (abst) 300
proteinuria (abst) 380
renal hemodynamics, protein (abst) 191
retinal alterations (abst) 328
somatomedin inhibitor in dialysis (abst) 341
strict metabolic control in streptozotocin 47
vasoactive hormone in hyperfiltration (abst) 259
Diabetic nephropathy
hypertension (abst) 388
platelet inhibitors stabilize (abst) 197
Dialysate
blood osmolality, acid-base equilibrium, CAPD (abst).. 866
blood parallel flow in HD filter (abst) 869
CAPD, host defenses (abst) 1046
kinetics of water and electrolytes in CAPD 866

Dialysis
acetate change to bicarbonate (abst) ... 227
acetate metabolism, bicarbonate generation during ... 1194
Al in the development of hypercalcemia ... 766
amyloidosis, tissular distribution (abst) ... 1416
antacid Al (abst) ... 234
BioLogic HD machine (abst) ... 227
Brazil, HTLV-III (abst) ... 231
calcitriol, Ca and PTH ... 795
calcium citrate as phosphate binder (abst) ... 239
CAPD in Greece (abst) ... 861
cell counts receiving intermittent (abst) ... 250
choosing death (abst) ... 243
congestive heart failure ... 240
coping skills in children (abst) ... 252
deferoxamine for aluminum chelation ... 986
dialysate to blood transport (abst) ... 249
dimethylamine, urea, creatinine kinetics (abst) ... 251
disrupting fluid films may enhance transport (abst) ... 254
effluent, anti-viral factor in (abst) ... 251
frequent saline flush-high blood flow technique (abst) ... 194
heparin free, high risk patients ... 1350
high bicarbonate dialysate for repletion (abst) ... 240
high flux (abst) ... 232
high flux and conventional (abst) ... 235
high-flux (abst) ... 226
influenza vaccine booster (abst) ... 1046
internal jugular access route (abst) ... 230
limulus amebocyte lysate reactivity (abst) ... 239
long term survivors (abst) ... 257
mortality among 405 chronic hemodialysis (abst) ... 245
mortality, outcome of diabetics (abst) ... 239
neoplasms (abst) ... 242
paired filtration (abst) ... 870
particles from equipment stimulate interleukin 1 (abst) ... 228
percent changes in red cell, plasma volume (abst) ... 241
peritoneal, B_2M (abst) ... 197
peritoneal, iron dextran (abst) ... 862
peritoneal, maximum ultrafiltration rates ... 731
phosphate removal by different types of (abst) ... 245
placticizers inhibit water transport (abst) ... 250
prolonged dwell peritoneal, transplantation ... 981
protein binding (abst) ... 252
racial, sexual and age discrimination (abst) ... 236
rapid blood flow, short (abst) ... 244
rare seropositivity to HTLV-III (abst) ... 236
regiment for children (abst) ... 251
relation of Ca, PTH and bone Al, osteomalacia (abst) ... 355
removal of Al, vitamin D (abst) ... 346
reuse of dialyzers (abst) ... 230
sequential changes in dialysate HCO_3 (abst) ... 236
single needle, a review (abst) ... 1045
systemic lupus erythematosus persistance (abst) ... 254
tidal peritoneal (abst) ... 250
Dialyzer
cellulose vs. cuprammonium cellulose (abst) ... 243
coil vs. capillary cuprammonium cellulose (abst) ... 234
performance and biocompatibility on 5 (abst) ... 233
serial and parallel pairs in treatment (abst) ... 247
Diastolic pressure, kidney size (abst) ... 204
Diazepam, Na transport (abst) ... 444
Diazoxide, K^+ channel (abst) ... 167
Diciofenac, proteinuria (abst) ... 1418
Diet
hemodialysis (abst) ... 235
low protein, phosphate (abst) ... 380
low purine, high Al and alopurinol in uremia (abst) ... 221
low sodium, amino acid infusion ... 992
objectives and design for modification of in RD (abst) ... 210
renin angiotensin system localization ... S-2
Diffuse proliferative lupus nephritis
children (abst) ... 205
Digital subtraction angiography (abst) ... 867
Diltiazem, transplantation (abst) ... 465
Dimethyl sulfoxide
AVP (abst) ... 292
ischemia (abst) ... 372
Diphenylthiazole induced PKD (abst) ... 212
Diphosphonate APD, osteodystrophy (abst) ... 1048
Dipyridamole slows diabetic GN (abst) ... 194
Diuretic
amiloride in medullary collecting duct ... 1121
ANF, comparative effects of ... 946
antidiuretic state; composition of renal medullary tissue ... 556
benzodiazepine binding site interaction (abst) ... 278
loop
in renal insufficiency (abst) ... 222
inhibition of Cl^- independent Na^+ influx (abst) ... 180
Na-2Cl-K transport identified in utricle (abst) ... 174
metolazone-probenecid response in man (abst) ... 218
thiazide, electroneutral Cl entry (abst) ... 441
thiazide mechanism, indomethacin ... 1097
DNA solubilization of IC deposits (abst) ... 322
Donation, kidney, attitudes (abst) ... 468
Donor
specific transfused renal transplant, outcome (abst) ... 453
Dopamine
agonist SKF38393 (abst) ... 310
intrarenal natriuretic hormone (abst) ... 258
normal and renal diseased man (abst) ... 1044
phospholipase activity (abst) ... 166
receptor, DA-1 (abst) ... 432
Dose-response relationship, ANF (abst) ... 288
Drug receptor, aminoglycoside ... 59
Drug, i.v., AIDS related glomerulopathy ... 1167
Duct
H^+ secretory mechanism (abst) ... 181
inner medullary collecting, cells ... 1080
Duodenal response to vitamin D (abst) ... 352

E. collendotoxin, PGE_2 (abst) ... 323
Edema
in nephrotic syndrome (abst) ... 192
nephrotic syndrome (abst) ... 1048
EGF mitogen, PGN (abst) ... 167
Eicosanoid
production, immune complex ... 1316
synthesis in glomeruli ... S-95
Electrical impedance in HD (abst) ... 232
Enalapril
ACE inhibition (abst) ... 212
coarctation hypertension (abst) ... 294
CRF hypertensives decreases proteinuria (abst) ... 212
K homeostasis during ACE inhibition (abst) ... 216
protein load increases GFR (abst) ... 194
renal effects in dogs ... S-148
renal insufficiency, disposition ... S-117

verapamil, reduced renal mass (abst) 380
End-stage renal disease
fibrillary glomerulonephritis 781
localization of renin (abst) 269
CAPD in center city hospital (abst) 249
changes of LH in patients with (abst) 177
correction of anemia (abst) 198
epinephrine fails to lower serum K concentration (abst) 199
erythropoietin-hematocrit feedback circuit in anemia .. 1205
factors in each state (abst) 214
interleukin-1 elevated, hemodialysis (abst) 237
intravenous drug abuse (abst) 234
low sodium diet, amino acid infusions 992
lymphocytes and monocytes in peripheral blood (abst) . 862
Navajo, 1971–1985 209
primary etiologies reported to Medicare (abst) 203
random sample study in US (abst) 196
role of income (abst) 231
schistosomal specific nephropathy 1006
surgical drainage of pericardial effusion (abst) 237
tumorous degeneration in ARCD (abst) 210
Endocytosis, transport (abst) 164
Endopeptidase, neutral, ACE S-45
Endosome heterogenity in cortex (abst) 168
Endostreptosin in kidney (abst) 317
Endotoxin
glomerular mesangial cells, shape change (abst) 314
interleukin 1, PGE secretion (abst) 320
nordihydroguaiaretic acid (abst) 385
PGE release (abst) 291
Energy
requirement in HD (abst) 246
reserves, change during ischemia 1239
Enterocytes, calcium flux (abst) 345
Enzyme
ACE inhibition and normal kidney S-104
acetazolamide effect on renal metabolism 1279
angiotensin I and kinin 744
composition, energy reserves during ischemia 1239
control of renal renin release S-89
hydrochlorothiazide effect on Na-K-ATPase activity ... 918
serum bone alkaline phosphatase ISO (abst) 868
Eosinophil protein, kidney disease(abst) 338
Eosinophilia, tissue, rejection (abst) 453
Epidemic of renal disease in Zuni (abst) 203
Epidermal growth factor (abst) 285
effect on cultured mesangial cells (abst) 184
Na^+/H^+ (abst) 182
Epinephrine
fails to lower serum K concentration in ESRD (abst) .. 199
Epithelia
fate of in situ immune complexes formed on (abst) 182
GBM synthesis (abst) 332
renal myo-inositol polyphosphate mass determination (abst) 181
visceral, lymphohemopoietic antigens (abst) 185
Epoxyeicosatrienoic acid (abst) 269
(abst) 289
Erythrocyte
immune complex glomerulonephritis connection 877
mesangial, peritoneal exudate cells and (abst) 158
Erythropoiesis
androgen therapy in hemodialysis 100
Erythropoietin
adenosine receptor regulation (abst) 290
hematocrit feedback circuit, ESRD 1205
Esmolol, beta-blockade (abst) 423
Essential mixed cryoglobulinemia (abst) 337
Ethanol, hyperparathyroidism (abst) 348
Ether phospholipid synthesis (abst) 293
Excretion
calcium in newborns 1181
correlation: age, hemodynamics, prostaglandin (abst) .. 189
measurement of blood flow by cine computed tomography 1038
of neutral proteinases 32
potassium recycling 695
sodium homeostasis in rat vs. man (abst) 436
urate, modification by inhibitors (abst) 448
water, impaired in aged (abst) 219
Exercise
improves renal function (abst) 386
muscle substrates in uremic rabbits (abst) 391
Experimental membranous nephropathy
evaluation of development 1267
Experimental models
IgA-associated nephritis 1

Familial nephritis, Alport (abst) 206
Familial systemic disorder, GBM (abst) 336
Fanconi syndrome, P leak (abst) 415
Fatty acid
binding in MCN (abst) 200
localizations of macrophages (abst) 329
nephrotic syndrome (abst) 199
skeletal muscle in uremia (abst) 391
transport, pH gradient (abst) 451
Fenestrae, charge barrier of capillaries 52
Fenoldopam, hypertension (abst) 309
Ferritin
RBC, in hemodialysis (abst) 226
size restrictive structure 710
Fibrillary glomerulonephritis 781
Fibrinogen, coagulopathy nephrotic child 772
Fibrinolysis
lupus nephritis (abst) 337, 222
Fibronectin binding antigen (abst) 316
Filtration fraction
preglomerular and postglomerular vascular resistance S-229
Fine needle aspirate
allograft, flow cytometry, immunologic phenotyping (abst) 457
biopsy
trial of (abst) 458
ultrasonically guided (abst) 462
citology, glomerulonephritis (abst) 193
Fish oil
serum lipids and creatinine (abst) 386
SLE (abst) 318
supplements (abst) 268
Flow cytometry
fine needle aspirates (abst) 457
Fluorescence microscopy
carbonic anhydrase cells of B type (abst) 413
Fluorescent stilbene, SO4 (abst) 444
Focal glomerular sclerosis
lowering of arterial BP limits S-123

Focal glomerulosclerosis
castration benefits (abst) 388
Focal segmental sclerosis, AIDS 1167
Foot process fusion
epithelial cell vacuolization, in children (abst) 336
Forskolin, cAMP, vasopressin (abst) 448
Fractional clearances, dextran (abst) 448
Fructose 2,6 bisphosphate (abst) 401
FURA 2 measurements of Ca (abst) 350
Furosemide
ARF, alterations in RBF (abst) 368
bumetanide (abst) 213
conjestive heart failure (abst) 211
GFR, Na, K-ATPase (abst) 442
mechanisms in congestive heart failure 1401
no protection against ischemic ARF (abst) 373
prazosin and captopril 135
sensitive Na^+-K^+ cotransport (abst) 294
urate excretion (abst) 448

GABAergic mechanisms (abst) 311
Gamma glutamyl-transferase (abst) 397, 864
Gating, brush border vesicles (abst) 174
Gelonin, proteinuria in MN (abst) 313
Genetic disease, PKD 1000
Gentamicin
cisplatinum administration in cancer patients (abst) 215
fluidity of spin-labeled BBM (abst) 368
nephrotoxicity
Ca and nitrendipine (abst) 369
nitrendipine (abst) 373
protein synthesis (abst) 364
polyaspartic acid protects against nephrotoxicity (abst). 374
proteinuria and hyperfiltration (abst) 377
toxicity, microsomal protein synthesis (abst) 364
tubulointerstitial nephropathy (abst) 368
increases Ca_2^+ (abst) 186
proteinases in proximal tubule 372
Glococorticoid receptor
Na-K ATPase activity (abst) 165
Glomerlonephritis
crescent compsition (abst) 334
Glomerular basement membrane
Alport-type familial nephritis, collagen (abst) 206
ATPase, adriamycin nephrosis, proteinuria 704
degradation by glomerular metalloproteinases (abst) ... 313
degredation by cysteine proteinases (abst) 177
familial systemic disorder (abst) 336
Goodpasture target antigens (abst) 340
intrarenal hemodynamic alterations 8
polycation, macromolecule sieving (abst) 313
proteinuria 8
synthesis (abst) 332
thickening, microalbuminuria, diabetic nephropathy ... 673
Glomerular filtration rate
absence of vasopressin, and urine concentration 634
ACE inhibition effects on hemodynamics of stenosis . S-173
age and vascular disease 1153
age related differences in natriuretic response (abst) ... 868
Ang II, ACE inhibition in CRF S-112
angiotensin I and II effect on function (abst) 280
angiotensin II effect on isolated, cultured glomeruli ... S-74
biological activity of PTH 937
BP in diabetic nephropathy 898
bradykinin antagonist infusion, blood flow (abst) 419
Ca antagonists in Dahl rat kidney 941
concentration of urine, absence of vasopressin 634
deterioration of renal function, protein (abst) 1045
dopamine in normal and diseased kidneys (abst) 1044
enalapril increases (abst) 194
fluid intake on protein-induced increase (abst) 379
heterogeneity of nephron anatomy S-25
increase mediated by prostaglandin (abst) 208
localization of Ang II receptors by autoradiography .. S-40
markers to inulin (abst) 213
Na restriction in hypertension 815
nephrotoxic serum nephritis (abst) 289
oral individual amino acids (abst) 382
oxygen free radical (abst) 363
papio hamadryas (abst) 380
prerenal azotemia (abst) 293
prostaglandins modulate ang II S-95
protein dietary and loading (abst) 422
renal adaptation to P deprivation (abst) 35
renal adaptation to P deprivation (abst) 355
renin-angiotensin system and nephron function S-57
risks of ACE inhibition S-180
somatostatin limits rise after protein load (abst) 420
systemic circulatory derangement (abst) 293
tubuloglomerular feedback control of (abst) 420
vascular resistance alterations on filtration fraction .. S-229
Glomerular function, protein (abst) 381
Glomerular immune deposits, $HgCl_2$ (abst) 320
Glomerular sclerosis
CEI (abst) 389
lowering of arterial BP S-123
serial micropuncture analysis of same nephrons (abst) . 384
Glomerular ultrafiltration (abst) 392
coefficient, leukotriene D4 antagonist (abst) 363
Glomeruli
IgA subclasses in Blacks and Whites with IgAN (abst) . 337
resident T-lymphocytes (abst) 319
short and long loop nephron 597
Glomerulonephritis
anti-GBM-GN 8
CAPD program (abst) 861
crescentic, protracted course 790
erythrocyte-immune complex connection 877
essential mixed cryoglobulinemia (abst) 337
estimation of circulating immunocomplexes (abst) 863
excretion of neutral proteinases 32
fibrillary 781
fine needle aspiration citology (abst) 193
human serum contains lymphotoxin found in MCN ... 1186
IgA, complement membrane attack 820
immune complex,gene for interleukin (abst) 180
immunotherapy in immune complex (abst) 863
induced in sheep by immunization with human GBM ... 25
K and Na handling (abst) 364
monoclonal antibodies, leukocyte analysis 964
primary, epidemiology in rural population (abst) 218
proliferative, EGF 167
rapidly progressing, T-cells and macrophages (abst) ... 204
SLE, IgG idiotype immune deposit (abst) 336
trypanosomiasis-related, antibodies (abst) 1047
tubuloglomerular feedback activity (abst) 386
Glomerulopathy
AIDS (abst) 213
AIDS-related 1167
albumin (abst) 315

Glomerulosclerosis
urinary protein excretion rates (abst) 392
vascular disease and age-associated changes in kidney 1153
Glomerulus
glycoconjugates (abst) 332
measurement of renin secretion (abst) 261
Glucagon
amino acid induced hyperfiltration (abst) 418
urinary acidification (abst) 407
Glucocorticoid
alter distal tubule water permeability (abst) 446
effect on nephron (abst) 316
Glucose
Ca modulation of renal responses (abst) 395
metabolism (abst) 404
peritubular, BLM potential (abst) 451
production, luminal perfusion (abst) 400
Glutamine
glucocorticoids and, in acidosis (abst) 410
glucocorticoids on, in acidosis (abst) 417
15N labelled (abst) 400
Glutathione
depletion or G reductase inhibition (abst) 404
oxidative stress (abst) 366
supplementation (abst) 372
Glycemic changes in diabetes 1012
Glycoconjugates of glomerulus (abst) 332
Glycolysis
induction in proximal tubule cells (abst) 402
Glycolytic induction of PTC (abst) 402
Glycoprotein
leukocyte Mol/LFA-1/LeuM5 (abst) 312
in hemodialysis (abst) 234
processing, BBM (abst) 188
Glycosaminoglycans, urinary (abst) 864
Goodpasture's syndrome
experimental nephritis in sheep 25
frequency in France (abst) 1415
type IV collagen from GBM (abst) 319
Granulocyte cytoplasm
autoantibodies against (abst) 337
Granulocytes, albuminuria (abst) 1043
Growth
hepatoma medium favors glomerular endothelial (abst) . 165
Growth factor
epidermal (abst) 285
induced Na/H exchange (abst) 169
insulin-like, mesangial cells (abst) 163
platelet derived (abst) 158
Growth rate, collecting duct (abst) 161
Guanine, PTH (abst) 176
Guanylate
cyclase/cGMP system (abst) 445

H^+ ATPase
heterogeneity (abst) 169
Heart failure
Ang II, ACE inhibition in congestive S-200
CEI and renal function S-216
congestive, in hemodialysis (abst) 240
experimental models, renin S-210
renal and curculatory mechanisms in congestive 1384
renal function, Ang II S-220
renin-angiotensin system and renal circulation S-203
role of Ang II in altered renal function S-213
Heart, open surgery, ARF (abst) 195
Hematopoiesis, spermine and spermidine 72
Hematuria
crescentic glomerulonephritis 790
Hemoaccess, ischemic neuropathy (abst) 239
Hemodialysis
acetate metabolism and bicarbonate generation 1194
Al associated bone disease (abst) 341
Al transfer (abst) 243
amyloidosis (abst) 227
androgen therapy 100
β_2 microglobulin and membranes (abst) 248
β_2 microglobulin levels in uremics (abst) 229
bicarbonate and phosphorus levels, correlation (abst) .. 231
blood ionized Ca (abst) 346
bone aluminum (abst) 353
bone disease in children (abst) 357
calcium ATPase in RBC (abst) 236
cardiac abnormalities, Al (abst) 238
CPK heart isoenzyme (abst) 871
deferoxamine and iron dialysance (abst) 244
deferoxamine therapy (abst) 246
desferrioxamine infusion test (abst) 226, 868
diabetes (abst) 238
diet (abst) 235
enalapril, enalaprilat in renal insufficiency S-117
energy requirements (abst) 246
enhanced neuropsychological function in CAPD (abst) . 253
fluid status measurement (abst) 232
glycoprotein, flow cytometry (abst) 234
heparin free 1333
heparin-free improves (abst) 194
high flux (abst) 226, 229
HTLV-III reactivity (abst) 227
human monocytes, interleukin-1 (abst) 238
hypoxemia, COPD (abst) 231
interleukin 1 and 2 levels (abst) 241
interleukin 1 modulation 245
intravenous drug abuse in ESRD (abst) 234
Japan, new castle disease (abst) 237
L-carnitine (abst) 226
L-carnitine does not normalize creatine kinase (abst) .. 233
leukocyte C5a receptor modulation 112
leukopenia and hypoxemia (abst) 869
low-dose streptokinase infusions in catheters 1210
machine performance and biocompatiblity of 5 (abst) .. 233
maintenance, oral calcitriol (abst) 865
malnutrition effect on anemia (abst) 870
measurement of transcellular fluid shifts (abst) 1046
media enrichment of infected CAPD bags (abst) 255
metabolic acidosis in ESRD (abst) 230
mortality associated (abst) 245
mortality factors (abst) 245
mucormycosis associated with desferroxamine (abst) .. 247
natural killer cell function (abst) 235
osteodystrophy, PTH and Al 842
phosphate removal by different types (abst) 245
plasma Al levels (abst) 229
PTH response to Al 15
PTH, Al and osteodystrophy 842
rapid high efficiency bicarbonate (abst) 235
RBC ferritin is increased (abst) 226
red cell transfusion effect on hypotension (abst) 247
replacement therapy on monocyte IL-1 (abst) 242

reprocessing dialyzers, β_2M (abst) 238
role of income in ESRD patients (abst) 231
salvage of hemoaccess (abst) 242
self-care in center (abst) 228
serial and parallel pairs of dialyzers (abst) 247
serum amylase isoenzymes and lipase (abst) 193
spohdylarthropathies (abst) 1399
thymosin alpha-1 effect (abst) 217
uremic cardiomyopathy 973
vitamin D_3 effect on leukocyte funtion (abst) 339
vitamin D_3 treatment in uremics (abst) 868
without anticoagulation (abst) 240
1α(OH)D_3, cellular immunological status (abst) 870
59Fe and 51Cr studies (abst) 865
Hemodialyzer
re-use (abst) 237
Hemodynamics
ACE inhibition and, renal artery stenosis S-173
ACE inhibition, Ang II in CRF S-112
AII and prostaglandin in low protein fed (abst) 422
Ang II effect, ultrafiltration coefficient S-108
beta blockade (abst) 423
fish oil supplements (abst) 268
hANF 102–126 in volunteers (abst) 270
heart failure, renal function and Ang II S-220
immune complex effects on glomerular eicosanoid production 1316
NVA2 cyclosporine (abst) 466
protein load in captopril and indomethacin treated (abst) 208
renal reserves in UNX and casein-fed rats (abst) 419
tubular effects of angiotensin II S-81
verapamil (abst) 391
Hemofiltration
plasma interleukin-1, protein inhibitor (abst) 245
Hemolytic uremic syndrome
(abst) 200
immunoglobulin infusions (abst) 217
Hemorrhage
blood pressure on ARF recovery 725
Henoch Schonlein pupura nephritis
complement membrane attach, IgA glomerulonephritis . 820
Heparan sulfate proteoglycan
streptozotocin-induced diabetes (abst) 171
Heparin
decreased sensitivity in nephrotic syndrome 1378
free dialysis 1333
sepharose affinity (abst) 321
Hepatic membrane, LDL binding (abst) 181
Hepatitis B vaccine in CAPD (abst) 249
Hepatoma, endothelial growth (abst) 165
Hepatotoxicity, cyclosporine (abst) 865
Hereditary diseases
Alport syndrome, X-linked (abst) 1044
Hexose monophosphate shunt, EGF (abst) 182
Heymann nephritis
anti-FX1A (abst) 317
anti-Gp600 antigen shared by epithelial and type II (abst) 174
arachidonate 5-Lipoxygenation (abst) 277
circulating immune complexes (abst) 323
cross reactivity of antigen (abst) 324
glomerular heterogeneity and pathology (abst) 393
$HgCl_2$ (abst) 328
immune deposit formation (abst) 170
nephritogenic antibody (abst) 328
passive, polyethyleneimine (abst) 1043
vasoconstriction, complement activation (abst) 329
passive, experimental membranous nephropathy 1267
High flux dialysis
(abst) 229, 235
β_2M adsorption to membranes (abst) 244
new synthetic membranes (abst) 241
Histidine, PTH on cAMP (abst) 343
Histotopagraphy
urinary concentrating process 538
HLA peptides, T lymphocytes (abst) 461
Hormone
aldosterone-stimulating, heart failure S-210
peptide, urinary concentrating 611
receptor, cell interaction 521
thyroid, tissue responsiveness in uremic patients 808
vasoactive, ANP in nephrotic syndrome 1390
vasopressin absence, GFR and urine concentration 634
HTLV-III
associated nephropathy (abst) 193
Brazil population (abst) 231
rare seropositivity to in dialysis (abst) 236
Hybridoma model in HN (abst) 313
Hydrala, albuminuria (abst) 395
Hydrochlorothiazide
indomethacin 1097
Na-K-ATPase (abst) 918
Na-K-ATPase changes (abst) 299
Hydrogen
ATPase characterization (abst) 414
Hydrogen peroxide
mechanism for resistance to (abst) 323
Hydrolysis, kinin, angiotensin I 744
Hydronephrotic kidney, Ang II effects S-64
Hydrostatic pressure
prostaglandin (abst) 434
Hydroxyl radical scavenger (abst) 330
Hyperammonemia, uremia (abst) 220
Hypercalcemia
aluminum 766
cAMP system in vasopressin-sensitive nephron 1065
malignancy 142
renal phosphate (abst) 353
Hypercalciuria
urinary oxalate excretion (abst) 867
vitamin D_3 (abst) 864
Hypercapnic, Na-H antiporter (abst) 418
Hypercholesterolemia
glomerular injury (abst) 383
Hypercholesterolemia, nephrotic (abst) 200
Hypercoagulability
thrombo-embolic phenomena 830
Hyperfiltration
diabetes associated with ANP levels (abst) 282
protein induced (abst) 206
theory test (abst) 394
Hyperglycemia in diabetes, insulin 1012
Hyperkalemia
beta adrenergic blockade (abst) 428
lack of renal autoregulation (abst) 424
metabolic acidosis of the hyperchloremic (abst) 209
pH and 31P NMR (abst) 404
Hyperlipemia, nephrotic syndrome 1367
Hyperosmotic MDCK cells, solutes (abst) 176

Hyperparathyroidism
ethanol (abst) ... 348
oral calcitriol in maintenance HD (abst) ... 865
renal mass and reserve of vitamin D ... 1174
Hyperperfusion
impaired Na conservation (abst) ... 420
postprandial, denervated human kidneys (abst) ... 419
Hyperphosphatemia
Ca in renal biopsies ... 93
transplantation (abst) ... 463
Hyperplasia
cyst formation in ADPKD ... 1145
morphological aspects of renin synthesis ... S-18
Hyperpolarization, flow-dependent (abst) ... 431
Hypersensitivity nephritis (abst) ... 330
Hypertension
abnormal vitamin D_3 receptor (abst) ... 303
ACE inhibition and normal kidney ... S-104
ACE inhibition and renal disease ... S-102
AII modulates glomerular AII receptors (abst) ... 287
amlodipine monotherapy (abst) ... 295
anti-, high Ca diet (abst) ... 298
autonomic insufficiency (abst) ... 297
biologic variability of rats (abst) ... 301
BP and family history (abst) ... 298
Ca loading, BP, mesenteric artery (abst) ... 307
Ca, PTH, BP in (abst) ... 312
Ca, salt intake (abst) ... 308
catecholamines, renal function in man ... 107
chloride as determinant of NaCl-sensitive (abst) ... 301
clonidine suppression test (abst) ... 299
coarctation, enalapril (abst) ... 294
control with converting enzyme inhibitor (abst) ... 215
converting enzyme inhibition ... S-168
countertransport in red cells (abst) ... 299
CRF, plasma Na-K-ATPase (abst) ... 300
CyA, hyperreninemic hypoaldosteronism (abst) ... 303
cyclosporine in multiple sclerosis (abst) ... 300
cyclosporine induced (abst) ... 464
cyclosporine nephrotoxicity (abst) ... 465
diabetes, prostaglandins in (abst) ... 277
diabetic nephropathy (abst) ... 388
diazoxide opens ATP-sensitive K^+ channel (abst) ... 167
dietary Cl as determinant of (abst) ... 301
effects of Ang II in renal artery stenosis ... S-157
essential
age related differences, GFR (abst) ... 868
ANP ... 296
BP, electrolytes and renin-aldosterone (abst) ... 868
intracellular calcium (abst) ... 869
FURA-2 measurements of Ca_2^+ (abst) ... 302
glomerular abnormalities, ACE inhibition ... S-138
glomerular and vascular injury (abst) ... 315
glucocorticoid-induced ... 1213
glucocorticoid, prostaglandin I2 (abst) ... 269
Goldblatt, ANF (abst) ... 295
high dietary K, endothelium (abst) ... 307
injury in DAHL salt sensitive rats ... 718
injury in desoxycorticosterone-salt rats ... 718
K diet reduces hypertrophy of heart, arteries (abst) ... 298
maladaptation of recovery from injury (abst) ... 379
mechanism of vascular response to Ang II ... 906
membrane Na-H exchange (abst) ... 296
microalbumin excretion (abst) ... 311
Na restriction, ACE inhibition ... 815
Na^+ nitropresside reduced BP (abst) ... 306
nitrendipine on hemodynamics (abst) ... 302
norepinephrine vs. Ang II on intrarenal arteries ... S-193
preferential injury, diabetes (abst) ... 300
pressor control, K, norepinephrine or Ang II mediated, pre- ... 956
production of calcitriol (abst) ... 362
prostaglandin
excretion (abst) ... 301
hemodynamics, age correlations (abst) ... 189
heparin in SHR (abst) ... 303
protection vs. glomerulosclerosis, proteinuria (abst) ... 296
protein restriction (abst) ... 297
pulmonary, thromboxane ... 1072
refractory, fenoldopam (abst) ... 309
renal angioplasty in renovascular (abst) ... 869
renin-related, intracranial hemorrhage (abst) ... 302
renovascular, ACE inhibition ... S-154
in renal artery stenosis ... S-173
reversing glomerular, injury ... 752
risks of ACE inhibition ... S-180
role of nervous system, cardiac transplant (abst) ... 309
salt feeding induces renal lesions, reduced GFR (abst) ... 310
sex difference in response to Ca (abst) ... 298
sympathetic nervous system activity (abst) ... 306
transplantation ... 1024
treatment preserves renal function (abst) ... 296
vascular disease and age ... 1153
Hypertonic
exchange, ultrafiltration ... 731
mannitol, ischemic ARF (abst) ... 371
urine formation ... 668
Hypertonicity
medium, inhibits cotransport (abst) ... 440
peritubular, electrical conductance (abst) ... 439
Hypertriglyceridemia (abst) ... 362
Hypertrophy
PTH, adenylate cyclase (abst) ... 355
organ regeneration (abst) ... 177
uremic cardiomyopathy ... 973
Hypervolemia
aldosterone response, ANP (abst) ... 274
Hypoalbuminuria
hypercoagulability and thrombo-embolic phenomena ... 830
Hypoaldosteronism, CyA (abst) ... 266
Hypocalemia
renal handling of Ca in newborns ... 1181
Hypomagnesemia
autosomal dominant ... 1140
bone marrow transplant (abst) ... 223
chronic obstructive pulmonary disease (abst) ... 221
cyclosporine induced (abst) ... 360
Hyponatremia
AIDS (abst) ... 221
brain dehydration (abst) ... 219
Schwartz-Bartter syndrome (abst) ... 275
severe (abst) ... 207
symptomatic, relation to brain damage (abst) ... 190
untreated in children (abst) ... 190
Hypoperfusion induced ARF (abst) ... 378
Hypophosphatemia
phospholipid metabolism, P transport (abst) ... 349
Hypoproteinemia
fluid volumes (abst) ... 437

Hypotension
PAF-acether (abst) ... 271
prevention, blood dialysate parallel flow in HD (abst) ... 869
Hypothalmus, Na-KATPase (abst) ... 435
Hypotonic dehydration
central pontine myelinolysis (abst) ... 212
Hypotonic, cytoskeletal disruption(abst) ... 429
Hypotonicity, isotonicity, ions (abst) ... 435
Hypoxemia
during hemodialysis (abst) ... 231
Hypoxia
metabolic alterations (abst) ... 163
MTAL and IOMCT (abst) ... 374
phospholipid and free fatty acid levels (abst) ... 372
Hyproproteinemia, fluid volumes (abst) ... 1049

Iatrogenic complications of CAPD (abst) ... 861
Ibuprofen, piroxicam, sulindac (abst) ... 224
Idiopathic glomerulonephritis
HLA-A, B, DR antigens in Greek patients (abst) ... 863
Idiopathic intramembranous dense deposit
children (abst) ... 338
Idiopathic membranous glomerulonephritis
steriods and chlorambucil (abst) ... 863
Idiopathic membranous nephropathy
food allergy (abst) ... 1398
HLA-A, B, DR, and Bf allotypes ... 130
IgA
BSA antigen in immune complexes (abst) ... 340
antibody, transplantation (abst) ... 1047
glomerulonephritis, complement membrane attack ... 820
nephritis associated, experimental models of ... 1
IgA nephropathy
children, prognosis (abst) ... 202
complement activation ... 1019
differences in IgA subclasses (abst) ... 337
Henoch-Schönlein purpura in children ... 1132
increased immunoglobulin-secreting cells in blood (abst) ... 338
intra-intestinal administration of antigen (abst) ... 1046
prednisone (abst) ... 222
rheumatoid factor in (abst) ... 339
viral respiratory pathogen (abst) ... 324
IL-1 mRNA in mesangial cells (abst) ... 325
Immune complex
changes in function in vitamin D_3 (abst) ... 342
clearance, lupus nephritis (abst) ... 321
Clg131I in Clq receptor (abst) ... 330
deposit solubilization by DNA (abst) ... 322
effects on glomerular eicosanoid production ... 1316
erythrocyte, glomerulonephritis connection in man ... 877
formed on glomerular epithelial cells (abst) ... 182
Heymann nephritis (abst) ... 323
IgA, BSA antigen (abst) ... 340
IgA, complement system (abst) ... 323
mediated glomerular injury (abst) ... 319
nephritis, urinary protein excretion rates (abst) ... 392
neutrophil activation (abst) ... 326
PAF inhibits injury (abst) ... 314
PG synthesis via phosphoinositide metabolism (abst) ... 325
U937, phorbol esters (abst) ... 326
Immune deposition
independent of glomerular microcirculatory dynamics (abst) ... 334
in passive HN (abst) ... 170
Immune dysfunction, lupus neph. (abst) ... 334
Immune hemolysis, ARF, clinoril (abst) ... 368
Immunity
cellular, CAPD and HD effect on patient (abst) ... 862
Immunoadsorption, tubules (abst) ... 166
Immunoassay
Tamm-Horsfall protein interaction with bacterial extracts ... 77
Immunoglobulin infusion in HUS (abst) ... 217
Immunoregulation, lymphotoxin in MCN ... 1186
Immunotherapy
immune complex glomerulonephritis (abst) ... 863
Immunoultrastructural analysis (abst) ... 401
Indomethacin
blocks arginine induced rise of RPF, GFR in man (abst) ... 201
control euvolemia, PGE (abst) ... 281
isoproterenol, theophylline induced renin release (abst) ... 263
mechanism of attenuated hydrochlorothiazide response ... 1097
streptozotocin induced nephrogenic D.I. (abst) ... 191
Inflammatory responses, RF (abst) ... 320
Influenza vaccine for dialysis (abst) ... 1046
Inhibitors, proton secretion (abst) ... 410
Injury
accelerated glomerular, protein diet (abst) ... 390
Ca uptake in HgCl2 tubules (abst) ... 365
CEI (abst) ... 383
chronic renal, internephron heterogeneity (abst) ... 392
determinants of glomerular (abst) ... 319
enhancement of Na-K-ATPase (abst) ... 376
glomerular
antihypertensive therapy ... 718
cholesterol (abst) ... 387
hypercholesterolemia (abst) ... 383
vascular in hypertension (abst) ... 315
glutathione (abst) ... 404
hydrogen peroxide oxidant (abst) ... 159
hypertension a maladaptation of recovery (abst) ... 379
immune glomerular, proteinuria (abst) ... 312
medullary, modulation by adenosine (abst) ... 367
oxidative, glutathione (abst) ... 372
platelet activating factor in nephrotoxic nephritis ... 1248
prostaglandin formation in membranous nephropathy ... 1126
renal
ablation (abst) ... 385
ischemia-reperfusion, O2 metabolites (abst) ... 369
target structures in allograft rejection ... 1310
IgA-associated nephritis experimental models ... 1
lactic dehydrogenase a marker for (abst) ... 367
reversing glomerular hypertension ... 752
Inositol
diabetes (abst) ... 387
trisphosphate, APII (abst) ... 277
Insulin
angiotensin II, PG biosynthesis (abst) ... 288
binding, internalization and degredation (abst) ... 187
diabetes mellitus (abst) ... 426
endotoxin in renal failure (abst) ... 388
glucocorticoid-induced hypertension ... 1213
glycemic changes in diabetes ... 1012
like growth factor
modulation in ARF (abst) ... 395

Na, K-ATPase response to (abst) ... 436
pentose cycle in BBMV uptake of P (abst) ... 343
proinsulin (abst) ... 398
PTH phosphaturic action (abst) ... 341
RBC receptor in uremia (abst) ... 388
stimulates transport (abst) ... 428
Interleukin
alkalinization (abst) ... 169
gene is expressed by mesangial cells (abst) ... 180
Interleukin 1
elevated in ESRD patients on HD (abst) ... 237
induction from human monocytes (abst) ... 238
interferon gamma, endotoxin are activation antigens (abst) ... 322
modulation by hemodialysis and hemofiltration (abst) ... 245
particles from dialysis equipment stimulate (abst) ... 228
PGE secretion, endotoxin (abst) ... 320
renal replacement therapy (abst) ... 242
Interleukin 1 and 2
levels during hemodialysis (abst) ... 241
Interleukin 2 therapy (abst) ... 220, 224
Interlobular arterial resistance ... 1291
Interstitial fluid, cortical (abst) ... 452
Interstitial nephritis
analgesic abuse, tumors of kidney and ureter, (abst) ... 1399
anti-tubular basement antibody (abst) ... 316
anti-tubular basement membrane, antisera (abst) ... 322
oxalate induced (abst) ... 364
oxalate-induced (abst) ... 364
suppressor T cells (abst) ... 324
Intervention therapy, transplant (abst) ... 458
Intestinal schistosomiasis, ESRD ... 1006
Intracranial aneurysm, PKD (abst) ... 204
Intrarenal natriuretic hormone (abst) ... 258
Inulin
GFR markers (abst) ... 213
iothalamate clearance and (abst) ... 202
PAH clearance (abst) ... 424
Ion
content, isotonicity (abst) ... 435
fluidity in BBM and BLMV (abst) ... 439
pump activity (abst) ... 168
transport, shark rectal gland (abst) ... 185
uptake in S2 segments (abst) ... 450
Iopamidol, radiocontrast agent (abst) ... 371
Iothalamate
creatinine clearances HPLC (abst) ... 389
clearance (abst) ... 202
Iron
cysteine induced malonaldehyde (abst) ... 377
dextran, peritoneal dialysis (abst) ... 862
serum, in ARF (abst) ... 865
suppresses PTH (abst) ... 359
59Fe and 51Cr studies in chronic HD (abst) ... 865
Ischemia
ACE inhibition and acute tubular necrosis ... S-143
acquired resistance to ARF ... 1233
ANF on renal failure (abst) ... 371
ATP-$MgCl_2$ and thyroxin (abst) ... 376
Ca and endothelium derived relaxing factor (abst) ... 374
change in energy reserves during ... 1239
DMSO (abst) ... 372
hemmorhagic reduction in BP in ARF ... 725
iron in ARF (abst) ... 373
isoenzymic changes (abst) ... 871
mechanism of reduced BBM glucose transport (abst) ... 371
morphopathology following (abst) ... 370
O_2 metabolite dependence, injury (abst) ... 377
renal effects of enalapril ... S-148
renal failure with hypertonic mannitol (abst) ... 371
renal failure, lipohilic antioxidant probucol (abst) ... 364
restricted dietary protein (abst) ... 363
splenectomy in ARF (abst) ... 370
transient following urography ... 378
vascular obstruction in renal ... 65
31P MRS (abst) ... 469
Ischemic renal failure
management after hemoaccess placement (abst) ... 239
lipohilic antioxidant probucol (abst) ... 364
Isolated perfused kidney
kininase activity (abst) ... 263

Jaundice, obstructive (abst) ... 398
Juxtaglomerular cells, renin release ... S-89
Juxtamedullary nephron
tubuloglomerular feedback mechanism (abst) ... 421

Kaliuresis
amiloride, K (abst) ... 443
Kallikrein
aprotinin augmentation by vasopressin ... 1092
salt and water balance ... 836
Ketoacid
phosphate and PTH (abst) ... 357
respiratory acidosis, alkalosis regulate (abst) ... 410
Ketoacidosis, occult, osmolar gap (abst) ... 224
Ketotifen, histamine in uremia (abst) ... 233
Kidney cold storage (abst) ... 453
Killer activity, pyelonephritis (abst) ... 335
Kinase, cAMP, Na^+-H^+ exchanger (abst) ... 186
Kinin
AI converting enzyme and ... 744
Kininase
activity in vascular interstitial space (abst) ... 263
Kininase II, neutral endopeptidase ... S-45

L-carnitine
hemodialysis (abst) ... 226
serum creatine kinase in HD (abst) ... 233
Lactate, cation transport (abst) ... 185
Lactic alkalosis: new syndrome (abst) ... 191
Lactic dehydrogenase injury marker(abst) ... 367
Lamina densa, size restriction ... 710
Laminin A, B chain (abst) ... 325
Laminin
collagen IV chains in diabetics (abst) ... 171
Lead
blood, blood pressure and response to Ca supplement (abst) ... 209
in bone, role in renal disease (abst) ... 196
neonatal exposure (abst) ... 292
nephropathy, x-ray fluorescence (abst) ... 224
Lecithin-cholesterol-acyltransferase
uptake of lipoproteins (abst) ... 168
Lesion
coagulopathy in nephrotic syndrome ... 772
glomerular abnormalities, ACE inhibition ... S-138
idiopathic membranous nephropathy allotypes ... 130
ischemic, donor age for transplantation (abst) ... 1047
organic anion transport (abst) ... 445

severe lupus glomerulonephritis (abst) 217
Leukocyte
analysis, monoclonal antibodies in glomerulonephritis.. 964
C5a receptor modulation, hemodialysis 112
endotoxin and nordihydroguaiaretic acid (abst) 385
Mol/LFA-1/LeuM5 glycoprotein family (abst) 312
regression of renal cancer (abst) 340
Leukopenia 237
hypoxemia during HD (abst) 869
Leukotriene
D4 antagonist SK&F 104353 (abst) 363
Leupeptin in acute uremia (abst) 375
Light chain disease
discrepancy in (abst) 1415
Limulus amebocyte lysate (abst) 239
Linoleic acid inhibits renin (abst) 308
Lipid
clathrin-coated vesicle proton pump (abst) 187
marine in mitochondrial membranes (abst) 370
pathway, NH3 permeates MDCK cells (abst) 408
peroxidation, CyA and cisplatin (abst) 375
profile in CAPD (abst) 1050
profile, omega-3, CAPD (abst) 255
Lipophilic antioxidant probucol (abst) 364
Lipoprotein
density classes in CRF (abst) 379
uptake in culture (abst) 168
Liposome delivery of CyA (abst) 462
Lipoxins (abst) 286
Lipoxygenase
pathway metabolites on NaK ATPase activity (abst)... 278
Lithium
clearance, sodium restriction (abst) 438
marker of Na and H_2O handling (abst) 189
protein Ns enhances cAMP (abst) 258
uric acid in cirrhosis (abst) 198
Lithotripsy, catheterization (abst) 204
Liver
hemodynamics, amino acid (abst) 427
PKD, corticosterone changes 1088
transplant in children (abst) 213
transplant, renal failure (abst) 195
LLC-PK1
ammoniagenesis (abst) 400
cells
phosphate transport (abst) 179
role of Na^+/H^+ antiporter (abst) 411
mutant (abst) 168
phlorizin (abst) 176
vasopressin signaling in kidney cells 521
voltage dependance of Na/K-ATPase (abst) 431
Local graft irradiation (abst) 465
Loop diuretics
Cl^- independent Na^+ influx (abst) 180
Loop of Henle
historical aspects 507
Luerlock plastic adapter in CAPD (abst) 861
Luminal perfusion, glucose (abst) 400
Luminal surface, anionic sites 52
Lupus erythematosus
persistence in peritoneal dialysis (abst) 254
Lupus glomerulonephritis
anti-interleukin 2 receptor antibody (abst) 324
antibody to RNA polymerase I (abst) 331
clearance of immune complex (abst) 321
effective fibrinolysis (abst) 222
evolution (abst) 334
glomerular lesions in (abst) 217
fibrinolysis (abst) 337
plasmapheresis therapy (abst) 201
plasmapheresis therapy (abst) 208
prostaglandin (abst) 316
renal transplantation (abst) 464
thromboxane receptor antagonist (abst) 283
Lupus nephropathy
CyA improves graft survival in transplantation (abst) .. 466
Lymphatic absorption, CAPD (abst) 252
Lymphatics
peritoneal ultrafiltration kinetics (abst) 253
Lymphocyte
membranous glomerulonephritis (abst) 335
Tamm Horsfall protein (abst) 325
Lymphohemopoietic antigen, marker (abst) 185
Lymphotoxin in MCN 1186
Lysosomes of the renal cortex 886

Macromolecules
uptake enhanced by Fc portion of antibodies (abst).... 327
Macrophages, fatty acid (abst) 329
Magnesium
calcium excretion (abst) 357
circadian rhythm (abst) 344
dietary acid on tubular handling of (abst) 362
increased renin secretion (abst) 266
wasting in PKD 1140
Maleic acid, P homeostasis (abst) 348
Malignancy and hypercalcemia 142
Malnutrition, anemia, HD (abst) 870
Malonaldehyde formation, Fe (abst) 377
Mathmatical models of CAVH (abst) 240
Matrice, glomerular extracellular (abst) 326
Matrix constituents, culture (abst) 318
MCDK cells
benzyl alcohol (abst) 166
bradykinin changes in inositol triphosphate mass (abst) 178
cyst growth inhibited by amiloride (abst) 184
intracellular solutes (abst) 176
Mechanism
of IgA-associated nephritis 1
resistance to H_2O_2 (abst) 323
Mechanoreceptors, renal (abst) 300
Mecuric chloride, Heymann neph. (abst) 328
Medicare report of ESRD (abst) 203
Medulla
renal pelvis 621
Medullary collecting duct
amiloride 1121
ANP receptors (abst) 271
inner, intercalated cells 1080
outer, acidic compartments (abst) 417
potassium recycling 695
Medullary microcirculation, models 662
Medullary solute reconstitution (abst) 445
Medullary thick ascending limb
aminoacid utilization (abst) 403
Na-dependent modulation of Na-KATPase (abst) 434
Medullary tissue composition 556
Meglumine-diatrizoate, uremia (abst) 378

Membrane attack complex (abst) 33
..... 333
Membrane, brush border
glycoprotein processing (abst) 188
phosphonoformic acid, Na^+ uptake of Pi (abst) 183
Membranoproliferative glomerulonephritis
antibody to solid phase C1q (abst) 331
Membranous glomerulonephritis
activated lymphocytes (abst) 335
antibodies reactive with deposits (abst) 338
complement C5b-9 (abst) 329
complement, leukocyte independent (abst) 328
enhanced prostanoid formation (abst) 265
hypercoagulability and thrombo-embolic phenomena ... 830
mesangial overloading (abst) 331
prostaglandin formation 1126
type IV collagen and laminin (abst) 338
urinalysis and biopsy (abst) 218
Mercuric chloride
glomerular immune deposit (abst) 320
Mesangial cell
culture of chicken (abst) 179
epidermal growth factor 184
IL-1 mRNA (abst) 325
peritoneal exudate cells and erythrocytes (abst) 158
pH regulation (abst) 161
proliferation by phorbol myristate acetate (abst) 188
growth factor (abst) 158
release platelet-derived growth factor molecule (abst) .. 182
shape change (abst) 314
tussular-plasminogen activator (abst) 172
Mesangial changes, spermine (abst) 381
Mesangial hyperplasia, AIDS 1167
Mesangial overloading in MN (abst) 331
Metabolic acidosis
altered intestinal bicarbonate fluxes (abst) 302
hemodialysi, ESRD (abst) 230
Metabolic alkalosis
furosemide infusion (abst) 208
sodium chloride determines severity 1338
Metabolic alterations in tubules (abst) 163
Metabolic control in diabetic rat 47
Metabolism
insulin in cultured kidney cell line (abst) 187
peripheral, PTH 937
phosphoinositide, aminoglycoside-induced alterations ... 59
Metal, alkali detection 1225
Metalloproteinases, GBM (abst) 313
Metolazone-probenecid (abst) 218
Mevinolin, hypercholesterolemia (abst) 200
Microalbumin, hypertension (abst) 311
Microalbuminuria 673
Microcatheterization, amiloride 1121
Microcirculation
medullary 641
dynamics (abst) 334
Microelectrode
intracellular, nephron 1055
ionsensitive (abst) 164
Microfilament, anti-FX1A (abst) 317
Microscopy, video-enhanced (abst) 170
Midcortical nephron
renin-angiotensin system and function S-57
Mineralization, bone cell, Al, PTH 736
Mineralocorticoid
AVP, Rb^+ (abst) 285
escape, Na handling (abst) 430
pretreatment, pH gradient across CCD 930
regulation of intracellular K activity (abst) 441
Minimal change disease
in adult (abst) 206
human serum also contains lymphotoxin found in 1186
NSAIDs (abst) 223
Zollinger-Ellison syndrome (abst) 225
Mitochondrial rich cell
immunodissection (abst) 406
Mitogenesis, Ca_2^+ (abst) 180
Mitogens, Na/H exchange (abst) 169
Modeling, CyA (abst) 455
Molecule LH in ESRD (abst) 177
Monoclonal antibodies
anti-GP 330, cell adhesion (abst) 175
immunoadsorption, collecting cortical tubules (abst) ... 166
immunoultranstructural analysis (abst) 401
T cells and monocytes in nephritis 1160
Tamm-Horsfall protein to probe tubular obstruction (abst) 1417
Monocyte
defect in uremia (abst) 232
T cells in nephritis 1160
Morphogenesis, proteoglycan (abst) 178
Mortality, hyponatremia in rat (abst) 207
Mucomycosis in hemodialysis (abst) 247
Multiple sclerosis
cyclosporine (abst) 211
hypertension in cyclosporine-treated (abst) 300
Multiply myeloma, renal failure (abst) 1417
Murine
kidney, MHC (abst) 463
congenital PKD (abst) 165
glomerulonephritis
role of H-2 (abst) 319
synthetic protease (abst) 318
lupus, water metabolism (abst) 290
Muzolimine
Na^+ transport (abst) 171
transport mechanism (abst) 447
Myeloma
casts, tubular obstruction (abst) 1417
kidney, rifampin therapy (abst) 219
Myo-inositol polyphosphate (abst) 181
Myocardial calcification, verapamil 41
Myohemoglobinuric ARF, resistance to 123
Myohemoglobinuric ARF, resistance to 1233

Na-K pump
activity in proximal tubular cells (abst) 173
ouabain (abst) 165
uremic erythrocytes (abst) 387
Na, K-ATPase
circulating inhibitor of (abst) 307
prostaglandin (abst) 265
Natriuresis
albumin induced in children 1390
ANF failure to induce (abst) 264
ANP in cirrhotic rats (abst) 276
atrial peptides (abst) 270
GFR after ANP (abst) 433
not GFR after ANP is blunted (abst) 1049

Natriuretic
action, mechanism (abst) ... 1049
ANF is at physiologic concentrations (abst) ... 293
effect, diuretics, ANF ... 946
mechanism of ANF (abst) ... 273
system, kallikrein, kininogen and kinin ... 836
Natural killer cell function HD (abst) ... 235
Navajo, ESRD ... 209
Necrosis
cytoprotection by acidosis (abst) ... 375
restore after reversing vascular obstruction ... 65
Neoplasms in dialysis (abst) ... 242
Neopterin in transplantation (abst) ... 870
Nephrectomy
compensatory renal hypertrophy, cyclosporine (abst) ... 454
transport functions in reduction of renal mass (abst) ... 394
Nephritis
glomerulonephritis induced in sheep, human GBM ... 25
Heymann, glomerular heterogeneity, pathology (abst) ... 393
human anti-tubular basement membrane, target antigen ... 800
hypercoagulability and thrombo-embolic phenomena ... 830
IgA associated, children ... 1132
T cells and monocytes ... 1160
Nephrocalcin
in proximal tubule (abst) ... 176
measurement (abst) ... 361
Nephrocalcinosis, verapamil ... 41
Nephrology
renal disease in one hospital (abst) ... 196
rural experience (abst) ... 201
Nephron
cAMP in vasopressin-sensitive ... 1065
function heterogeneity, renin-angiotensin system ... S-57
heterogeneity of anatomy ... S-18
K^+ conductive pathways ... 1055
serial micropuncture analysis glomerular sclerosis (abst) ... 384
short and long loop ... 597
Nephropathy
acetaminophen (abst) ... 192
AIDS associated (abst) ... 199
AIDS, ultrastructural markers (abst) ... 335
HTLVIII associated (abst) ... 336
idiopathic membranous, allotypes ... 130
lead, x-ray fluorescence (abst) ... 224
life table analysis (abst) ... 193
tubular in AIDS (abst) ... 195
Nephrosclerosis
hypertension in transplant recipients ... 1024
Nephrosis
adriamycin, ATPase ... 704
albumin isoelectric point (abst) ... 321
albumin synthesis, albuminuria and hyperlipemia ... 1367
ANF (abst) ... 283
fish oil benefits serum lipids, creatinine (abst) ... 386
Nephrotic syndrome
albumin synthesis, hyperlipemia ... 1367
aminonucleoside-induced, ANF (abst) ... 272
ANP and other vasoactive hormones ... 1390
children, serum free fatty acids (abst) ... 199
coagulopathy in children ... 772
decreased sensitivity to heparin ... 1395
discrepancy in light chain disease (abst) ... 1415
indomethacin on circadian rhythm, proteinuria (abst) ... 1048
loss of edema-preventing force (abst) ... 192, 1048
minimal change in adults (abst) ... 206
osmostat parameters (abst) ... 865
proteinuria, captopril (abst) ... 199
pulmonary embolism, lung perfusion (abst) ... 864
refractory, cyclosporine (abst) ... 214
steroid-dependent minimal change (abst) ... 205
urine protein-creatinine ratio (abst) ... 216
Nephrotoxic
ACE inhibition ... S-132
acquired resistance to ARF ... 1233
adriamycin nephrosis ... 704
cisplatin, ANF (abst) ... 365
CsA, CsG (abst) ... 461
CyA, hemodynamic deficit (abst) ... 366
CyA, prostaglandins in (abst) ... 365
cyclosporine
A (abst) ... 373
calcium channel blocker (abst) ... 454
hypertension (abst) ... 465
gentamicin, Ca alteration, PTH (abst) ... 366
gentamicin, vitamin D (abst) ... 366
nephritis
(abst) ... 379
collagen (abst) ... 317
GFR (abst) ... 289
glomerular hypertension and sclerosis ... 752
PAF and injury ... 1248
renal failure ... 275
renal effects of enalapril in dogs ... S-148
urinary gamma-glutamyl transferase for detection (abst) ... 864
Nerve
activity in hypertension (abst) ... 306
growth factor, localization (abst) ... 259
renal mechanoreceptors (abst) ... 300
sural, cryoglobulinemia (abst) ... 864
Neurohypophyseal hormones (abst) ... 451
Neutral dextran, clearance method ... 855
Neutron activation analysis (abst) ... 205
Neutrophil
activation (abst) ... 326
O_2 metabolites (abst) ... 369
New Castle disease in Japan (abst) ... 237
Nicotinamide, phosphaturic action (abst) ... 350
Nifedipine
acute changes of renal function after (abst) ... 865
preservation effect in ARF (abst) ... 871
hemodynamics in hypertensives (abst) ... 302
nephrotoxicity (abst) ... 373
Non-diabetic renal disease (abst) ... 189
Nonsteriodal ant.inflammatory drugs
prostaglandins modulate actions of Ang II ... S-95
variable pathology in minimal change disease (abst) ... 223
Norepinephrine
α_2-adrenoceptors, CEI ... S-191
Ang II mediated pressor control in prehypertension ... 956
angiotensin II comparison, intrarenal arteries ... S-193
β-adrenoceptor vasodilation (abst) ... 425
decreases planar surface area of mesangial cell (abst) ... 424
organic ion transport (abst) ... 447
NR6 cells, TGF-beta receptor (abst) ... 187
Nucleotide
cyclic in pregnancy (abst) ... 421
exogenous, increase Ca_2^+ in LLC-PK1 (abst) ... 185

Obstruction, ureteral (abst) 393
Obstructive pulmonary disease (abst) 221
OKT3
allograft rejection (abst) 456
Oncogenes, hypertrophy (abst) 177
Ontogeny, AII mRNA expression (abst) 268
Optical measure of glucose (abst) 404
Ornithine decarboxylase activity (abst) 462
Osmolality
ANP in dehydrated rats 760
dialysate (abst) 866
GFR, concentration in absence of vasopressin 634
models of urinary concentrating mechanism 648
pathways of urea in mammalian kidney 629
serum, in renal failure (abst) 869
Osmolar gap, urine, ketoacidosis (abst) 224
Osmolytes, renal inner medulla 562
Osmosis
short and long loop nephron 597
Osmostat parameters in NS (abst) 865
Osmotic equilibrium
composition of renal medullary tissue 556
Osmotic equilibrium, collecting duct 556
Osteodystrophy
aminohydroxypropylideenbisphosphonate (abst) 349
calcium citrate a therapeutic agent (abst) 344
diphosphonate APD (abst) 1048
PTH and Al 842
reversed by 1,25(OH)$_2$D (abst) 353
Osteomalacia
relation of Ca, PTH and bone Al (abst) 355
Osteosarcoma, protein kinase C (abst) 355
Ouabain
insensitive, vanadate sensitive ATPase activity (abst) .. 413
Na-K pump (abst) 165
Oxalate
clearance, CRF (abst) 382
induced interstitial nephritis (abst) 364
induced TIN (abst) 364
Oxidation phosphorylation (abst) 162, 403
Oxygen
metabolite dependence, ischemia (abst) 377
radicals on prostaglandin (abst) 312
transport dependent consumption of (abst) 365
Oxygen free radical
ATPase activity induced by adriamycin (abst) 1045
suppression, GFR (abst) 363

P-31 nuclear magnetic resonance (abst) 401
PAF-acether
(abst) 283
renal action (abst) 271
PAH, inulin clearance (abst) 424
Paired filtration dialysis (abst) 870
Pancreas transplantation (abst) 1050
Papillary acidification (abst) 407
Parathyroid
secretion, guanine nucleotide regulatory proteins (abst) 176
Parathyroid glands, deferoxamine 1326
Parathyroid hormone
adenylate cyclase (abst) 355
Al action on bone cell, vitamin D$_3$ 736
Al induced bone disease (abst) 356
aluminum in renal osteodystrophy 842
ATP (abst) 400
biological activity of 937
brain Al and vitamin D (abst) 354
Ca absorption in cTAL 913
Ca transport (abst) 311
calcemic response in SHR (abst) 306
calcitriol and Ca 795
cytosolic Ca_2^+ (abst) 346
cytosolic free calcium (abst) 361
dual pathway cell activation (abst) 356
estimation in CRF (abst) 867
facilitates Ca transport (abst) 347
function in transplanted patients (abst) 465
histidine effect of on cAMP (abst) 343
insulin release in CRF (abst) 384
intraperitoneal calcitriol, Ca 795
Na-Ca exchange in cortical cells, age (abst) 348
osteodystrophy, aluminum 842
pH in PCT cells (abst) 413
phosphaturic action, insulin (abst) 341
phospholipid metabolism (abst) 354
regulation of Ca channel by phorbol ester (abst) 351
renal mass and reserve of vitamin D 1174
response to aluminum 15
suppression by iron (abst) 359
vitamin D$_3$ (abst) 382
Patch clamp technique, nephron pathways 1055
Pelvis, renal 621
Pentose cycle, BBMV, P (abst) 343
Pepdites, ANP, dehydration 760
Peptide
calcitonin degradation (abst) 399
changing salt and water balance 836
hormones, urinary concentrating mechanism 611
Percutaneous transluminal angioplasty
atherosclerotic renovascular disease (abst) 192
Perfusion
vascular obstruction, renal ischemia 65
verapamil, preservation (abst) 464
Periarterial pathway, renin S-51
Pericardial effusion drainage (abst) 237
Peristalsis, renal pelvis 621
Peritonitis
algae misdiagnosed as fungal (abst) 256
fungal in CAPD (abst) 861
intraperitoneal vancomycin (abst) 256
multiple enteric organism (abst) 254
pseudomonas (abst) 254
reduction in CAPD, UV-XD (abst) 256
Peritubular HCO$_3$ (abst) 405
Permeability
calcium (abst) 449
function of thin loops of Henle 565
glomerular sieving in proteinuric rats 1257
high chloride (abst) 439
ion fluidity in BBM and BLMV (abst) 439
models of medullary microcirculation 662
response, proteins (abst) 169
single channel fluctuations from bone cells (abst) 348
vasopressin and ANF (abst) 450
water diffusive, proton NMR (abst) 444
Pertussis toxin, tubular membrane (abst) 179
pH
acute hyperkalemia measured (abst) 404
alkalinization of cell, HCO_3^- or Na^+ concentration

(abst) ... 413
Ca, ADH and collecting duct ... 530
coupled lactate transport (abst) ... 412
cytoplasmic regulation in renal proximal tubule cells ... 1113
cytosolic in cortical tubules (abst) ... 402
cytosolic, angiotensin II (abst) ... 271
disequilibrium, ammonia secrection (abst) ... 416
extracellular effect on phosphate uptake, Na pump (abst) ... 184
generation of gradient across CCD ... 930
gradient stimulated long chain fatty acid transport (abst) ... 451
mechanism to regulate urea synthesis rate (abst) ... 396
recovery of cell, from respiratory acidosis (abst) ... 409
regulation in glomerular mesangial cells (abst) ... 161
regulation in S3 proximal tubule (abst) ... 412
regulation, vasopressin, PMA (abst) ... 264
serosal effect on Ca transport (abst) ... 352
steady state and, Na^+ independent $Cl^-HCO_3^-$ exchange (abst) ... 414
Phagocytes, mesangial cell study (abst) ... 158
Phlorizin binding, LLC-PK1 (abst) ... 177
Phorbol ester
ammoniagenesis (abst) ... 396
on Fc receptor (abst) ... 326
sodium absorption (abst) ... 435
Phorbol myristate acetate (abst) ... 188
Phosphate
chronic hypercalcemia (abst) ... 353
depletion on brain catecholamines (abst) ... 342
deprivation, renal adaptation (abst) ... 355
glucose and valine transport (abst) ... 445
leak in Fanconi Syndrome (abst) ... 415
reabsorption, age (abst) ... 349
reabsorption, protein deprivation (abst) ... 360
removal by different types of dialysis (abst) ... 245
respiratory acidosis, transport (abst) ... 351
restriction in CRF (abst) ... 398
restriction, low protein diet (abst) ... 380
thiol redox, nicotinamide (abst) ... 358
transport (abst) ... 356
transport, sodium (abst) ... 160
Phosphatidylcholine in UF (abst) ... 246
Phosphatidylinositol, gentamicin (abst) ... 369
Phosphaturia, $23(OH)D_3$ (abst) ... 357
Phosphoinositide metabolism (abst) ... 325
Phospholipase
activity, dopamine (abst) ... 166
C, A2, AII and PGE_2 (abst) ... 285
Phospholipid
free fatty acid levels in hypoxia (abst) ... 372
metabolism, P transport, hypophosphatemia (abst) ... 349
Phosphonocarboxylic acid
Na/Pi synporter in BBM (abst) ... 183
Phosphonoformic acid
mechanism (abst) ... 359
Pi (abst) ... 183
Phosphorus
calcitriol synthesis (abst) ... 352
homeostasis, maleic acid (abst) ... 348
protein restriction in CRI (abst) ... 384
taurine (abst) ... 344
Phosphorylation
substrates for vasopressin (abst) ... 273
Physiology of renin-angiotension system ... S-49
Pituitary thyroid function, CRF (abst) ... 201
PKD
cyst formation and growth ... 1145
Plasma
C3 and C4, complement activation in IgA nephropathy ... 1019
exchange in RPGN (abst) ... 867
fresh frozen in HUS (abst) ... 200
urine, ANP characteristics in renal diseases (abst) ... 278
Plasma arginine vasopressin
diabetes (abst) ... 190
severe congestive heart failure (abst) ... 191
Plasmapheresis therapy
severe lupus nephritis (abst) ... 201, 208
Platelet activating factor
glomerular mesangial cells (abst) ... 161
inflammatory injury (abst) ... 314
mediates injury in nephrotic patients ... 1248
permeability to dextrans (abst) ... 331
proteinuria mediator (abst) ... 267
Platelet derived growth factor
human mesangial cells release (abst) ... 182
modulates Ca^{++} in mesangial cells (abst) ... 175
PMA, ADH increase immunolabelling (abst) ... 174
Polyacrylonitrite as a binder (abst) ... 245
Polyaspartic acid, gentamicin (abst) ... 374
Polycation, GBM sieving (abst) ... 313
Polycystic kidney disease
analysis of cellular and molecular defects (abst) ... 186
ANF in normotensive, hypertensive (abst) ... 295
autosomal dominant, hypertension and renal structure (abst) ... 297
basement membrane genes in murine congenital (abst) ... 165
cardiac abnormalities (abst) ... 203
cellular basis of cyst formation, growth (abst) ... 384
cellular, transport-related defects (abst) ... 394
children ... 1000
chromosome 16 (abst) ... 206
ciprofloxacin for treatment (abst) ... 193
corticosterone changes in cpk mouse ... 1088
cyst accumulation of β_2-microglobulin ... 85
diagnosis of cyst infection in (abst) ... 216
diphenylthiazole induced (abst) ... 212
elevated C-MYC in mouse (abst) ... 163
functional changes (abst) ... 392
genetic murine model of ADPKD (abst) ... 385
histogenesis of renal cysts (abst) ... 339
intracranial aneurysms (abst) ... 204
renal structure and concentrating ability (abst) ... 197
renal structure and hypertension (abst) ... 297
Polypeptide
Ang II on vessels of split hydronephrotic kidney ... S-64
Polysulfone capillary membrane (abst) ... 244
Na handling in glomerulonephritis (abst) ... 364
Postglomerular capillaries (abst) ... 427
Potassium
amonium transport by MTAL (abst) ... 408
apical membrane conductance (abst) ... 431
ATP sensitivity of channels (abst) ... 436
bicarbonate load, K, Cl, or KCl depletion (abst) ... 410
BP in elderly (abst) ... 311
Ca loading in hypertension (abst) ... 307
Ca^{++} sensitive, sodium blocks (abst) ... 438
calcium activated channels in MTAL (abst) ... 431
channel study (abst) ... 440

chlorine conductances, BLM (abst) 452
Cl transport systems in BLMV (abst) 432
conductance, volume regulation (abst) 434
conductive pathways in the nephron 1055
depletion, metabolic alkalosis 1355
diet, hypertensive hypertrophy of heart (abst) 298
enhanced transcelllar secretion of, CRF 1376
excretion during hypokalemia, DOCA (abst) 443
flow dependent secretion (abst) 432
furosemide, prazosin and captopril 135
high dietary, hypertension (abst) 307
lack of autoregulation during hyperkalemia (abst) 424
load induced kaluiresis in amiloride treated (abst) 443
loading, aldosterone-independent stimulation (abst) 433
low-threshold transient Ca^+ channels (abst) 279
mineralocorticoid regulation of intracellular (abst) 441
Na diurnal excretory cycles (abst) 440
Na handling in acute GN (abst) 364
norepinephrine, Ang II, pressor control, prehypertension 956
picomole analysis of alkali metals 1225
Rb transport comparison (abst) 443
recycling 695
Prazosin, captopril during furosemide 135
Prednisone
IgA nephropathy (abst) 222
Pregnancy
adaptation of intravascular volume (abst) 281
calcium oxalate and caronate supersaturation in (abst) 209
cyclic nucleotides (abst) 421
dietary protein intake (abst) 426
nephrocalcin, CaOx (abst) 359
PG synthesis (abst) 290
xyloside effect on fetal kidney (abst) 173
PreproEGF localization (abst) 261
Preservation of kidney, ischemia (abst) 871
Primary glomerulonephritis
epidemiology in rural population (abst) 218
Primate stimulation of renin (abst) 263
Proinsulin, renal degradation (abst) 398
Prostacyclin
cAMP and Ca (abst) 264
formatin, CyA (abst) 457
Prostaglandin
AII, hemodynamics in low-protein fed (abst) 422
antibody to mesangial cell membrane (abst) 315
calcium (abst) 267
control evolemia and acute indomethacin (abst) 281
CyA nephrotoxicity (abst) 365
DAHL rat production (abst) 308
dietary protein modulates (abst) 267
E. collendotoxin stimulates (abst) 323
enhanced formation in experimental membranous nephropathy 1126
excretion in borderline hypertension (abst) 301
GFR increase after meat meal (abst) 208
glomerular and mesangial synthesis in diabetes (abst) 260
glomerular, in hypertensive diabetes (abst) 277
glycerol-induced ARF (abst) 378
heparin in SHR (abst) 303
I2 and glucocorticoid-hypertension (abst) 269
lupus nephritis (abst) 316
modulate glomerular ations of angiotensin II S-95
oxygen radicals (abst) 312
protein induced hyperfiltration (abst) 206
RBF autoregulation (abst) 387
sodium excretion, hydrostatic pressure (abst) 434
sulindac in renal insufficiency (abst) 276
synthesis in adrenalectomized rabbit, inhibition (abst) 265
tubuloglomerular feedback (abst) 423
6-keto-$PGF_{1\alpha}$ prodution (abst) 272
Prostaglandin E_2
calcium intake in hypertension (abst) 292
cyclosporin A inhibits (abst) 288
endotoxin stimulates release (abst) 291
insulin-AII interaction (abst) 288
receptors (abst) 287
synthesis during pregnancy (abst) 290
Prostanoid
formation in MN (abst) 265
metabolism, mesangial (abst) 159
production, captopril (abst) 275
Protease, synthetic, GN (abst) 318
Protein
abnormal, uremic cardiomyopathy (abst) 390
aldosterone-induced, to luminal surface (abst) 183
binding and bactericidal activity in dialysis (abst) 252
deprivation, phosphate (abst) 360
deterioration of renal function (abst) 1045
dietary
effects in ARF (abst) 363
adenylate cyclase activity (abst) 430
vascular reactivity (abst) 425
drug binding during CRF (abst) 221
effects of dietary, loading (abst) 422
eosinophil major basic protein in kidney diseases (abst) 339
gentamicin nephrotoxicity (abst) 364
glomerular
injury (abst) 390
sieving of high molecular weight 1257
uridine utilization (abst) 396
heparan sulfate proteoglycan core (abst) 170
heterogeneity in handling 886
hormonal and glomerular responses to intake (abst) 215
induced increase in GFR and kidney mass (abst) 379
ischemia, restricted dietary in (abst) 363
kinase C
and ADP ribosylation, Na transport (abst) 280
Ca/lipid dependent following nephron loss (abst) 399
osteosarcoma (abst) 355
phorbol ester, diacylglycerol translocation (abst) 164
large meal, diseased glomeruli (abst) 381
load in diabetic renal hemodynamics (abst) 191
modification in diabetic nephropathy (abst) 225
platelet derived growth factor (abst) 158
pregnancy, dietary intake (abst) 426
prostaglandin prodution (abst) 267
renal function in CRI (abst) 197
restriction
and captopirl on proteinuria (abst) 314
and CEI on adriamycin nephrosis (abst) 1043
in hypertension (abst) 297
urea in concentrating defect (abst) 449
synthesis inhibitors, vasopressin challenges (abst) 446
translocation mechanism (abst) 160
tubular uptake, anionic proteins (abst) 449
volume expansion and phosphorylation (abst) 264
280 kD, identification by monoclonal antibodies (abst) 327

Proteinase
effect of gentamicin (abst) ... 372
neutral, excretion of ... 32
Proteinuria
acetazolamide (abst) ... 210
adriamycin nephrosis (abst) ... 393
ATPase, adriamycin nephrosis ... 704
children (abst) ... 203
chronic serum sickness (abst) ... 327
circadian rhythm, indomethacin (abst) ... 1048
complement dependent, gelonin (abst) ... 313
complement, leukocyte independent (abst) ... 328
development of experimental membranous nephropathy ... 1267
diabetes (abst) ... 380
diclofenac decreases (abst) ... 1418
dimethylthiourea (abst) ... 330
enalapril maintains renal function in CRF (abst) ... 212
glomerular structure and permselectivity (abst) ... 424
hypercoagulability and thrombo-embolic phenomena ... 830
hyperfiltration, gentamicin (abst) ... 377
immune glomerular injury (abst) ... 312
increased glomerular pressure, diabetic nephropathy ... 898
membranous nephropathy, antibody (abst) ... 333
microalbuminuria a predictor of diabetic nephropathy ... 673
platelet activating factor (abst) ... 267
protection vs. glomerulosclerosis and (abst) ... 296
reduction with ACE inhibition (abst) ... 1044
reversing glomerular hypertension, injury ... 752
size-selectivity of glomerular capillary barrier (abst) ... 314
5-lipoxygenase inhibitor (abst) ... 273
Proteoglycan
aminonucleoside nephrosis ... 1298
morphogenesis (abst) ... 178
Proton
Ca fluxes from calvariae (abst) ... 361
compartmentation (abst) ... 401
NMR, water diffusive permeability (abst) ... 444
pump, chloride stimulates (abst) ... 417
pump, clathrin-coated (abst) ... 416
secretion, effect of inhibitors (abst) ... 410
Proximal S2 segment, ion uptake (abst) ... 450
Proximal tubular cells
ATP content (abst) ... 170
ontogeny of Na-K pump (abst) ... 173
Pseudohyperphosphatemia (abst) ... 362
PTH-adenylate cyclase, cadium (abst) ... 173
Pulmonary embolism in NS (abst) ... 864
Pulmonary hypertension, thromboxane ... 1072
Pump
sodium
aldosterone induced proteins (abst) ... 186
and proton activity in epithelial cells (abst) ... 179
extracellular pH effect on phosphate uptake and (abst) ... 184
novel design to control CAVH (abst) ... 229
proton, clathrin-coated vesicle, lipid requirement (abst) ... 187
Puromycin aminonucleoside (abst) ... 170, 1043
Pyelonephritis
CT scan (abst) ... 210
natural killer activity (abst) ... 335
Pyruvate carboxylase, cloning (abst) ... 166

Quadruple induction therapy (abst) ... 468

Radiocontrast agent, iopamidol (abst) ... 371
Radioreceptor assay (abst) ... 259
Random sample study of ESRD in US (abst) ... 196
Rapidly progressive glomerulonephritis
crescentic, protracted course ... 790
plasma exchange treatment (abst) ... 867
Rats, biologic variability (abst) ... 301
RBF-autoregulation
hypertensive resetting (abst) ... 390
PG (abst) ... 387
Receptor
along the nephron, ANP (abst) ... 262
Ang II localization ... S-40
antagonist H2, cimetadine (abst) ... 356
CyA (abst) ... 460
prostaglandin E2 (abst) ... 287
Reconstitution, medullary solute (abst) ... 445
Red blood cells
oxidant stress in uremia (abst) ... 218
Reflection coefficient, solutes (abst) ... 446
Rejection
allograft, OKT3 treatment (abst) ... 456
anti-thymocyte globulin vs. high dose steroids (abst) ... 454
anti-thymocyte serum, reverses acute allograft (abst) ... 460
infection in cadaver allograft (abst) ... 470
intra-operative renal allograft biopsy (abst) ... 453
local graft irradiation (abst) ... 465
renal target structures in acute allograft ... 1310
tissue eosinophilia (abst) ... 453
Renal ablation, injury (abst) ... 385
Renal artery stenosis
ACE (abst) ... 299
ACE inhibition, hemodynamics of ... S-173
intrarenal effects of Ang II ... S-157
nephrotoxicity of ACE inhibition ... S-132
risk of ACE inhibition in ... S-180
transrenal changes in renin, Ang II ... S-184
Renal disease
epidemic in Zuni Indians (abst) ... 203
hormonal and glomerular responses to protein intake (abst) ... 215
modification of diet, objectives and design (abst) ... 210
one hospital (abst) ... 196
Renal failure
acquired resistance to ... 1233
anaphylactoid purpura with nephritis (abst) ... 192
autoantibody formation (abst) ... 320
hypoperfusion induced (abst) ... 378
inflammatory responses (abst) ... 320
insulin and endotoxin effect on skeletal muscle (abst) ... 388
liver transplant (abst) ... 195
nephrotoxic, microvascular prostanoid production (abst) ... 275
platelet inhibitors stabilize diabetic nephropathy (abst) ... 197
34 myeloma patients (abst) ... 1400
Renal function
exercise (abst) ... 386
impaired, infant (abst) ... 214
Renal hypertrophy
Ca_2^+ uptake an early event (abst) ... 399
Renal injury
anti-GBM-GN ... 8
Renal inner medulla, organic solute ... 562
Renal innervation, sodium (abst) ... 306
Renal insufficiency

acidification in distal tubule (abst) ... 411
enalapril, enalaprilat in ... S-117
loop diuretics (abst) ... 222
Renal ischemia, morphopathology (abst) ... 370
Renal memory, Na-K-ATPase (abst) ... 429
Renal metabolism, ammoniagenesis ... 1279
Renal pelvis ... 621
Renal reserve
(abst) ... 211
hemodynamics (abst) ... 419
Renal scans in transplantation (abst) ... 461
Renal stone
mass and reserve of vitamin D, hyperparathyroidism . 1174
Renin
ACE inhibition in normal kidney ... S-104
aldosterone, BP electrolytes, essential hypertension (abst) ... 868
angiotensin
distribution ... S-4
II system and renal circulation in heart failure S-203
system, localization ... S-2
system, congestive heart failure ... S-200
atriopeptin III, cGMP effect on (abst) ... 272
calcium agonists and release of (abst) ... 260
control of renal release ... S-89
experimental models of heart failure ... S-210
isoproterenol, theophylline induced, release (abst) 263
linoleic acid inhibits (abst) ... 308
localization in ESRD (abst) ... 269
magnesium loading (abst) ... 266
measurement of secretion (abst) ... 261
morphology ... S-18
neonatal lead exposure (abst) ... 292
periarterial pathway for distribution of ... S-51
physiologic concentrations of atrial peptide (abst) ... 263
physiology of renin-angiotensin system ... S-49
related hypertension, intracranial hemorrhage (abst) ... 302
release, bradykinin (abst) ... 426
release: amines, monensin and nigericin (abst) ... 287
renovascular hypertension, ACE inhibition ... S-154
stimulation of release (abst) ... 263
transrenal changes, renal artery stenosis ... S-184
Renin-angiotensin system
anti-GBM antibody induces intrarenal hemodynamic alterations ... 8
nephron function heterogeneity ... S-57
Renin-angiotensin-aldosterone system
nephrotoxicity of ACE inhibition ... S-132
Renovascular hypertension, Ang II ... 906
Respiration, Na^+,K^+-ATPase (abst) ... 403
Retinal alterations, diabetes (abst) ... 328
Rheumatoid factor in IgAN (abst) ... 339
Rifampin therapy in ARF (abst) ... 219
Rural nephrology experience (abst) ... 201

Saint Louis encephalitis, fish oil(abst) ... 318
Saline loading, AII (abst) ... 419
Salt
hypertension in renal transplant recipients ... 1024
Saturated fatty acids, TXB2 (abst) ... 287
Scan, cine-computed tomography ... 1038
Schistosomal specific nephropathy
ESRD ... 1006
Schwartz-Bartter syndrome (abst) ... 275
Sclerosis
glomerular, puromycin aminonucleoside (abst) ... 1043
progressive, hypertension ... 752
Secretion, ammonia (abst) ... 405
Secretory mechanism in duct (abst) ... 181
Seldinger technique, catheter (abst) ... 256
Sensitization, transfusion (abst) ... 457
Seriod, glucocorticoid hypertension ... 1213
Serum sickness nephritis
glomerular eicosanoid ... 334
Serum $1,25(OH)_2D_3$ in SHR (abst) ... 346
Sieving, glomerular, proteinuric rats ... 1257
Signal, tubuloglomerular feedback (abst) ... 425
Single agent therapy, dialysis (abst) ... 254
Single effect multiplier ... 580
Single needle dialysis (abst) ... 1045
SK&F 101926, antidiuretic (abst) ... 267
Skeletal muscle
CRF, PTH and fatty acids (abst) ... 393
Skeleton
thyroparathyroidectomy modifies response to Al loading ... 923
Sodium
ANF response to saline infusion (abst) ... 282
ANP
effect on reabsorption (abst) ... 290
elevated in rats with myocardial infarction (abst) ... 279
renal effects in aging rat (abst) ... 265
atrial natriuretic factor (abst) ... 257
balance, time course (abst) ... 306
bile taurocholate, vassopressin (abst) ... 257
blocks Ca^{++} sensitive K^+ channel (abst) ... 438
calcium exchange (abst) ... 345
cardiac and renal enlargement (abst) ... 303
chloride
alters chloride reabsorption (abst) ... 433
cortical thick ascending limb, distal convoluted ... 590
functional transitions in countercurrent system ... 668
medullary thick limb ... 580
PCO_2 effect on absorption (abst) ... 433
peptide hormones ... 611
urea, composition of renal medullary tissue ... 556
cytoplasmic vs. external transport (abst) ... 434
dependent modulation of Na-KATPase (abst) ... 434
dependent phosphate transport from cortex (abst) ... 182
dietary salt and ANP (abst) ... 288
ECF, renin-angiotensin system in congestive heart failure ... S-203
feeding induces lesions, reduced GFR (abst) ... 310
function of thin loops of Henle ... 565
furosemide, prazosin and captopril ... 135
gradient dependent phosphate transport (abst) ... 358
gradient on phosphate carrier (abst) ... 160
H antiporter
and Na/HCO_3 cotransportor, acidosis (abst) ... 404
bicarbonate reabsorption (abst) ... 418
chloride (abst) ... 443
exchange in platelets (abst) ... 296
H^+ antiporter
ph regulation of LLC-PK1 cells (abst) ... 411
quantitation (abst) ... 428
H^+ exchanger (abst) ... 406
handling of Ca in newborns ... 1181
handling, mineralocorticoid escape (abst) ... 430
HCO_3 concentration, alkalinization of cell pH (abst) ... 413
homeostasis in rat vs. man (abst) ... 436

hydrogen antiporter activity (abst) 436
hydrogen exchange regulation (abst) 442
hypochlorite, cuprophan membranes (abst) 230
H_2O handling, lithium as a marker for (abst) 189
impaired conservation, prehepatic portal hypertension (abst) 420
independent Cl-HCO_3- exchange in MDCK cells (abst). 414
inrarenal substance P (abst) 286
internephron heterogeneity to urine concentration 549
K
diurnal excretory cycles (abst) 440
pump activity, amphiuma collecting tubules (abst) ... 447
2Cl cotransporter, molecular size (abst) 171
linked transport, immune modulation of (abst) 172
low, diet response to amino acid infusions 992
meglumine diatrizoate, artery contraction (abst) 420
metabolic determinants of, H^+ transport (abst) 180
mineral intake alters maturation (abst) 294
monitoring by NMR (abst) 430
natriuresis, GFR after ANP (abst) 433
NH_3 permeates MDCK cells via lipid pathway (abst) .. 408
phorbol esters inhibit absorption (abst) 435
picomole analysis of alkali metals 1225
plasma irANF, in cirrhotic (abst) 269
proton pump activity in epithelial cells (abst) 179
pump activity, arachidonic acid (abst) 395
renal nerves, complement activation (abst) 327
restriction in hypertensives, ACE inhibition 815
restriction, lithium clearance (abst) 438
role of Ang II in heart failure S-213
supplementation in partially nephrectomized rat (abst) . 385
taurine symport (abst) 452
transport in BBMV (abst) 309
water balance on kallikrein, kininogen and kinin 836
Sodium K-ATPase
aldosterone-independent stimulation (abst) 433
changes, hydrochlorothiazide (abst) 299
circulating inhibitor of (abst) 307
collecting duct heterogeneity (abst) 441
contribution to respiration (abst) 403
expression of α-subunit in CCD 1104
furosemide (abst) 442
hydrochlorothiazide 918
inhibitor, target organ sensitivity (abst) 435
injury (abst) 376
in response to insulin (abst) 436
renal memory (abst) 429
response to Ca (abst) 295
urinary concentrating mechanisms 512
voltage dependance (abst) 431
Sodium chloride
determines severity of chronic metabolic alkalosis 1338
Solute cycling, concentrating 648
Somatomedin inhibitor, dialysis (abst) 341
Somatostatin
GFR after protein (abst) 420
PGE_2 (abst) 262
receptors (abst) 266
Sorbitol, gradient (abst) 448
SO_4 transporter
fluorescent stilbene (abst) 444
Spermine
mesangial changes (abst) 381
spermidine, hematopoiesis 72
Spinal chord injury, creatinine (abst) 205
Splenectomy
ischemic ARF (abst) 370
Steblay's nephritis
binding in GBM 25
Stenosis
renal artery, ACE inhibition S-154
Steriods
alternate day, growth in pediatric transplant patient (abst) 460
chlorambucil in GN (abst) 863
Stone former
gender and acidification in (abst) 347
uric acid excretion during Ca-restricted (abst) 215
Streptoccal component (abst) 321
Streptococcus mutans specificity (abst) 315
Streptokinase, low-dose in catheter 1210
Streptozotocin
induced diabetes, heparan sulfate proteoglycan (abst) .. 171
induced nephrogenic D.I. by indomethacin (abst) 191
metabolic control 47
Stroke, thromboxane in SHR (abst) 310
Substance P, renal effects (abst) 422
Sucralfate and $Al(OH)_3$ (abst) 214
Sulfation, aminonucleoside nephrosis 1298
Sulindac
metabolites in CRI (abst) 220
prostaglandin production in renal insufficiency (abst) .. 276
therapy in CRF (abst) 217
Suppressor activity, T cell (abst) 467
Sympathetic tone, GABAergic (abst) 311
Symport
Na-taurine (abst) 452
Na/Pi in BBM (abst) 183
Systemic anticoagulation, dialysis 1350
Systemic lupus erythematosus
analysis of transplantation results (abst) 467
IgG idiotype in immune deposits (abst) 336
IL-2 production by T cell lines (abst) 340

T cell
activation (abst) 469
alloactivated (abst) 467
CD_3 molecule (abst) 332
crescentic nephritis, signals (abst) 318
helper inducer cells, allograft (abst) 466
macrophages is RPGN (abst) 204
monocytes in nephritis 1160
monitoring in allograft recipients (abst) 458
sera from SLE patients on Il-2 production by (abst) ... 340
suppressor induction, CyA (abst) 468
suppressor, interstitial nephritis (abst) 324
T lymphocyte
HLA peptide (abst) 461
resident in rabbit glomeruli (abst) 319
transformation in CAPD and HD (abst) 862
Tachycardia, UN_aV (abst) 280
Tamm Horsfall protein
bacterial extracts 77
lectin induced mitogenesis of lymphocytes (abst) 325
Taurine
P depletion (abst) 344
uptake, chloride action (abst) 187
Taurocholate, vasopressin action (abst) 257
Teleologic, urinary concentrating 538
Tert-butylydroperoxide, stress (abst) 366

Tetradecapeptide somatostatin (abst) 266
Thiazide diuretics, distal tubule (abst) 441
Thick ascending limb of Henle
  single-effect multiplier 580
Thin ascending loop of Henle
  functional transitions in countercurrent system 668
  function of 565
Thiol group, redox, phosphate (abst) 358
Thrombo-embolic phenomena 830
Thromboxane
  A_2 receptor BM 13.177 (abst) 283
  cortical macrophages (abst) 257
  cuprophan-induced pulmonary hypertension 1072
  receptor antagonist, lupus nephritis (abst) 283
  suppression in CyA nephrotoxicity (abst) 367
  suppression in transplantation (abst) 457
  synthase in stroke prone SHR (abst) 310
  synthesis in platelets (abst) 287
  synthetase inhibitor, allograft function (abst) 456
  tubuloglomerular feedback response (abst) 427
Thymosin α-1, hemodialysis (abst) 217
Thyroid hormone
  CRF (abst) 207
  uremia 808
Thyroidectomy, CRF (abst) 381
Thyroparathyroidectomy, Al (abst) 923
Thyrotopin assay, CRF (abst) 201
Ticarcillin-clavulanic acid (abst) 250
Tissue
  blunted epripheral responsiveness to thyroid hormone . 808
  composition of renal medullary 556
Tissular-plasminogen activator (abst) 172
Titanium adapter in CAPD (abst) 861
Toxicity
  ACE inhibition S-130
  adenine nucleotides (abst) 374
  CyA, ATP-MGCL2 and thyroxin (abst) 376
Transformed glomerular cells (abst) 172
Transforming growth factor beta (abst) 187
Transfusion
  red cell, effect on hypotension during HD (abst) 247
  third party, sensitization (abst) 457
Translocation machinery (abst) 160
Transplantation
  AIDS and possibly related conditions (abst) 456
  AIDs in recipient, β_2M (abst) 461
  artificial heart effect on ANP levels (abst) 202
  blood pressure in donor, recipient 1382
  bone marrow, prednisone potentiates CyA (abst) 297
  cadaver graft, diltiazem (abst) 465
  cadaver, CyA (abst) 467
  CAPD in insulin-dependent diabetics (abst) 1415
  combined kidney and pancreas (abst) 1050
  conversion from CyA to AZA (abst) 1044
  cyclosporine
    after 3 years (abst) 470
    converted to standard immunosuppression (abst) 454
    in diabetic nephropathy (abst) 459
    no Mg renal wasting (abst) 200
    on fractional excretion of lithium, K (abst) 1048
  cytomegalovirus infection (abst) 1050
  diabetes, CyA lowers risk of thromboembolism (abst) .. 458
  donor age (abst) 1047
  donor specific blood transfusion (abst) 455
  growth after pediatric (abst) 460
  haploidentical live related donor (abst) 469
  hypertension 1024
  hypertension treatment (abst) 296
  IgA antibody response (abst) 1047
  impaired GFR, CyA (abst) 471
  indium-111–labeled white blood cell renal scan (abst) .. 468
  in elderly (abst) 471
  intervention therapy in progressive renal failure (abst) . 458
  ischemic damage evaluation by 31 P MRS (abst) 469
  linear C-3 deposits on TBM (abst) 463
  liver in children (abst) 213
  liver, RF (abst) 195
  lupus nephropathy, CyA graft survival (abst) 466
  natural killer activity in CyA treated (abst) 462
  non-utilized kidneys from US centers, results (abst) ... 459
  outcome after age 50 (abst) 456
  outcome, donor-specific transfused (abst) 453
  panel of hypersensitized patients (abst) 455
  pediatric experience with triple therapy (abst) 470
  pediatric, CyA induced facial changes (abst) 467
  prolonged dwell peritoneal dialysis in children 981
  PTH function (abst) 465
  quadruple induction therapy (abst) 468
  recurrence of lupus nephritis (abst) 464
  rejection
    anti-thymocyte serum (abst) 460
    ATG vs. high-dose steroids (abst) 454
    from infection in cadaver (abst) 470
  renal
    reserve (abst) 211
    scans (abst) 461
    target structures in rejection 1310
  serum neopterin levels (abst) 870
  successfull, unrelated living donors, transfusions
    (abst) 459
  systemic lupus erythematosus (abst) 467
  T cell monitoring (abst) 458
  T helper-inducer cells (abst) 466
  thromboxane suppression (abst) 457
  thromboxane synthetase inhibitor, allograft function
    (abst) 456
  ultrasonography (abst) 470
  urosepsis (abst) 469
  vascular disease, graft outcome of cadaver renal (abst). 466
  zinc metabolism and taste acuity (abst) 361
Transport
  acetazolamide on Na/HCO_3 co- (abst) 415
  active urea (abst) 450
  age affects furosemide sensitive (abst) 294
  amiloride in medullary collecting duct 1121
  amiloride-sensitive Na (abst) 301
  ammonium, K concentration on (abst) 408
  ascites (abst) 253
  bicarbonate
    and ammonia (abst) 408
    characteristics of in collecting tubules (abst) 412
    in CCT (abst) 409
    in ICT (abst) 418
  bradykinin inhibits O_2 consumption (abst) 293
  calcium channel in UMR-106 cells (abst) 188
  calcium, vitamin D-deprived SHR (abst) 350
  cAMP and Ca in cultured epithelia (abst) 162
  cation, release of lactate (abst) 185
  Ca_2^+ influx of SHR isolated enterocytes (abst) 308
  cell heterogeneity of collecting duct (abst) 415

chloride measured by fluorescent indicator (abst) 437
conductance, pH and Ba^{++} (abst) 429
counter, Na-Li (abst) 299
dependent O2 consumption (abst) 365
diazepam stimulates transport (abst) 444
disrupting stagnant fluid films enhance (abst) 254
distal tubule adaptation to increased fluid (abst) 437
electrical in BBMV (abst) 429
electrical, peritubular hypertonicity (abst) 439
electroneutral NaCl (abst) 438
epithelial, muzolimine (abst) 447
function of thin loops of Henle 565
functions after reducing renal mass (abst) 394
glucose, ischemia (abst) 371
HCO_3, effects of acetate (abst) 408
insulin stimulates (abst) 428
ion, hormone sensitive in chark rectal gland (abst) 185
KCL systems in BLMV (abst) 432
kinetic analysis of Na^+ dependent phosphate (abst) 182
lactate, pH coupled (abst) 412
luminal and basolateral mechanisms, alkalinization (abst) 415
mechanism for urinary dilution, history 507
medium hypertonicity inhibits co- (abst) 440
medullary thick limb 580
metabolic acidosis increases glutamine (abst) 399
metabolic determinants of Na^+ independent H^+ (abst) 180
metabolic support of, in CCT (abst) 398
muzolimine, Na^+ (abst) 171
Na by BBMV in SHR (abst) 309
Na-coupled base, CO_2/HCO_3- (abst) 411
Na-2Cl-K identified in utricle, loop diuretics (abst) 174
NaCl capacity, cell hypertrophy (abst) 432
organic anion lesion, Heymann nephritis (abst) 445
organic ion, norepinephrine (abst) 447
papillary collecting duct, ANP (abst) 430
papillary collecting duct, purification (abst) 402
peptide hormones, urinary concentrating mechanism 611
peritonal dialysate to blood (abst) 249
peritoneal solute in long term CAPD (abst) 248
pH dependence of ATP-driven Ca_2^+ transport (abst) 359
phosphate
(abst) 356
capacity in LLC-PK1 cells (abst) 179
glucose and valine (abst) 445
sodium (abst) 358
picomole analysis of alkali metals 1225
potassium secretion in CRF 1376
protein kinase C and ADP-ribosylation (abst) 280
proton by acetazolamide (abst) 164
PTH facilitates Ca (abst) 347
PTH in Ca (abst) 311
Rb and K comparison (abst) 443
related defects in PKD (abst) 394
renal clearance for dextran 855
renal Mg in CyA 360
serosal pH on Ca (abst) 352
slow CAVH (abst) 246
sodium
cortiocosterone stimulation (abst) 268
lithium counter, red blood cells (abst) 190
linked, immune modulation of (abst) 172
V1 and V2 analogs of vasopressin (abst) 272
solute and water, models of medullary microcirculation 662
solute in slow CAVH (abst) 246
stoichiometry of Na and K fluxes (abst) 382
transepithelial bicarbonate (abst) 407
tubular effects of Ang II S-81
urea, pathways in mammalian kidney 629
uremia, non-uremic differences (abst) 253
vanadate-sensitive proton (abst) 406
vanadate-sensitive, resistant H^+ (abst) 188
video-enhanced microscopy (abst) 170
water, dialysis plasticizers inhibit (abst) 250
Transporter, co-, molecular size (abst) 171
Treatment of ESRD by state (abst) 214
Trifluperazine, AVP (abst) 284
Triiodothyronine syndrome
CRF (abst) 867
uremia 808
Triple therapy
pediatric experience in transplantation (abst) 470
Trypsin inhibitor in pancreas (abst) 223
Tubule
ambystoma isolated proximal, pH and Ba^{++} (abst) 429
amphiuma collecting, Na and K pump activity (abst) 447
ANF on cyclic nucleotide accumulation (abst) 281
angiotensin receptors on proximal convoluted (abst) 291
basolateral membrane of PCT, K channel (abst) 440
CCT, vasopressin receptors localized (abst) 275
Cl/HCO_3 exchange at BLM (abst) 415
cortical collecting, flow-dependent K secretion (abst) 432
cortical collecting, K recycling 695
cortical, proton compartmentation (abst) 401
cytoskeleton role in volume control (abst) 173
distal, glucocorticoids alter permeability (abst) 446
distal, increased fluid delivery (abst) 437
exogenous ATP (abst) 402
hypoxia and substrate limitation effect (abst) 374
initial collecting, bicarbonate transport (abst) 418
Na monitoring by NMR (abst) 430
proximal
α2-adrenergic receptors (abst) 178
cell adhesion in culture, Anti-GP300 (abst) 175
convoluted, determinants of ammonia entry (abst) 416
convoluted, gentamicin (abst) 369
cytoplasmic pH regulation 1113
nephrocalcin (abst) 176
proximal straight, apical membrane K^+ (abst) 431
proximal straight, Cl activity (abst) 437
reflection coefficients for solutes (abst) 446
Na monitoring by NMR (abst) 430
S1, compatible monolayers 161
Tubuloglomerular feedback
(abst) 284
antiglomerular basement membrane antibody nephritis (abst) 386
mechanism in in vitro (abst) 421
prostaglandin (abst) 423
response, thromboxane (abst) 427
signal for control of GFR (abst) 420
signal transmission (abst) 425
stability of hypertonic urine formation 668
Tubulointerstitial nephritis
aminonucleoside nephrosis (abst) 317
cyclosporine (abst) 330
gentamicin, tubular necrosis (abst) 368
target antigen 800
tubular damage (abst) 335

Tumor, hypercalcemia and malignancy 142
Tunnel infection management, CAPD (abst) 869

Ultrafiltration
angiotensin II effect on isolated glomeruli..... S-74
AVP removal stimulates secretion of AVP (abst)..... 258
CAHV filter characteristics (abst)..... 242
coefficient, AII
(abst)..... 426
on hemodynamics and (abst)..... 427
on hemodynamics..... S-108
correlation with structure and function in disease
(abst)..... 392
dialysate dextrose rate to (abst) 252
histological changes of peritoneal membranes, CAPD
(abst)..... 866
kinetics of lymphatics (abst) 253
maximum rates during peritoneal dialysis..... 731
peritoneal, phosphatidylcholine (abst)..... 246
phosphatidylcholine increases (abst)..... 246
Tc99m dilution in children (abst)..... 255
Ultrasonography, allograft (abst) 470
Ultrastructure
PTH response to Al in vitro 15
Uranyl nitrate, ARF, K^+ loading (abst) 376
Urea
collecting duct in urinary concentration 606
composition of renal medullary tissue..... 556
models of medullary microcirculation..... 662
models of urinary concentrating mechanism..... 648
renal concentrating defect, protein restriction (abst) ... 449
synthesis rate mechanism, pH (abst) 396
transport pathways in mammalian kidney..... 629
Uremia
abnormal cation flux (abst) 383
acidosis promotes BCAA (abst) 386
defective antigen presentation (abst)..... 232
defective muscle metabolism (abst)..... 389
differences in transport characteristics (abst)..... 253
exercise and muscle substrates (abst)..... 391
fatty acid, skeletal muscle (abst)..... 391
histamine levels (abst)..... 233
human red cell ghosts (abst) 389
intracellular Ca in RBC (abst)..... 347
ketoacid effect on PTH and phosphate (abst)..... 357
LDL binding to hepatic membranes (abst)..... 181
leupeptin (abst) 375
low purine diet, high Al and alopurinol doses (abst) ... 221
oxidant stress, red blood cells (abst)..... 218
racial, sexual and age discrimination, dialysis (abst) ... 236
RBC insulin receptor defect (abst) 388
stoichiometry of Na, K fluxes (abst)..... 382
thyroid hormone effects..... 808
zinc modulates $1,25(OH)_2D(125)$ (abst)..... 351
Uremic cardiomyopathy
(abst) 175
inadequate left ventricular hypertrophy 973
proteins (abst) 390
Uremic cataract, vitamin D_3 (abst) 871
Ureteral obstruction
(abst) 393
alters AII mediated vascular tone (abst)..... 421
P-31 NMR (abst) 401
Ureteral occlusion
AII, thromboxane A2 mediate vascular resistance
(abst)..... 394
Uridine
glycolytic ATP (abst)..... 403
protein intake (abst)..... 396
Urinalysis, biopsy in MGN (abst) 218
Urinary acidification (abst) 405
Urinary albumin
excretion, microalbuminuria predictor of diabetic 673
in MCN (abst) 200
Urinary bladder, ADH (abst) 447
Urinary concentrating mechanism
adaptation of TAL, internephron heterogeneity..... 549
Berliner tribute..... 502
collecting duct 606
cortical thick ascending limb and distal convoluted.... 590
functional transitions in renal countercurrent system... 668
histotopography 538
history 507
models of 648
pathway of urea transport in mammals..... 629
physiological control by peptide hormones..... 611
short and long looped nephron 597
Urinary excretion
catecholamines, renal function in man 107
Urine
angiotensin I converting enzyme, neutral
endopeptidase..... S-45
anion gap in acidification (abst)..... 202
Ca excretion, $KHCO_3$ (abst) 353
concentration, composition of renal medullary tissue .. 556
congestive heart failure, Ang II and ACE..... S-200
dextran..... 855
flow and osmolality, models of concentrating
mechanism 648
flow, zinc excretion (abst)..... 866
function of thin loops of Henle 565
hypertonic, heterogeneity of nephron anatomy..... S-25
kinetics, amdinocillin (abst)..... 196
loss of magnesium 1140
ocalate excretion, hypercalciuria (abst) 867
osmolality, flow, aprotinin augumentation by
vasopressin..... 1092
physiological control of urinary concentrating
mechanism 611
preproEGF localization (abst)..... 261
protein-creatinine ratio in nephrotic syndrome (abst)... 216
renal pelvis..... 621
sediment in aminoglycoside nephrotoxicity (abst) 370
concentration, composition of renal medullary tissue .. 556
Urography, transient uremia (abst) 378
Urosepsis, transplantation (abst) 469

Vanadate
adenine nucleotide concentration (abst) 396
H^+ transport (abst) 188
Na-K pump in uremic erythrocytes (abst) 387
sensitive proton transport (abst) 406
Vancomycin
clearance (abst) 211
in CAPD (abst)..... 255
peritonitis (abst)..... 256
Vasa recta, models 662
Vascular
obstruction in renal ischemia 65
Vascular bundles, medulla 641

Vascular disease, age changes in kidney 1153
Vascular resistance, filtration fraction S-229
Vasoactive binder PAN (abst) 245
Vasoactive hormone
  cytosolic free calcium levels (abst) 172
Vasoactive hormones, diabetes (abst) 259
Vasoactive substances, PAN (abst) 245
Vasoconstriction
  amphotericin B (abst) 377
  ANP (abst) 277
Vasopressin
  ADH control 512
  α_2 adrenoceptor agonist (abst) 270
  ANF
    in pulmonary edema (abst) 195
    interaction with arginine (abst) 274
    on permeability (abst) 450
  aprotinin 1092
  cAMP binding proteins in medullary collecting tubules (abst) 270
  cytosolic calcium (abst) 449
  GFR, concentration of urine in absence of 634
  pH regulation (abst) 264
  phosphorylation (abst) 273
  protein synthesis inhibitors (abst) 446
  Rb^+ in CCT (abst) 285
  receptors localized to cortical collecting tubule (abst) .. 275
  receptors to, and other hormones 512
  sensitive nephron segments, cAMP system 1065
  signaling in kidney cells 521
  V1, V2 analogs of, transport (abst) 272
  water flow and cell volume, Cl- (abst) 261
Vein stenosis/occlusion (abst) 242
Veinogram, superiority of access (abst) 230
Verapamil
  cisplatin (abst) 1046
  CRF (abst) 381
  enalapril, reduced renal mass (abst) 380
  glomerular hemodynamics (abst) 391
  peripheral blood mononuclear cell function (abst) 471
  renal preservation (abst) 464
  experimental chronic renal failure 41
Vesicles, brush border
  gating activity of cation-permeable channels (abst) 174
Vesicular traffic, aggrephore (abst) 164
Vessels
  interlobular arterial resistance 1291
Viral respiratory pathogen (abst) 324
Virus Ad5-SV40, transfected cells (abst) 172
Viscoelastic properties of cysts (abst) 383
Vitamin B6, azotemic rat (abst) 248
Vitamin D
  Ca regulation of (abst) 352
  deprivation, BP and Ca in SHR (abst) 310
  evaluation in calcium stone formers (abst) 1416
  deprivation, BP and Ca in SHR (abst) 310
  hypercalcuira (abst) 864
  induced calcium binding protein in human 121
  leukocyte function in HD (abst) 339
  PTH stimulated Ca absorption 913
  renal mass and reserve of 1174
  treatment to uremics on HD (abst) 868
Voltage
  K^+ conductive pathways in nephron 1055
Volume
  ANP in dehydration 760
  during pregnancy (abst) 281
  ECF depletion, Na hydrogen antiporter (abst) 436
  expansion
    and contraction, ANP (abst) 285
    Cya nephrotoxicity (abst) 366
    protein phosphorylation (abst) 264
  fluid, hypoproteinemia (abst) 437
  hyproproteinemia (abst) 1049
  intracapillary, AII (abst) 276
  regulation
    CyA (abst) 376
    K^+ conductance (abst) 434
    of MTAL (abst) 440

Water balance, ADH 530
Water metabolism, murine lupus (abst) 290

Xyloside, fetal kidney development(abst) 172

Yersinia enterocolitica, DFO (abst) 247

Zinc
  excretion and urine flow in healthy volunteers (abst) ... 866
  hypertension, captopril (abst) 294
  in CRF (abst) 863
  modulates 1,25$(OH)_2$D(125) levels (abst) 351
  nutritional status, low Ca diet (abst) 358
  tranplant recipient, metabolism (abst) 361
Zollinger-Ellison syndrome (abst) 225

1-α hydroxyvitamin D_3
  uremic cataract (abst) 871
1,25$(OH)_2$D
  reverses osteodystrophy (abst) 353
  abnormal receptor in hypertensive rat (abst) 303
  calcitriol, Ca and PTH 795
  changes in immune function (abst) 342
  pathophysiology (abst) 346
  PTH (abst) 382
  PTH, Al action on bone cell metabolism 736
  synthesis of by peritoneal macropahges of CAPD (abst) 249
  regulation by ionized Ca (abst) 360
1,3-diethyl-8-phenylxanthine (abst) 265
1$\alpha$$(OH)D_3$, chronic HD (abst) 870
25$(OH)D_3$
  calmodulin antagonists (abst) 347
  effect on 1,25$(OH)_2D_3$ in CRF (abst) 345
  phosphaturia, PTH (abst) 357
25,26-dihydroxyvitamin D_3
  serum Ca, intestinal Ca absorption (abst) 362
28 kDa vitamin D-induced calcium binding 121
5-Lipoxygenase
  inhibitor (abst) 273
  in HN (abst) 277
6-Mercaptopurine and AZA (abst) 1047
8,9- and 14,15-Regioisomers (abst) 289